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Some 12-16 hours after the invasion of the human erythrocyte by the malaria parasite Plasmodium 
falciparum, there appear in the erythrocyte membrane ‘new permeability pathways’ which 
mediate an increased permeability of the infected cell to a range of low molecular weight solutes, 
including anions, cations, amino acids, polyols and nucleosides. There is evidence that the 
pathways have an important bi-functional role: firstly, that the new permeability pathways are 
required for the uptake of essential nutrients, and secondly, for the removal of metabolic wastes 
from the infected cells. Reported screening of 165 analogues of the new permeability pathways 
inhibitor furosemide, and the related compound bumetanide, for their effect on the malaria 
parasite-induced choline influx resulted in the identification of 13 effective compounds. Of these, 5 
showed inhibitory activity in vitro against the parasite at a concentration of 10 µM. Analysis of the 
data on all the 165 compounds revealed some preliminary structure-activity relationships. Based 
on this preliminary structure-activity relationship data, compounds with specific diversity sites 
were designed for synthesis. 
 
Acetolactate synthase (also known as acetohydroxyacid synthase) is the enzyme which catalyzes 
the first step in the biosynthesis of branched chain amino acids, including valine, leucine and 
isoleucine. It is a target for several classes of herbicides including sulfonyl ureas and 
imidazolinones. The complete crystal structure of yeast acetolactate synthase has been shown to 
share 26% homology with the Mycobacterium tuberculosis enzyme. On this basis, docking studies 
were initiated, which resulted in the generation of a virtual library of biaryl-based sulfonyl ureas. 
Exploratory libraries of sulfonyl ureas, imidazolinones, sulfonylcyanoguanidines, acylthioureas and 
related compounds (phthalimides) with the potential of having antituberculosis activity, 
presumably targeting acetolactate synthase, were synthesized. 
 
Studying the general approaches to the synthesis of sulfonyl ureas, the general procedure is to 












isocyanate with a primary or secondary amine. Both approaches work well chemically. However, 
the lack of diverse commercially available (sulfonyl) isocyanates, as well as the instability of 
isocyanates in general are drawbacks. A method that generates a vast selection of (sulfonyl) 
isocyanates from a range of commercially available starting materials would, hence, be very useful. 
A new approach to the synthesis of sulfonyl ureas was envisaged. This strategy involves the use of 
1,2,4-dithiazolidine-3,5-dione, which should provide an alternative route to the arylsulfonyl ureas. 
 
(i) Compound H157 (one the five compounds that showed inhibitory activity in vitro against the 
parasite at a concentration of 10 µM) was chosen as a basis for structure-activity relationship 
studies. H157 and its derivatives bearing an altered “side chain” length, numerous carboxylic acid 
and ester derivatives bearing hetero atoms, heterocyclic as well as aromatic moieties (in the place 
of the naphthyl functionality of H157) and the hydroxamic acid bioisostere of H157, were 
synthesized. All potential new permeability pathways inhibitors and intermediates, as well as, all 
available potential acetolactate synthase inhibitors and their respective intermediates, were tested 
in the sorbitol uptake assay for their potential of inhibiting the new permeability pathways. Four 
compounds were identified to demonstrate significant inhibition of the sorbitol uptake, namely 
RKG256 (synthesized H157), RKG340 (an extended ‘side-chain’ derivative of H157), RKG404P2 
(hydroxamic bioisostere of H157) and RKG359 (sulfonyl urea, and analogue of classical Cl- anion 
inhibitor, glibenclamide). RKG359 and RKG340 showed almost complete inhibition down to the 
concentration of 9 µM. RKG404P2 proved to be the most active derivative [(IC50 = 1.2 µM)]. The 
compounds were further tested for in vitro activity against the chloroquine-sensitive D10 strain and 
chloroquine-resistant W2 strains of Plasmodium falciparum. The most active compound was found 
to be a 7-chloroquinoline bearing H157 derivative having equipotent activity against both strains 
[D10 (IC50 = 1.28 µM) and W2 (IC50 = 0.89 µM)]. From the four compounds that showed good new 
permeability inhibition in the sorbitol uptake assay, only RKG256 (H157) [D10 (IC50 = 17.9 µM)] and 
RKG404P2 [D10 (IC50 = 16.9 µM) and W2 (IC50 = 17.7 µM)] showed notable in vitro activity. This 
activity is not as potent when compared to the control chloroquine, but presents the possibility 













(ii) Synthesized sulfonyl ureas, imidazolinones, sulfonylcyanoguanidines, acylthioureas, 
phthalimides, intermediate compounds, and a collection of 13 commercially available herbicides 
were tested against the Mycobacterium tuberculosis H37Rv strain using the Alamar blue assay, as 
well as in the Mycobacterium tuberculosis Resazurin assay. Only commercially available 
ethoxysulfuron (RKGC5Et) showed inhibition of greater than 90% in the primary screening against 
the H37Rv strain at the concentration of 6.25 µg/ml. Other compounds that showed low to 
moderate inhibition (21-41%) at the concentration 6.25 µg/ml were acylthioureas: RKG162A, 
RKG1541, RKG1542 and RKG1543; and commercially available sulfonyl ureas: triasulfuron 
(RKGC11Tria) and thifensulfuron-methyl (RKGC12Th). From the primary screening in the resazurin 
assay, only acylthioureas RKG162A and RKG1541 showed good inhibition of the reduction of 
resazurin [approximate (IC50 = 16.9 µM) and (IC50 = 10.7 µM)].  
 
(iii) The new synthesis of sulfonyl ureas envisaged using 1,2,4-dithiazolidine-3,5-dione as the 
starting scaffold, which was proposed to work via a 4-arenesulfonyl-1,2,4-dithiazolidine-3,5-dione 
intermediate, was unsuccessful. The coupling of 1,2,4-dithiazolidine-3,5-dione with a sulfonyl 
chloride was attempted under a variety of conditions, however, the 4-arenesulfonyl-1,2,4-
dithiazolidine-3,5-dione intermediate could not be isolated or confirmed. Another new route to 
sulfonyl ureas was envisaged involving the reaction of N-alkyl-1,2,4-dithiazolidine-3,5-dione with 
sulfonamides in the presence of triphenylphosphine and a weak base. This alternate method was 
successful, and eleven sulfonyl ureas were synthesized to demonstrate the success of the method 
with yields ranging from 32 – 79%. Due to this new method being initially limited to N-alkyl-1,2,4-
dithiazolidine-3,5-diones, broadening this new synthetic method to include N-aryl-1,2,4-
dithiazolidine-3,5-diones was envisaged. Transition metal-catalyzed (Pd and Cu) amidation 
methodology was used to attempt the coupling of 1,2,4-dithiazolidine-3,5-dione with arylbromides. 
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LIST OF ABBREVIATIONS 
 
AcOH  - acetic acid 
AIDS  - acquired immunodeficiency syndrome 
ALS  - acetolactate synthase 
Ar  - aromatic 
ATP  - adenosine triphosphate 
CQ  - chloroquine 
CQR  - chloroquine resistant 
CQS  - chloroquine sensitive 
DCM  - dichloromethane 
DMAP  - 4-(dimethylamino)pyridine 
DMF  - dimethylformamide 
DMSO  - dimethyl sulfoxide 
E1cB - E1: unimolecluar elimination; cB: conjugate base; leaving group is lost from 
conjugate base of starting material  
ED50 - mean effective dose of drug needed to produce a therapeutic effect in 50% of 
test sample 
EI(MS)  - electron impact mass spectroscopy 
EPA  - United States Environmental Protection Agency 
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Et3N  - triethylamine 
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FGI  - functional group interchange 
h or hrs - hour/s 
H-bond - hydrogen bond 
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HRMS  - high resolution mass spectroscopy 
IC50  - inhibitor concentration reducing Vmax by 50% 
iPr  - iso-propyl 
IR  - infrared 
Ki  - inhibition constant 
LD50  - lethal dose required to kill 50% of a group of animals 
LRMS  - low resolution mass spectroscopy 
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MEM  - a general cell culture medium 
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NMP  - 1-methyl-2-pyrrolidinone 
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NPPB  - 5-nitro-2-(3-phenylpropylamino)-benzoic acid 
P.  - genus Plasmodium 
Ph  - phenyl 
Rf  - ratio of movement of solute to solvent in TLC 
Rpm  - rotations per minute 
RPMI 1640 - a cell culture medium (Seromed, Munich)   
rt  - ambient temperature  
SAR  - structure-activity relationship 












T.  - genus Trypanosoma 
TB  - tuberculosis 
THF  - tetrahydrofuran 
TI  - therapeutic index = parasite ED50/Mammalian cells ED50 
TLC  - thin layer chromatography 
UV  - ultraviolet 
WHO  - World Health Organization 
Xantphos - (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine 
XDR  - extensively drug resistant 
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HETCOR - correlated spectroscopy [(H, C)-correlated NMR spectroscopy] 
J  - coupling constant 
m  - multiplet 
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Malaria is a disease caused by protozoan parasites of the genus ‘Plasmodium’. These are four 
species which are pathogenic to humans. It is spread by the bite of an infected female 
Anopheles mosquito, and is transferred from the infected bloodfeeding female mosquitoes (as 
male mosquitoes do not bite) into the bloodstream of the human hosts. These four species 
include: Plasmodium falciparum, P. vivax, P. ovale, P. malariae. Plasmodium falciparum is the 
most lethal of the malaria infections, and results in the most severe clinical malaria cases and 
deaths. It is estimated that a child dies as a result of malaria infection every 30 seconds,1 and 
that an estimated 350 – 500 million cases of malaria, resulting in approximately 700,000 – 2.7 










Figure 1.1: Geographical distribution of malaria endemicity3 
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Most infections and fatalities occur in sub-Saharan Africa, however, parts of Asia, Europe, Latin 
America and the Middle East are also at risk. It is further approximated that 40% of the world’s 
population is at risk1 (risk areas are displayed in Figure 1.1). 
 
1.1 Life Cycle of the Parasite Plasmodium falciparum 
 
The spread of the malaria parasite, in nature, is reliant on the successive infection of two hosts: 
the female Anopheles mosquito and humans. Starting at the infected mosquito host (Figure 
1.2), threadlike structures (known as sporozoites) in the salivary glands are injected into the 
human host, along with the mosquito’s saliva, when the mosquito takes a blood meal. The 
 
 
sporozoites travel via the human host’s bloodstream to the liver and invade hepatocytic 
(parenchymal) cells. In the liver, the sporozoites asexually multiply and parasitize the liver cells, 
forming thousands of another kind of spore called the merozoites. The infected hepatocytes 
eventually rupture and merozoites are released into the bloodstream. The merozoites invade 
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the oxygen transporting erythrocytes. Here they devour the hemoglobin, and asexually multiply 
by a factor of up to 16-fold, destroying the red blood cells. In the asexual reproduction process, 
the parasites can be first differentiated as a ring stage which develops into trophozoites. The 
trophozoites become schizonts, and these schizonts eventually turn into merozoites. This round 
of asexual multiplication can take place in a rapid time of as little as 48 hours. Upon 
disintegration of the red blood cell, the merozoites are freed, and can either infect other fresh 
red blood cells and repeat the asexual reproduction cycle, or develop into male and female 
gametocytes. The gametocytes are taken up by a female Anopheles mosquito during feeding, 
and make their way to the host’s stomach. It is here in the gut of the mosquito that another, 
different cycle of growth and multiplication of the parasite takes place. Sexually active 
gametocytes come together, and fuse to form a zygote. The zygotes develop into oocytes in the 
wall of the stomach. The oocytes develop over a period of 10 – 18 days, and contain numerous 
sporozoites. These sporozoites are released, and migrate to the mosquito’s salivary glands, 




The fever or flu-like illness associated with malaria is a result of the merozoites invading and 
destroying red blood cells, and usually starts around 8-30 days after infection. When the red 
blood cells are destroyed; waste, toxins, and other debris are released into the blood stream. 
This results in the body producing an immune response (fever) to promote other immune 
defenses to combat the foreign material. The fever occurs in recurring incidents, initially 
starting with sudden, violent chills, followed by an intense fever which leads to intense 
sweating. The typical fever episode lasts approximately 12 hours. Severe anemia (due to the 
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Occurrence of fever and other related symptoms is varied according to the species of 
Plasmodium infection. Plasmodium falciparum, P. vivax and P. ovale produce fevers typically 
every 48 hours, where P. malariae produces fevers every 72 hours. Plasmodium falciparum 
infection is associated with the highest fatality rates. Symptoms of P. falciparum can include 
severe headaches, convulsions and delirium, and in the worst cases, it can actually develop into 
cerebral malaria. Cerebral malaria occurs when infected red blood cells attach to the walls of 
tiny blood vessels in the brain, and this leads to the inflammation and blocking of blood and 
oxygen flow in the brain. In some cases of Plasmodium vivax and Plasmodium ovale, merozoites 




Due to the nature of the periodic fever and variable symptoms of malaria, it is difficult to 
diagnose based on these attributes alone. Instead, a patient’s blood sample is usually examined 
as a blood smear under a microscope to detect if the malaria parasite is present in the red 
blood cells. It is also possible to tell the species of Plasmodium present by observing their 
appearance under the microscope. However, it is difficult to detect malaria under a microscope 
in its early stages or if there are only a few parasites present. Recent developments using the 
polymerase chain reactio  makes diagnosis more accurate. The method works by detecting and 



















Despite a worldwide effort to eradicate the causative agents or combat the disease, malaria 
remains the parasitic disease with the greatest threat to mankind. The three main strategies of 
defense are a combination of vaccination, vector control and drugs. However, parasiticidal 
drugs remain the current main line choice for disease control.   
 
Quinine, the first known antimalarial drug, is a compound present in the bark of the cinchona 
tree, and was applied by the 15th century ancient Inca people for the treatment of fever. The 
antimalarial properties of quinine, and later quinine-type compounds, are believed to be a 
result of its interference with the parasite’s metabolism. However, due to its bitter taste and 
severe side effects, which includes nausea, headaches, ringing in the ears, temporary loss of 
hearing, blurred vision, and even death when large doses are administered, it is no longer a 
frontline choice drug candidate in malaria treatment. Today, quinine is still used in some 
developing third world countries because of its low cost and effectiveness.  
 
In the 1940’s, chloroquine, a synthetic compound with similar chemical properties to quinine, 
was discovered. It almost immediately became the antimalarial drug of choice due to its high 
efficacy, ease of manufacture and less severe side effects. However, resistance to chloroquine 
by the malaria parasite has grown and spread over the last few decades, and has rendered the 
drug useful to only some parts of Central America and the Middle East. 
 
Mefloquine, another compound related to quinine and chloroquine, is largely used today due 
to its effectiveness. It, however, has quite severe and adverse permanent side effects, is still too 
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Medicines that are currently prescribed with less risk of severe side-effects, and which are 
equally effective for malaria prevention are Malarone (combination of atovaquone and 
proguanil) and doxycycline. 
 
Drug resistance appears to be more prevalent in south-east Asia. This phenomenon has been 
studied intensively in Thailand where only after a few years of monotherapy resulted in the 
emergence of mefloquine-resistant parasites.7 It was discovered that when artemisinins are 
combined with previously effective drugs, which are no longer as effective as a result of 
resistance, the efficacy can be in some areas be restored. It was found that more than 95% of 
patients were cured by the combination of artesunate and mefloquine, when compared with 
the 50 - 60% of cases where mefloquine was taken alone.7,8 Two advantages of using 
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combined with antimalarials from different compound classes, and the development of 







Due to the emergence of multi-drug-resistant malaria parasite strains and the ever increasing 
resistance to available drugs, there is a need for the development of new antimalarial drugs. 
The development of new antimalarial drugs can range from the modification of existing drugs, 
to the studying and isolating historically known natural product remedies, to the search and 
development of new leads and novel antimalarial candidates. 
 
1.5 Malaria Drug Targets 
 
Recently, in 2002, the genome of Plasmodium falciparum was sequenced, and this has unlocked 
many opportunities and possibilities of finding and exploring new drug targets.9 Approximately 
5300 protein-encoding genes, of which about 60% function could not be assigned, were 
identified. This entails a large group of unique malarial proteins which could be potential drug 
targets. Several other unique features of the parasite were also identified. This includes an 
apicoplast with 30 genes in its own genome, an unusual electron transport chain, an apparent 
non-functional F1F0 ATP synthase, and a proton-translocating pyrophosphatase which is 
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The identification of purine and nucleoside transporters, as well as purine salvage enzymes 
hypoxanthine phosphoribosyltranferase (HPRT) and purine nucleoside phosphorylase (PNP), 
were further assigned from the genome. These are good potential drug targets as all 
pathogenic protozoan parasites do not synthesize their own purines de novo, and rely on the 
host for their purine provision.10  
 
New Permeability Pathways (NPP) (this shall be discussed in detail in Chapter 2) are induced 
into the host cells membrane, making it more permeable to a variety of required small 
molecular weight compounds, after invasion of the red blood cells by the parasite. There is 
much debate of the origin of these transport systems, but they could potentially be a good drug 
target.11 
 
Quinoline derivatives (including chloroquine, quinidine, halofantrine and mefloquine) are main 
line drugs which are believed to inhibit haem detoxification. The human host haemoglobin is 
the primary source of amino acids for the malaria parasite. As haemoglobin is consumed 
(haemoglobin proteolysis) within the food vacuole of the parasite (this process occurs during 
the intra-erythrocytic stage of the malaria parasite’s life cycle), free haem *Fe(II)protoporphyrin 
IX] is produced. The haem is oxidized to haematin [HO-Fe(III)protoporphyrin IX] which is toxic to 
the parasite.12 The parasite detoxifies itself by converting the haematin into haemozoin (known 
as malaria pigment), which is believed to be a polymer of β-haematin.13,14 The quinoline anti-
malarials are believed to interfere with this process of detoxification. The inhibition of the 
formation of synthetic crystalline β-haematin has been demonstrated by the presence of 
several 4-aminoquinolines.15 The acculmulation of toxic haematin, as a result of the inhibition of 
haemazoin formation, is believed to kill the parasite. 
 
Artemisinin and its derivatives are increasingly becoming more important and favorable for the 
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Wormwood, which grows throughout the world, and was used in ancient times by Chinese 
herbalists for the treatment of fever. The effectiveness of these compounds for the treatment 
of malaria has been attributed to several modes of action. Artemisinin drugs are believed to be 
converted to dihydroartemisinin by haem [Fe(II)protoporphyrin IX], generating toxic, carbon 
centered free radicals which are believed to alkylate important parasitic enzymes.16,17 
Artemisinin has also been proposed to be the source of hydroperoxide which may lead to the 
generation of hydroxyl radicals. These hydroxyl radicals can result in disastrous effects for the 
parasite by hydroxylating parasitic proteins and possibly leading to the production of reactive 
oxygen species.18,19 More recently, artemisinins have been found to inhibit a malarial Ca2+-
ATPase, PfATP6,20 as well as, have an anti-inflammatory effect by inhibiting the parasite 
induced form of a nitric oxide synthase.21 
 
Some other important classes of drugs include antifolate agents and protease inhibitors. 
Pyrimethamine and sulfadoxine (first line therapeutics in some African countries) inhibit two of 
the five required enzymes (namely dihydrofolate reductase and dihydropteroate synthase 
respectively) for the synthesis of folate.22,23,24 Peptidyl fluoromethyl ketones25 and vinyl 
sulfones26 are potent antimalarials that inhibit proteases. Aspartyl proteases (plasmepsin I and 
II),27,28,29 cysteine proteases (falcipain 1, 2 and 3)30-34 and trypanothione reductase34 are classes 
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Chapter 2 
Inhibitors of the New Permeability Pathways 
 
2.1 New Permeability Pathways (NPP) 
 
New permeability pathways (NPP) are induced by the malaria parasite Plasmodium falciparum 
into human host red blood cells (erythrocytes) about 12 - 15 hours after infection.1 These NPP 
cause the infected erythrocyte to have a higher permeability to a range of small low molecular 
weight and structurally unrelated solutes, including anions, cations, amino acids, polyols and 
nucleosides. It has been proposed that the NPP are predominantly anion-selective channels 
which also allow the transport of electroneutral and cationic solutes.1 However, this postulation 
has recently been challenged.2  
 
There is evidence that shows that these NPP may have a bifunctional role. Firstly, they are 
required for the uptake of essential nutrients, and, secondly, they are required for the removal 
of metabolic wastes from the infected cells.3,4,5,6 It has been recently shown that the activity of 
the NPP increases as the parasite matures.7 Human erythrocytes do not have high nutritional 
demands and, hence, are lacking in the ability to take up vast quantities of lipids, amino acids 
and nucleic acids.6 This presents problems for the invading parasite, as it requires all the above 
mentioned nutrients to survive. Additionally, to survive, the parasite requires the uptake of 
pantothenate,8 and the removal of lactic acid which forms from the high rate of glucose 
metabolism.6 The initial amount of monocarboxylate transporter present in the host red blood 
cell is not sufficient to cope with extra lactic acid generated by the parasite. The induction of 










Chapter 2 Inhibitors of the New Permeability Pathways | 14  
 
required nutrients and to facilitate the removal of metabolic wastes. Another recent proposal is 
that the NPP may also assist in the volume regulation of the infected host erythrocyte.9 
 
The NPP have only been studied for just over two decades and there is still much confusion and 
debate about the origin, over the amount and the nature of the NPP.10 Several research groups 
have proposed that NPP can be induced by a single channel,1,11-14 whereas others have 
hypothesized, as result of their observed and published data, that more than one channel type 
or pathway is required.15-20 It is further postulated that the origins of NPP could be both 
endogenous13,19,20 and parasite-derived.10  
 
Four possible reasons for the increased permeability of the host cell membrane induced by the 
malaria parasite are illustrated in Figure 2.1:  
i) existing native transporters and channels in the host cell membrane are activated (red) 
ii) parasitic proteins cause structural defects to existing transporters and channels (yellow) 
iii) the parasite inserts channels into the host cell membrane (blue) 
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iv) fluidization in the host cell membrane increasing defects and leaks (green) 
 
To date, none of the above hypothesis are conclusive, and many discrepant results still present 
many questions.2,11,21,22 Continuous work is constantly challenging and attempting to explain 
these questions. For example, Staines, H. M. et al. [2006]10 have recently reported data 
suggesting that solute transport via NPP is not consistent with a single-channel model. 
 
2.2 Classical Cl- Transport and NPP Inhibitors 
 
The NPP show the characteristics of ‘classical’ anion channels, and it has been demonstrated 
that they can be blocked by a range of anion channel inhibitors including furosemide,1 
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more recently, furosemide and bumetanide analogues.26 All of these compounds have 
demonstrated the inhibition of NPP, however, their major downfall is their general lack of 
specificity over human anion transporters.27 
 
To date, not much work has been done on extending the size, and developing libraries, of 
compounds which are specific NPP inhibitors. Out of a small library of NPPB analogues, Kirk, K. 
et al. [1995]28 reported a NPPB derivative that has shown higher selectivity for parasite NPP 
over three other human anion transporters. In conclusion, the development of large libraries of 
analogues of these potent anion and NPP inhibitors could result in the discovery of a drug that 
is both specific and potent for NPP inhibition. 
 
2.3 Structure-Activity Relationship (SAR) Studies 
 
As mentioned in Chapter 2.2, not much work has been done to extend the size of libraries in 
search of compounds that show potent NPP inhibition, and, more importantly, inhibitors which 
are NPP specific. The initial screening of 165 analogues of the NPP inhibitor furosemide, and of 
the related compound bumetanide (piratinide-like molecule), for their effect on the malaria 
parasite-induced choline influx resulted in the identification of 13 effective compounds.  
 
Of these, 5 compounds (H156, H157, H158, H159 and H161) (Figure 2.3) showed inhibitory 
























Analysis of the data on all the 165 compounds revealed some preliminary structure-activity 
relationship (SAR) with respect to the importance of the primary sulfonamide and carboxylic 
acid functional groups. Based on this preliminary data, further SAR studies were carried out and 
resulted in the identification of other possible derivations that could be investigated 
(summarized below in Figure 2.4). Compound H157 was chosen as the foundation of further 
SAR investigation. 
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Thus the envisaged SAR for piretanide-like molecules (also applicable to furosemide-like 
molecules) is summarized as follows: 
 
1) The length of the alkyl (-CH2-) spacer as well as its nature (X = CH2, NH, O) would be 
investigated. The aforementioned 5 compounds (H156, H157, H158, H159 and H161) all 
have a 2-carbon methylene spacer between the amino benzene and the bicyclic (e.g. 
naphthyl) group. This spacer has an effect on the lipophilicity, and hence membrane 
permeability, as well as the solubility properties, of the compounds. From the initial 
library of 165 compounds, it was noted that compounds with a 1-carbon methylene 
spacer displayed poorer activity. 
 
2) The carboxylic acid moiety would be transformed into suitable corresponding esters. 
This could not only enhance the membrane permeability properties of the compounds, 
but also result in potential prodrugs requiring in vivo biotransformation (presumably via 
hydrolysis mediated by esterases) to give the carboxylic acid moiety.  
 
3) Converting the carboxylic acid moiety into corresponding bioisosteres. Hydroxamic acids 
and tetrazoles are known carboxylic acid bioisosteres, and may result in alternative 
and/or additional mechanisms of action. In view of the known metal-chelating property 
of hydroxamic acids, these compounds may be expected to inhibit metalloenzymes and 
cysteine proteases (as metal-interactive inhibitors) amongst varied potential targets. 
This property would have implications for overcoming drug resistance and/or delaying 
its emergence. Having additional mechanisms of action could effectively result in the 
development of single agents that provide maximal antimalarial activity by acting 
against multiple targets within the parasite. 
4) The naphthyl group (e.g. in H156, H157, H158 and H159) could be replaced by other 
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5) All of the active compounds from the initial library of 165 compounds have a primary 
sulfonamide moiety. Systematically, it has been concluded that this primary 
sulfonamide group is vital for the activity of this class of compounds. However, a study 
of this group was proposed to be undertaken in order to explore its importance for 
activity. The primary sulfonamide could be replaced by other electron withdrawing 
groups including the nitro, cyano, and trifluoromethyl moieties. Another rational study 
would be the conversion of the primary sulfonamide to a secondary/tertiary sulfonyl 
(thio)urea. This conversion is supported by the known activity of sulfonyl ureas for the 
inhibition of classical chloride channel inhibitors. Tolbutamide and glibenclamide are 
examples of such sulfonyl ureas which have also displayed NPP inhibition. As described 
in point 3 above, this conversion could result in additional mechanisms of action, and 
potential single agents that address drug resistance by targeting different pathways. 
 
6) A systematic study of the nature of the Y group could be undertaken in order to explore 
the effect of the absence (Y = H) and presence of electron withdrawing and electron 
donating groups (Y = F, Cl, Br, I, CF3, OH and alkoxy).  
 
7) The nature of the aromatic group (Y = aryl/heteroaryl) could be examined by expanding 
the initial library to include a broader range of substituted aromatic and heteroaromatic 
(e.g. furan, thiophene, pyridine and quinoline) ring systems. 
 
Based on the envisaged SAR studies above, compounds were designed and synthesized in an 
attempt to answer some of the specific queries with a view to identifying a lead series of 
compounds, from initial hits, for subsequent optimization. All hits were envisaged to be 
considered carefully and prioritized according to a number of criteria. The criteria includes 
drug-like (as defined by Lipinski, C. A. et al. [2001]29), lead-like (as defined by Teague, S. J. et al. 
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chemical synthesis, amenability to chemical library generation, and availability and cost of 
starting materials. 
 
2.4 Proposed Synthetic Routes 
 
2.4.1 Synthesis of H157 
 
Following the protocol described in a patent,31 H157 can be synthesized by coupling an 
appropriate amine ester with an acid chloride. The resulting amide is reduced to its 








To synthesize the required amine ester (Scheme 2.4.2), commercially available 4-chloro-3-nitro-
5-sulfamoylbenzoic acid can be converted to the desired amine by reduction of the nitro 
functional group. The carboxylic acid can then be converted to an ester by acid catalyzed 




































The acid chloride can be obtained by converting the commercially available 1-naphthalene 

















carboxylic acid acid chloride
Scheme 2.4.3: Conversion of 1-naphthalene acetic acid to (1-naphthalenyl)-2-ethanoyl chloride 













amine ester4-chloro-3-nitro-5-sulfamoylbenzoic acid amine
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2.4.2 The Length of the Alkyl (-CH2-) Spacer 
 
To investigate the lengthening of the side chain (spacer between the aromatic moiety and the 
amine nitrogen), a simple retrosynthetic analysis was proposed based on having three CH2 units 
between the nitrogen and aromatic moiety (Scheme 2.4.4). This procedure, however, can be 
easily adapted to have CH2 units of more than three as shown below. Two main disconnections 
were identified: (I) Wittig C=C and (II) amide formation. 
 
Based on the (I) Wittig disconnection the following synthetic scheme (Scheme 2.4.5) was 
proposed. This synthetic scheme has been further adapted to include derivatives having a 
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It was envisaged that coupling the amine ester scaffold (synthesis described in Chapter 2.4.1; 
Scheme 2.4.2) with an appropriate commercially available chloro- acid chloride of variable 
chain lengths, would give the desired amide. The chloro- amide ester could be converted into a 
















































Targets (carboxylic acid)amine alkane
where n = 1,2,3,4, etc
Scheme 2.4.5: Proposed synthesis of lengthened “side chain” derivatives of H157 based 
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phosphorane by reaction with an inorganic base. The phosphorane is a prerequisite for a typical 
Wittig-type reaction, and can be reacted with commercially available 1-naphthaldehyde to give 
the desired Wittig product (alkene). The amide and alkene functionalities of the Wittig product 
can be reduced to give the free amine and alkane, and this resulting intermediate product must 
lastly be hydrolyzed to give the desired target products. 
 
Approach (II) involves the formation of an amide bond as the key step (Scheme 2.4.6). Coupling 
of the (already described) amine ester with an appropriate acid chloride would give the desired 
amide intermediate. Synthesis of the acid chloride also involves a typical Wittig reaction. 
Commercially available ethyl bromoacetate can be converted into a phosphonate salt by 
reaction with triphenylphosphine. The reaction of the phosphonate salt with an inorganic base 
gives the desired phosphorane, which can then be coupled with 1-naphthaldehyde under 
standard Wittig conditions to give the alkene ester. The alkene can be converted to the alkane 
by standard reduction of alkenes with H2 on Pd/C. The ester moiety must be converted to the 
acid chloride, so initially the ester is hydrolyzed to the carboxylic acid, which is then converted 
to the acid chloride by reaction with thionyl chloride. At this stage, the two key intermediates 
can be coupled to together to give the desired amide ester. Following approach (I), the amide 
must be reduced to the amine, and the ester hydrolyzed to the carboxylic acid to give the 











































(e.g NaOH or K2CO3)
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(key step - amide formation)
Scheme 2.4.6: Proposed synthesis of lengthened “side chain” derivatives of H157 based 
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2.4.3 The Nature of the Spacer and Replacement of the Naphthyl Group by 
Different Cyclic and (Hetero)Aromatic Moieties 
 
In the SAR studies it was envisaged that derivatives of H157 where the nature of the “side-
chain” is modified would be synthesized. These included derivatives in which a heteroatom is 
introduced and the naphthyl group is replaced with other (hetero)aromatic moieties. The 
following retrosynthetic scheme (Scheme 2.4.7) was designed to carry this out. 
 
This scheme involves a FGI from an amide to a secondary amine, followed by the 1,2-









The key step of this reaction involves the coupling of the required conjugated amide with an 
appropriate amine, alcohol or thiol. To make the conjugated amide, the amine ester (or amine 
acid where Y = H) scaffold (Chapter 2.4.1) can be coupled with commercially available acryloyl 










where X = OR, SR or NR1R2









Scheme 2.4.7: Retrosynthetic analysis of H157 derivatives where the naphthyl group is 
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alcohols and thiols. The (Michael) 1,4-conjugate addition products can be reduced (and 












2.4.4 Bioisosteric Analogues of H157 
 
The following retrosynthetic scheme (Scheme 2.4.9) shows the possible functional group 
interchanges and disconnections that could be used in order to postulate a procedure for the 
synthesis of both the hydroxamic acid and tetrazole derivatives of H157 starting from the ester 

























      (if Y = Me, Et)
where Y = H, Me, Et





Scheme 2.4.8: Proposed synthesis of H157 derivatives where the naphthyl group is 




















































(ester -> hydroxamic acid)
(hydroxamic acid -> cyano)
(cyano -> tetrazole)
where R = alkyl
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2.5 Methodology and Synthesis of Piretanide-like Analogues 
 
2.5.1 Synthesis of H157 
 
Commercially available 4-chloro-3-nitro-sulfamoylbenzoic acid was converted to 3-amino-4-
chloro-sulfamoylbenzoic acid (RKG211) by the reduction of the nitro group to the 
corresponding amine using stannous(II) chloride.32 Acid catalyzed esterfication of the carboxylic 
acid was carried out using concentrated H2SO4 in the appropriate alcohol giving the desired 
alkyl esters (RKG262 and RKG345) (Scheme 2.5.1). 
 
 
1-Naphthalene acetic acid was converted using thionyl chloride (SOCl2) to the corresponding 
acid chloride. The excess SOCl2 was removed under reduced pressure. The acid chloride was not 
isolated, but the residue dissolved in acetone and immediately added to the aniline RKG262. 
The amide precipitated out of the acetone solution, and was isolated via filtration and purified 
by washing with cold acetone. The amide was reduced to the corresponding secondary amine 
using the commercially available 1M borane-THF complex,33 and work up in glacial acetic acid. 
The amine was isolated via column chromatography, and the ester hydrolyzed to the carboxylic 
acid using sodium hydroxide in a solution of methanol to give the target compound RKG256 











EtOAc, 70 oC, 1h
ROH, H2SO4
reflux, 5h
RKG211 (87%) where R = Me   RKG262 (96%)
             R = Et     RKG345 (93%)
























As can be seen in Scheme 2.5.2, when the work-up of the reduction with borane-THF complex 
was performed using aqueous 3M HCl, only the alcohol RKG250BF4 was obtained. This 
demonstrates that the ester may be hydrolyzed in the presence of the aqueous acid, and the 
resulting carboxylic acid is further reduced by the excess borane, via an acyloxyborane 
intermediate, resulting in the formation of the alcohol. Based on this conclusion, the reduction 
was repeated using the weaker glacial acetic acid instead of the aqueous acid. After column 
chromatography, the target molecule (RKG252COL1) was obtained in a low yield of 27% 
accompanied by the alcohol RKG252COL3 (28%). This probably was a result of the glacial acetic 

































RKG252COL3 (28%)R = Me    RKG252COL1 (27%)
R = H      RKG256 (77%) (H157)
NaOH, MeOH, reflux, 2h
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2.5.2 The Length of the Alkyl (-CH2-) Spacer 
 
Approach (I): 
Initially, amine (RKG211) was reacted with 3-chloropropionyl chloride to give the amide 
(RKG204(ii)). The corresponding Wittig phosphonium salt was synthesized by refluxing the 
halogenated RKG204(ii) with triphenylphosphine in toluene. Applying the standard protocol for 
Wittig reactions, the phosphonium salt is converted into the corresponding phosphorane using 
a base, like NaOH or K2CO3, in an aqueous solution. Abstraction of the β-hydrogen (in relation 
to the amide carbonyl) was the desired pathway by the base. However, the apparently more 
acidic α-hydrogen was instead abstracted, leading to the stable conjugated product RKG209. 
This α-H abstraction led to formation of the intermediate enolate, which underwent conjugate 
elimination of the triphenylphosphine, a good leaving group. This E1cB-type elimination 
resulted in the formation of the conjugated product RKG209 (Scheme 2.5.3). 
 
With hindsight, the failure to obtain the desired product (phosphorane) was not a surprise, but 
obtaining the conjugated product prompted its use for nucleophilic (Michael) addition 
reactions, as well as the synthesis of other derivatives of H157 (piretanide-like) analogues 


















































































Scheme 2.5.3: Attempted synthesis of lengthened “side chain” derivatives of H157. 
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After the failure to produce the desired phosphorane, a decision was made to attempt a similar 
protocol using a longer chain acid chloride in which elimination of the triphenylphosphine 
would not be possible. Thus the amine RKG211 was reacted with 4-chlorobutyryl chloride to 
give the halogenated amide (RKG210) using the same protocol as discussed with 3-
chloropropionyl chloride. The phosphonium salt (RKG212) was also synthesized as discussed 
previously. The phosphonium salt was dissolved in H2O and after the addition of NaOH, 
allowing the reaction to stir for 40 hours and acidic work-up (standard procedure), a precipitate 
formed. This precipitate was isolated, washed and dried in vacuo. 1H, 13C NMR and mass 
spectroscopy analysis showed that the product was again not the desired phosphorane, but 
suggested the formation of a 10-membered macrocycle (RKG214) in a quantitative yield. This 
may be due to an intra-molecular nucleophilic substitution reaction involving the deprotonated 
































































































Scheme 2.5.4: Attempted synthesis of lengthened “side chain” derivatives of H157. 














Due to the failure of approach (I), the second approach via the amide retrosynthetic 
disconnection was evaluated. This approach would consist of coupling the aniline (RKG262) 
with an appropriate acid chloride synthesized via Wittig chemistry. 
 
Accordingly, ethyl bromoacetate was reacted with triphenylphosphine to give the phosphonium 
salt (RKG217) in quantitative yields. Using either NaOH or K2CO3 as the base in the standard 
Wittig procedure, the desired phosphorane (RKG218) was obtained also in comparably high 
yields. The phosphorane was coupled with 1-naphthaldehyde to give the desired alkene 
RKG258. The mixture of alkene and unreacted aldehyde (which was used in slight excess in 
coupling step) was isolated via flash chromatography, and subjected to hydrolysis using NaOH. 
Before acidification of the reaction mixture to obtain the free acid, the intermediate carboxylic 
anion was easily extracted into an aqueous phase. The pH of the aqueous phase was adjusted 
to acidic, resulting in the precipitation of the desired carboxylic acid (RKG259). The precipitate 
was filtered off and dried in vacuo, giving the carboxylic acid in a high yield (86% over two 
steps) and purity. The carboxylic acid was converted into the acid chloride with SOCl2, and 
added to a solution of aniline (RKG262) in acetone. After 6 hours of stirring at room 
temperature (~20 °C) had elapsed, the amide (RKG260) had precipitated out, and was filtered 
off and washed to yield a pure white product (Scheme 2.5.5). The reaction was also performed 




























Once amide RKG260 was obtained, it was noted that borane can reduce both amide and alkene 
moieties to amines and alkanes respectively. This was accordingly attempted but, as described 
in the previous chapter, the problem of the ester group being hydrolyzed by the slight presence 
of water in the acidic work-up, and subsequently being reduced by the excess borane to the 
alcohol, was a recurring one.  
 
To circumvent this problem, the alkene moiety of RKG260 was first hydrogenated using H2/Pd-C 
in methanol. The reaction was monitored over 5 days via TLC. During this time the alkene and 
alkane co-ran on the TLC. Excess catalyst (Pd-C) was added and the reaction was left stirring 

























NaOH, EtOH, reflux, 2h
SOCl2
100 oC, 1hacetone, rt, 6h
RKG258
(86% (over 2 steps))
RKG218 (93%)RKG217
(quantitative)
where R = Me     RKG260 (71% (over 2 steps))
            R = H         RKG223 (80% (over 2 steps))
Scheme 2.5.5: Synthesis of lengthened “side chain” lkene derivatives (RKG260 and 
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the Celite© was washed thoroughly with methanol. The solvent was removed under reduced 
pressure, yielding a yellowish/white powder. 1H and 13C NMR analysis revealed that the 
reaction had not gone to completion, and that a mixture of starting material (alkene) and 
desired product (alkane) was obtained. 
 
At this point, two alternative approaches were considered in order to obtain the desired 
analogues of H157: 
 
(i) excess styrene, or another volatile alkene, could be used to mop up any excess 
borane before the acid work-up step is performed, and 
(ii) the carboxylic acid (alkene) (RKG258) could be hydrogenated to the alkane with H2 
on Pd-C, before converting it to the acid chloride, and clipping it onto the aniline.  
 
Following approach (II), hydrogenation of the carboxylic acid RKG258 to the corresponding 
alkane with H2 on Pd-C was envisaged. The reaction was attempted using a 1:1 mixture of EtOH 
and THF, and left to stir for 48 hours under an atmosphere of H2 gas. Following the general 
reaction procedure, a white powder was obtained, but 1H and 13C NMR analysis confirmed it to 
be a mixture of both alkene and alkane. At this juncture, hydrogenation of the ester RKG327 
was considered. The reaction was performed in a 1:1 mixture of EtOH and EtOAc to help 
facilitate solubility, and left to stir for 48 hours under an atmosphere of H2 gas. A clear orange 
oil was obtained following the general reaction procedure, and desired alkane RKG329 was 
obtained in a 95% yield. This ester (RKG329) was hydrolyzed to the corresponding carboxylic 
acid RKG332 using NaOH following the same protocol as discussed above. The carboxylic acid 
(RKG332) was converted to the acid chloride using SOCl2, and immediately reacted with the 
aniline RKG262 resulting in amide RKG333 in a yield of 58% over the two steps. Borane 
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which was isolated using column chromatography as a clear brown oil in a low yield of 21%. The 
methyl ester group of compound RKG335 was hydrolyzed to the corresponding carboxylic acid 









































where X = OH     RKG332 (92%)
            
            X = Cl
SOCl2
100 oC, 1h
acetone, 20 oC, 18h
where Y = Me     RKG335 (21%)
            
            Y = H         RKG340 (58%)
NaOH, MeOH
reflux, 8h
(i) BH3.THF, reflux, 3h
(ii) acetic acid, reflux, 1h
RKG333 (58% (over 2 steps))
RKG329 (95%)RKG327 (quantitative)RKG218
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After obtaining the desired target RKG340 with a three carbon methylene spacer as well as 
H157, the one carbon methylene spacer derivative was next targeted. The compound was 








Commercially available 1-naphthoyl chloride was coupled with aniline RKG345 resulting in the 
formation of amide RKG409 in a yield of 69%. Instead of using the borane.THF complex for the 
reduction of the amide group, as previously performed, sodium borohydride in a solution of 
BH3 etherate in diglyme was used. Following the reduction procedure,
31 and after work-up, the 
desired amine RKG414F2 was isolated using column chromatography in a yield of 27%. 
Hydrolysis of the ethyl ester to the free carboxylic acid was carried out using NaOH in ethanol 
and the desired target compound RKG442 was isolated in a good yield of 79%. 
 
2.5.3 Synthesis of H157 Derivatives where the Naphthyl Group is Replaced by 
Different Cyclic and (Hetero)Aromatic Moieties 
 
As previously noted, an unintentional conjugated product (RKG209) was obtained due to a base 
















NaBH4, BH3 ethyl etherate
diglyme, 20 oC, 4.5h
where  R = Et   RKG414F2 (27%)
              R = H    RKG442 (79%)
RKG409 (69%)
NaOH, EtOH, reflux, 2h
RKG345
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phosphorane for a Wittig reaction. It was proposed in the SAR studies of piretanide-like 
molecules that derivatives containing heteroatoms in the side chain would be synthesized and 
compound RKG209 was identified as an ideal starting material for such studies.   
 
Instead of synthesizing the conjugated amide using the initial method via the phosphonium salt, 
the aniline RKG211 was coupled with the available acryloyl chloride to give the desired product. 
The yield for this coupling (30-58%) was not nearly as high as that obtained from the 
elimination reaction (95%), but does save a synthetic step. The conjugated amide RKG209 was 
reacted with various cyclic amines and tert-butyl thiol. The Michael addition reaction was 
accomplished with varying degrees of success. Yields in the range 8 - 65% were obtained. 
However, no reaction was observed using the thiol, and neither for the 4-amino-7-









Due to the low yields obtained above with the aniline and amide, the use of the corresponding 
methyl ester derivatives was attempted (Scheme 2.5.9). Aniline RKG262 was coupled with 
acryloyl chloride to give the conjugated amide RKG251 in a much improved yield of 84%. Four 















acetone, 20 oC, 6h
HNR1R2 or HSR3
MeOH, 20 oC, 20h
where X = pyrrolidine                  RKG2432 (12%)
                   piperidine                   RKG2441 (42%)
                   morpholine                 RKG2431 (21%)
                   4-methylpiperidine    RKG2471 (65%)
                   4-benzylpiperidine     RKG2462 (6%)
                   piperazine                   RKG2461 (31%)
RKG211 RKG209
Scheme 2.5.8: Synthesis of H157 derivatives where the naphthyl group is replaced by 
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resulting again in vastly improved yields of 72 - 82%. Two amides (namely RSON106 and 
RSON105) were selected for the borane reduction step to give the corresponding secondary 
amines. After column chromatography the desired diamine products (RSON108 and RSON109) 











2.5.4 Synthesis of Bioisosteric Analogues of H157 
 
Based on the SAR studies summarized earlier, carboxylic acid bioisoteres, namely the 
tetrazole34,35,36 and hydroxamic acid,37,38 are important analogues of H157. The conversion of 
the methyl ester analogue of H157 to the corresponding hydroxamic acid using the 




















acetone, 20 oC, 20h
HNR1R2
MeOH, 20 oC, 20h
X = morpholine,                                                     RSON104 (78%)
       piperidine,                                                       RSON106 (79%)
       4-methylpiperidine,                                       RSON105 (80%)
       4-benzylpiperidine,                                        RSON112 (82%)
       4-amino-7-chloroquinoline ethylamine,    RKG303A (72%)
(i) BH3.THF, reflux, 20h
(ii) acetic acid
X = piperidine,                          RSON109 (36%)
       4-methylpiperidine,         RSON108 (17%)
RKG251RKG262
Scheme 2.5.9: Synthesis of ester H157 derivatives where the naphthyl group is replaced 




















This reaction was attempted without success. Due to the low yields of the methyl ester 
analogue of H157 from the reduction step, an alternative strategy was adopted. Following the 
literature,37 RKG248 (and RKG346) were reacted with 50% aqueous hydroxylamine solution in 
the presence of a catalytic amount of KCN (Scheme 2.5.11). The reaction was monitored by TLC. 
As described in the literature, KCN is reported to increase the efficiency of transformation form 
the ester to the hydroxamic acid. The reaction appeared to be progressing as a new product 
spot was forming (Rf = 0.03; 1:19, MeOH:EtOAc) as the reaction was monitored at 12 hour 
intervals. In an attempt to drive the reaction to completion, further amounts of 50% aqueous 
hydroxylamine solution and KCN (approximately half molar equivalents) were added at the 12 
hour intervals. The methyl ester reaction appeared to be complete after 3 days (the ethyl ester 
reaction appeared complete after 6 days). A small amount of precipitate formed and was 
filtered off. This precipitate was determined to be the hydroxylamine hydroxamic acid salt as 
confirmed by 1H and 13C NMR in d6-DMSO. The hydroxamic acid could be isolated via column 
chromatography as a brown oil, which later crystallized to a white solid. The method was then 
applied to the methyl ester analogue of H157 to obtain the hydroxamic acid analogue and the 















Scheme 2.5.10: Proposed synthesis of hydroxamic acid bioisostere derivative of H157 



















To obtain the tetrazole analogue of H157, the following reaction procedure was initially 
proposed (Scheme 2.5.12) and attempted. This method avoids the borane reduction of the 





































NaN3, NH4Cl, DMF, 90 
oC
RKG364













where X = CO       RKG364 (64%)
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The proposed synthetic route could not be implemented as the first step involving the 
conversion of the hydroxamic acid moiety to the cyano group using phosphorous tribromide 
was unsuccessful. Through numerous attempts the reactions were monitored using TLC and the 
formation of numerous (and co-running) products was observed. Spots were isolated using 
column chromatography but none of them could be confirmed as the desired cyano product 
using 1H NMR spectroscopy. Phosphorous tribromide is a very harsh reagent, and studying the 
protocol as described in the literature,39 it was further observed that all the aromatic 
hydroxamic acids that were used were simple aromatic compounds bearing very few or no 
other functional groups. The solubility of RKG364 in toluene could have also been a 
contributing factor to the reaction being unsuccessful as even at a reflux temperature of >110 

























Based on the in-depth SAR studies that were initiated at the start of the project, there are many 
parts of the piretanide-type lead compound H157 that could be studied. Unfortunately, due to 
time constraints and the need to focus on other aims of the project, not all of the highlighted 
SAR studies described in Chapter 2.3 could be carried out. The successful synthesis of H157 and 
its derivatives bearing an altered “side-chain” length, numerous carboxylic acid and ester 
derivatives bearing hetero atoms, as well as heterocyclic and aromatic moieties in place of the 
naphthyl functionality, and the hydroxamic acid bioisostere of H157 were achieved. All final 
target compounds and relevant intermediate compounds that were synthesized were 
submitted for testing in the sorbitol uptake inhibition (NPP) assay as well as for in vitro testing 
against chloroquine sensitive and chloroquine resistant strains of Plasmodium falciparum. The 
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Tuberculosis (TB) is a chronic or acute bacterial infection caused by Mycobacterium tuberculosis 
(Figure 3.1). It primarily attacks the lungs, but there are cases where the central nervous 
system, circulatory system, genitourinary system, bones, joints, lymph nodes and skin are also 
affected. Tuberculosis can also be caused by Mycobacterium bovis, M. africanum, M. canetti 











The earliest traces of Mycobacterium tuberculosis have been detected in the remains of 
fossilized bison dating back some 18,000 years.3 It is still debated whether tuberculosis 
originated from cattle and at some stage transferred to human, or whether it came from a 
common ancestor.4 The earliest tubercular decay observations in prehistoric human remains 
date back approximately to 4,000 BC. There has also been evidence found in the spines of 
mummies dating around 3000-2400BC.5 Scrolls and writings of the ancient Babylonian, Egyptian 
and Chinese civilizations also refer to and describe the presence of tuberculosis.6 
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Tuberculosis was declared a global emergency in 1993 by the World Health Organization 














bacterium. Statistics from WHO reveal that a person is infected with TB every second. In the 
year 2005 alone, 8.8 million people contracted the disease and approximately 1.6 million died 
as a result.7 The statistics are overwhelming due to fact that if tuberculosis is detected early, it 
is curable. However, the prevention of tuberculosis is being continually challenged by the 
emergence of multi-drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB), the 
rise in HIV-associated TB, the neglect of TB control programs and poor health systems (mainly 
in developing nations).1,7 The WHO further predicted that if something is not done to counter 
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this growing epidemic, approximately 35 million people will die as a result of tuberculosis in the 
next 20 years.7  
 
3.1 Symptoms and Transmission 
 
Transmittance of TB occurs when a person with active pulmonary TB coughs, sneezes, speaks, 
or spits, releasing small bacteria-carrying droplets (aerosol) into the air (Figure 1.2.3), and these 
particles are inhaled by a non-infected individual in close proximity. The risk of contracting the 
disease is increased in areas where TB is common, unsterilized instruments and needles are 
used (tattoos, circumcisions and illicit drug abuse), employees and residents abide in highly 
congested settings, medical services are minimal (low-income populations), patients are 
immunocompromised by other conditions (e.g. suffering from HIV/AIDS or using 
immunosuppressant drugs) and health workers are attending to high-risk patients.8 Another 
route of transmission of TB is through the skin. This route, however, is less common, and the 
handling of the bacterium by pathologists and laboratory technicians with open skin wounds 
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The symptoms of a TB-infected person, include prolonged coughing, coughing up of mucus 
containing blood, chest pains, difficulty to breathe, fever, chills, night sweats, weight loss, loss 




Approximately 90 percent of all TB infections fall under the classification of asymptomatic, 
latent TB (LTB). In most of these cases, the human body’s immune system may inhibit or 
destroy the bacteria. Only 5 to 10 percent of people who are infected with TB actually develop 
the active disease, but of these, more than 50 percent die if the active TB disease is 
untreated.6,7 Upon contraction of TB, there are two possible development stages of the disease, 
namely the primary stage and the secondary stage.  
 
Primary TB: 
This primary stage of infection usually passes by unnoticed by the exposed subject as there are 
no noticeable symptoms, and the TB is not contagious during this phase either. Infection starts 
when the mycobacteria come in contact with pulmonary alveoli. The body’s immune cells, that 
destroy foreign material, detect and engulf the TB bacteria by aggregating to form literally a 
“wall” around the inactive bacteria. The contained bacteria are then transported to the local 
(mediastinal) lymph nodes. The wall is made up of aggregated macrophages, T lymphocytes, B 
lymphocytes and fibroblasts.2,12 It is within these tubercles or granuloma (alveolar 
macrophages), that the mycobacteria can remain inhibited and inactive, and even eventually 
destroyed as long as the subject’s immune system remains strong.12,13 Over time, the tubercles 
can gradually gather calcium deposits, and form what is known as a Ghon focus. Permanent 
scars, which can be seen as dark shadows in the lungs, are a result of the healing of the initial 
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awaiting a decline in the immune system, resulting in latent TB (secondary TB). However, within 
the tubercles, the mycobacteria may multiply resulting in active primary TB. It is at this stage 
that the symptoms, including coughing, fever, night sweats and weight loss, become prevalent. 
This stage can be recognized with the use of X-rays (Figure 1.2.4), by observing dark shadows in 









Secondary (latent) TB: 
As mentioned above, the mycobacteria can remain dormant within the tubercles for many 
years before becoming active and multiplying. This “awakening” is usually induced by the 
weakening of the body’s immune system. This weakening of the immune system is often a 
result of HIV/AIDS, or the use of immunosuppressant drugs. The mycobacteria replicate, 
resulting in the formation of more and more tubercles, and progressively destroy lung tissue. 
The mycobacteria spread around the body via the bloodstream, and can develop secondary TB 
lesions in the lung apices, peripheral lymph nodes, kidneys, brain, and bone.15 At this stage, the 
coughing up of blood or phlegm is a common symptom, and the disease is contagious to others. 
 
 
Figure 3.4: Chest X-rays of lungs reveals the presence of bilateral pulmonary infiltrate (white 















Diagnosis of tuberculosis is a not an easy process because the culturing procedure of this slow-
growing bacteria is very difficult in a laboratory. There are several different tests that are done 
in order to diagnose if a person has TB.  
 
To diagnose if an individual is infected with latent tuberculosis, a tuberculin skin test is carried 
out. This is performed by injecting purified protein derivatives, derived from M. tuberculosis, 
into the skin (Figure 1.2.5). If the subject has been exposed to the infection, swelling would be 
observed at inspection 48 to 72 hours later. This is possible as the subject would have acquired 
a hypersensitivity to the mycobacteria, even though the disease is not in an active state.  This 









For the diagnosis of the active pulmonary tuberculosis, sputum or other bodily fluids and tissue 
can be analyzed for the bacterium, including staining (Figure 1.2.6), microbiological smears and 
cultures, in combination with a chest X-ray to show any unusual anomalies in the lungs. Once 
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diagnosed, further testing is performed in order to determine which strain of the mycobacteria 
is present. This is done because different drugs are used to treat different strains of TB more 










New TB diagnostic tests are constantly being developed. Tests that are less time consuming, 
cheaper and more accurate would be the desired attributes, especially in the developing world. 
The use of genetic engineering and new polymerase chain reaction (PCR) are some of the new 
techniques being developed to rapidly duplicate any hereditary bacterial material and to 
identify bacterial DNA.2,6,16  
 
3.4 Prevention and Treatment 
 
Preventative measures to protect a person from being exposed to the TB bacteria would 
obviously be first choice in battling TB. Ventilation systems disperse the bacteria, and lower the 
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risk of being inhaled in public places, and ultraviolet light also can reduce the threat by killing 
large amounts of the bacteria. 
 
Vaccines, containing weakened bacteria, have been developed as another preventative 
measure. The M. bovis-derived bacillus Calmette Guerin (BCG) vaccine, developed at the 
Pasteur Institute in France between 1905 and 1921, is still the most effective preventative 
measure against infection amongst children.17 However, there is no vaccine currently available 
that offers adults complete and reliable protection. Recently, there have been concerns about 
the safety of BCG being used in vaccinating HIV-infected patients as results have varied 
significantly in trials.18,19 Newer vaccines that are being developed include a recombinant TB 
vaccine developed by the National Institute of Allergy and Infectious Disease (NIAID) in the 
United States which entered clinical trials in 2004,20 and the TB vaccine, MVA85A, developed by 
a group from Oxford University which is currently in phase II trials in South Africa.21 
 
Drug therapy remains to this day the most effective way of treating tuberculosis. The two most 
effective first-line antibiotics are rifampicin and isoniazid. Single-drug treatment is susceptible 
and at risk to the bacteria developing antibiotic resistance,22 hence, combination or multiple 
drug therapy is administered to patients with active pulmonary TB. Unlike the typical treatment 
of other bacterial infections, the course of antibiotic treatment for mycobacteria (regimen) is 
much longer, and usually ranges between 9 and 12 months. The most commonly prescribed 
combination of antibiotics for multi drug therapy includes isoniazid, rifampicin (rifampin), 
pyrazinamide, ethambutol and streptomycin. In some cases, latent TB is still treated by single-
drug therapy. The long term treatment of latent TB, with the combination drug therapy of 
rifampicin plus pyrazinamide, has recently been advised against by the Centers for Disease 
Control and Prevention (CDC) due to high incidences of hospitalization and death of patients 
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The effective treatment of TB using combination and multiple drug therapy has come under 
threat by the emergence of MDR-TB and XDR-TB. Drug resistance is believed to be a result of 
inadequate drug therapy, low quality medication, and the inappropriate use of drugs, for 
example, patients not taking the prescribed drugs for the total 9 to 12 months treatment 
course. Tuberculosis strains which are resistant to both first-line antibiotics are classified as 
MDR-TB. The classification of XDR-TB is used for a TB strain which is also resistant to three or 




The growing amount of global TB cases, the threat of MDR-TB, and the emergence of XDR-TB 
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3.5 Tuberculosis Drug Targets 
 
The mechanisms of action and targets of antituberculosis agents are diverse. The targets of the 
first-line antituberculosis agents: (i) isoniazid inhibits the synthesis of mycolic acid by targeting 
primarily InhA, and secondarily KasA and DfrA; (ii) rifampicin inhibits transcription by targeting 
the RNA polymerase β-subunit; (iii) ethambutol inhibits arabinogalactan synthesis by possibly 
targeting EmbB; (iv) pyrazinamide’s mechanism of action is currently unknown, but it is 
believed to possibly inhibit FAS-I or alter membrane energetics; and (v) streptomycin inhibits 
protein synthesis by targeting the 30S ribosomal subunit.24 
 
The targets of second-line antituberculosis agents: (i) capreomycin, kanamycin and amikacin all 
inhibit protein synthesis; (ii) fluoroquinolones inhibits DNA gyrase; (iii) ethionamide inhibits 
mycolic acid synthesis by targeting InhA; (iv) cycloserine inhibits peptidoglycan synthesis by 
blocking the synthesis and use of D-alanine (Ala) by targeting Ala racemase and D-Ala-D-Ala 
ligase; and (v) para-aminosalicylic acid by inhibiting folate metabolism by possibly targeting 
dihydropteroate synthase.24 
 
Tuberculosis continues to be a global threat despite all the above mentioned effective 
antituberculosis agents. The development of new drug candidates and the search for new 
targets is a continual process and currently several chemical entities are in clinical trials, 
including two approved fluoroquinolones, moxifloxacin and gatifloxacin,25,26 rifampicin 
analogues,27-29 SQ109 (ethambutol analogue),30 TMC207 (diarylquinoline),31 sudoterb (tetra-
substituted pyrrole),32,33 nitroimidazoles34-38 etc., as well as, many compounds, in the early 
stages of drug development, are showing good promise, including linezolid (3-aryl-2-
oxazolidinone antibiotic) and its analogues,39-41 β-lactams42,43 and phenothiazines44-48 etc.. In 
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resistance is expected to continually evolve. In this light, a deeper understanding of the disease 
basic biology, and how small molecules can interact with and modulate its existence, is key to 
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Chapter 4 
Acetolactate Synthase (ALS) as a Target for Anti-
Tuberculosis Agents and Known Inhibitors 
 
Acetolactate synthase (ALS), also known as acetohydroxyacid synthase (AHAS), is the enzyme 
which catalyses the first step in the biosynthesis of branched chain amino acids (valine, leucine, 















Figure 4.1: The biosynthetic scheme of branched amino acids, demonstating where ALS is needed 
































































































































Acetolactate synthase catalyzes the decarboxylation of pyruvate, which is then condensed with 
either another molecule of pyruvate or 2-ketobutyrate. The condensation results in the 
formation of the amino acid biosynthetic precursors, namely 2-acetolactate (AL) or 2-aceto-2-
hydroxybutyrate (AHB) respectively. With the aid of thiamin diphosphate as the principle 
cofactor, ALS cleaves the carbon-carbon bonds adjacent to the carbonyl group. Although their 
role is not currently understood with respect to the catalyzed decarboxylation reaction, a Mg2+ 
cation and flavin adenine dinucleotide (FAD) are also present within the structure.1,3 
 
The ALS enzyme is believed to be a biological target for several classes of herbicides (Figures 4.2 
and 4.3) including sulfonyl ureas,4,5 imidazolinones,5 triazolopyrimidines4,5 and pyriminidinyl 
oxybenzoates.5 Up until 2002 the structure of ALS had not be solved. In 2001, the catalytic 
subunit of ALS from Saccharomyces Cerevisiae was crystallized by Dugglebury, R. G. et al. 
[2001]5 Following soon afterwards, the complete structure of the crystal structure of yeast ALS 
was published.6 It was shown that the yeast ALS enzyme shares at least 26% homology with the 
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The antituberculosis activity of some ALS inhibitors was reported in 1998 by Grandoni, J. A. et 
al. [1998].2 More recently, the inhibition of ALS from M. avium by sulfonyl ureas and 
imidazolinones was published by Zohar, Y. et al. [2003]7 (Figure 4.3). The results showed that 
the inhibition of the M. avium enzyme by the tested sulfonyl ureas and imidazolinones was 
different to that of other plant ALSs previously reported. This highlights and demonstrates the 








































































Triasulfuron (TS)Metsulfuron methyl (MSM)
Primsulfuron methyl (PSM)Sulfometuron methyl (SMM)
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4.1 Sulfonyl Ureas 
 
Sulfonyl ureas fall into the class of compounds known as herbicides. They were first created in 
the mid-1970s and have been on the market since 1982. Due to their extraordinary potency, 
their application dose was one hundred times smaller than the herbicides that they were made 
to replace. In June 1975, the first sulfonyl urea, chlorosulfuron, was formulated as an 
insecticide by a DuPont chemist George Levitt. However, it was discovered during testing that 
the sulfonyl urea had a devastating effect on plants. This observed effect led to an alteration in 
the development of this compound, and in 1978, in was patented as an herbicide by DuPont.8,9 
Unlike traditional herbicides that kill plants via chemical burn, sulfonyl urea herbicides block the 










Another class of sulfonyl ureas has also been developed for the treatment of non-insulin 
dependent diabetes mellitus (NIDDM).8 Glibenclamide, and structurally related meglitinide and 
tolbutamide (Figure 4.1.2), are commercially available anti-diabetic agents, and their mode of 
action is related to their stimulation of insulin release from the pancreas.8,10 This mode of 
action is attributed to their effect on various ion channels. In the literature, glibenclamide 


















































Based on the fact that the yeast ALS enzyme shares at least 26% homology with the 
Mycobacterium tuberculosis enzyme, docking studies in collaboration with GlaxoSmithKline 
(GSK) Stevenage, UK were initiated. These studies have so far resulted in the generation of a 
virtual library of bis-aryl-based sulfonyl ureas. The docking studies concluded the proposal of a 
bis-aryl sulfonyl urea moiety template (Figure 4.1.3) as a source and starting point for the 
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It was proposed that R1 could be heteroaromatic or aromatic moieties bearing other functional 
groups, and could be at the ortho, meta or para position on the ring. For simplicity, the docking 
studies were performed with R2 being a chloro group in the ortho position. It was further 
proposed that the ring could bear other aromatic groups at R2, with variable substituents, at 
the different possible ring positions.  
 
4.1.1 Proposed Synthetic Routes 
 
There are several known procedures that can be followed in order to synthesize sulfonyl urea 









The mechanism of this reaction is shown in Scheme 4.1.2. The first step involves the attack of 
the lone pair of the nitrogen on the amine with the strongly electrophilic carbon of the sulfonyl 
isocyanate. The π-bond to the oxygen is broken as the electrons move to the more 
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carbon reforming the carbon-oxygen double bond, and pushing the π-electrons onto the 
nitrogen. Finally, a proton transfer takes place, and the disubstituted sulfonyl urea is formed. 
 
4.1.2 Synthesis of Sulfonyl Ureas 
 
Bromoanilines were (initially) used as the starting primary amine as palladium(0) mediated 
Suzuki catalyzed coupling reactions were initially envisaged. Suzuki coupling reactions follow 
the procedure of reacting a bromo-substituted compound with a boronic acid, and, hence, a 
library of biaryl substituted sulfonyl ureas could be created. 
 
The synthesis of six sulfonyl ureas was initially envisaged. The reaction was achieved by 
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isocyanate to the solution in a dropwise manner. The reaction is left to stir at room 
temperature overnight (18 hours) under an atmosphere of nitrogen. The precipitate which 
forms is filtered off, yielding the sulfonyl urea. The sulfonyl urea can be purified further (if TLC 






The following six sulfonyl ureas (shown below with their respective yields) were synthesized 
using the above mentioned protocol.  
 
The low yields of the sulfonyl urea RKG1492 may be attributed to the poor nucleophilicity of 
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pyridinyl ring. To increase the numbers of sulfonyl ureas for preliminary SAR studies, the 






















































































































































































































Imazapyr and other imidazolinone compounds were first discovered in 1956 by a BASF chemist 
named Sydney Upham, and these compounds were later patented due to their anticonvulsant 
activity. Dr. Marinus Los received much national recognition after discovering the unique and 
important herbicidal benefits of these compounds, and, today, this class of herbicidal 
compounds is known as imidazolinones. Imazapyr is a member of this group of compounds, and 











Imidazolinones are very attractive herbicides as they are very effective at low rates. This is due 
to the fact that they put less chemical load on the environment when used at the 
recommended labeled rates (compared with traditional and other commercially available 
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specific inhibition of ALS,2,6,12,13 and they are considered to be virtually non-toxic (determined 
by EPA-required testing). Acute human toxicity is measured by its LD50 value, and imazapyr 
(Habitat®) has an oral LD50 value of >5,000 mg/kg body weight, and a dermal LD50 value of 
>2,148 mg/kg body weight.14 
 
Studying the literature, imidazolinone derivatives have demonstrated a wide range of 
pharmacological activity, including anticonvulsant,15,16 anti-Parkinsonian17 and monoamine 
oxidase (MAO) inhibition.18 
 
4.2.1 Proposed Synthetic Routes 
 
As described in the patents,19,20 quinoline-type imidazolinone derivatives are synthesized in the 
following manner (Scheme 4.2.1): 
 
The substituted quinoline-2,3-dicarboxylic acid anhydrides are synthesized from di-, tri- and 
tetrasubstitued anilines. The quinoline-2,3-dicarboxylic acid anhydride is reacted with an 
aminocarboxamide or aminothiocarboxamide resulting in the formation of an isomeric mixture 
of quinaldic acid and 3-quinolinecarboxylic acid. The mixture is reacted with about 2 to 20 
molar equivalents of sodium or potassium hydroxide dissolved in water or a mixture of water 
and alcohol resulting in the formation of the desired 2-(5,5-disubstituted-4-oxo(or thio)-2-

























4.2.2 Imidazolinone Analogues 
 
The effective inhibition of ALS by Imazapyr, and other related imidazolinones, makes this class 
of compounds an excellent candidate for exploration for possible anti-TB activity. The inhibition 
of ALS (extracted from corn seedings) by Imazapyr, Imazaquin and the benzene analogue of 
Imazapyr was reported by Shaner, D. L. et al. [1984]12 Although several literature reports can be 
found on the inhibition of ALS by imidazolinones, little can be found on their structurally related 
benzene analogues. The synthesis and antimycobacterial evaluation of a small exploratory 


































where  W = O, S
             R1, R2 = H, alkyl, aryl




















quinaldic acid 3-quinolinecarboxylic acid
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4.2.2.1 Synthesis of Imidazolinone Benzene Analogues  
 
To obtain the imidazolinone benzene analogues, the last two steps described in the patents19,20 
(Scheme 4.2.1) were embarked on. The exception was that commercially available phthalic 
anhydride would be used as the initial starting material instead of the synthesized substituted 
quinoline-2,3-dicarboxlyic acid anhydrides. The synthesis of imidazolinone benzene analogues 










An amino-amide hydrochloride salt was dissolved in a mixture of 2 molar equivalents of 
triethylamine in deionised water. This mixture was added to a solution of commercially 
available phthalic anhydride dissolved in dioxane, and the resulting reaction mixture was stirred 
at room temperature for 30 to 45 minutes. The reaction mixture was concentrated by the 
removal of the solvent under reduced pressure, and an aqueous solution of 1M HCl added. The 
















Et3N, H2O, dioxane, 20 
oC
where R1 = H, R2 = H              (RKG114A, 77%)
             R1 = H, R2 = -CH2-Ph  (RKG123A, 93%)
             R1 = H, R2 = -CH2-iPr  (RKG125A, 99%)
             R1 = H, R2 = -iPr          (RKGANT3, 99%)
.HCl
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filtered off, washed with cold aqueous 1M HCl and water, and dried in vacuo to afford the 
phthalamic acid in good yield and high purity (Scheme 4.2.2).  
 
The second step involves a base-mediated intramolecular cyclisation of the phthalamic acid to 
the imidazolinone benzene analogue derivatives (Scheme 4.2.4). The excess base is believed to 
deprotonate the carboxylic acid group rendering it a carboxylate anion, which prevents it from 
being accessible for nucleophilic attack as the negative charge is stabilized by resonance within 
the carboxylate. Under the high reaction temperature, the primary amide nitrogen can attack 
the secondary amide carbonyl carbon resulting in the intramolecular cyclisation. The formation 
of an imine occurs, and results in the elimination of a hydroxyl anion. The mechanism of the 









































Scheme 4.2.3: Proposed mechanism for the base-mediated intramolecular cyclisation of the phthalamic 
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The phthalic acid is added to a solution of 4 molar equivalents of NaOH dissolved in water. The 
reaction mixture is stirred and refluxed for 3 hours, then allowed to cool to room 
temperature.Concentrated HCl was added to adjust the pH to promote precipitation of the 
product. The precipitate was isolated, purified and dried in vacuo to afford the pure 
imidazolinone derivatives (Scheme 4.2.4). 
 
4.2.2.2 Attempted Polymer-Assisted (Solid Supported) Synthesis in Solution 
 
In order to render the possible synthesis of libraries of this class of compounds, the use of a 
solid supported base in the last step was considered. Commercially available Amberlyst (A-29) (-
OH) resin was chosen to be the solid supported base in an attempt to effect the base-mediated 
intramolecular cyclisation step. The solid supported base was envisaged to have a bifunctional 
role; firstly, to be the source of a basic hydroxyl anion which performs the base-mediated 
cyclisation step, and, secondly, for the deprotonated carboxylic acid group to ionically bond 









where R1 = H, R2 = H              (RKGAS4EGLY, 42%)
             R1 = H, R2 = -CH2-Ph  (RKGAS4EPA, 75%)
             R1 = H, R2 = -CH2-iPr  (RKGAS4ELEU, 54%)
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benzene analogue could then be easily separated from the reaction mixture by filtration and 
washing, and subsequent acidification should result in resin detachment yielding the desired 









Unfortunately, the envisaged solid supported base step did not yield the desired imidazolinone 
benzene analogues. The glycinamide phthalamic acid (RKG114A) (where R1 = R2 =H) was chosen 
as the candidate for attempting the base-mediated cyclisation step using the solid supported 
base. The reaction was attempted using the standard conditions described when using the free 
base (NaOH).20 After acidification of the filtered resin, only the starting phthalamic acid was 
obtained. Since the base-mediated cyclisation was not taking place, the reaction was attempted 
with the solid supported base at elevated temperatures. As water boils at 100 oC, NMP was 
used as the polar solvent to reach reaction temperatures above 100 oC. 
 
In Table 4.2.1, below, all the reaction conditions that were attempted are shown. Higher 
reaction temperatures were believed to be what was required to supply adequate activation 
energy to allow for the base-mediated cyclisation using the solid supported base to occur. 
















(i) Amberlyst (A-29) (-OH)
(ii) acidification
phthalamic acid
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observed, however, that when attempting the reaction at 135 oC, a mixture of the starting 
phthalamic acid and benzene dicarboxylic acid was isolated. At 160 oC, no starting phthalamic 
acid was recovered and only benzene dicarboxylic acid was isolated. 
 Table 4.2.1: Various reaction conditions used to attempt base-mediated intramolecular cyclisation 
 
4.2.3 Synthesis of Phthalimides Derivatives 
 
Initially when attempting to synthesize the imidazolinone benzene analogues, the base-
mediated intramolecular cyclisation step was attempted using a catalytic amount (0.4 molar 
equivalents) of base (NaOH). Using an acidic work-up and column chromatography, a new 
product was isolated. The product, however, was not the imidazolinone benzene analogue, but 
rather the phthalimide derivative (Scheme 4.2.6). 
 
Phthalimides are a class of compounds that are not known for, or have shown, anti-TB activity. 
However, the phthalimide moiety has been structurally included in several compounds which 
Experiment Base Solvent Temperature (oC) Yield (%) 
417 NaOH (4 equiv.) H2O 90 42 
418 Amberlyst (-OH) (4 equiv.) H2O 90 -- 
419 Amberlyst (-OH) (4 equiv.) H2O 100 -- 
420 Amberlyst (-OH) (4 equiv.) NMP 135 -- 
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have recently shown good promising antimycobacterial,21 as well anticonvulsant,22,23 activities. 






















where R1 = H, R2 = H              (RKG119A, 67%)
             R1 = H, R2 = -CH2-Ph  (RKG133A, 37%)
             R1 = H, R2 = -CH2-iPr  (RKG131A, 29%)



























Sulfonylcyanoguanidines are a class of compounds known for their activity as thromboxane A2 
(TXA2) receptor antagonists and thromboxane synthase inhibitors,
24-26 and diuretics.27 
Thromboxane A2 is a potential target for the treatment of cardiovascular, renal and pulmonary 
diseases.28-30 Cyanoguanidines are well known to be ATP-sensitive potassium channel openers 
and inhibitors of insulin release31,32 and vascular KATP channel blockers.
33 This activity may lead 
to the treatment of overactive bladder (OAB)31 and metabolic and cardiovascular diseases.34,35 
Cyanoguanidines have also been shown to be HIV-1 protease inhibitors,36 antiproliferate 
(antitumour) agents37 and reversible acetylcholinesterase inhibitors (leading to insecticidal 
activity).38 
 
In the literature, Michaux, C. et al. [2003]26 conducted a study of sulfonyl ureas and 
sulfonylcyanoguanidines as thromboxane receptor antagonists and thromboxane synthase 
inhibitors. Both classes of compounds were identified as dual acting agents with comparable in 
vitro activities. This interesting observation led to the decision to synthesis two 
sulfonylcyanoguanidines (the analogues of two previously synthesized sulfonyl urea derivatives; 
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4.3.1 Proposed Synthetic Routes 
 
Following the literature method described by Hantzsch, A. et al. [1904],39 the 
sulfonylcyanoguanidines were synthesized starting with commercially available dimethyl N-
cyanodithioimine-carbonate. Carrying out two sequential substitution reactions with an amine 








4.3.2 Synthesis of Sulfonylcyanoguanidines 
 
The synthesis of sulfonylcyanoguanidines was initially attempted by a substitution reaction of 
dimethyl N-cyanodithioiminecarbonate with a sulfonamide in the presence of a weak base 
(K2CO3) to yield the desired intermediate product (N-cyano-N’-alkyl/arylsulfonamido-S-methyl-


























where R1, R2 = Alkyl, aryl
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First approach: 
The first step was performed as outlined by Chibale, K. et al. [2002].40 4-
Chlorobenzenesulfonamide and an equimolar equivalent of both finely ground anhydrous 
K2CO3 and dimethyl N-cyanodithioiminocarbonate were added to DMF. The reaction mixture 
was stirred at room temperature for 15 hours. An aqueous solution of 2M HCl was added, and 
the precipitate filtered off, and washed successively with the aqueous solution of 2M HCl and 
diethyl ether, to afford the desired intermediate iso-thiourea in good yield (72%). The second 
step was attempted as described by Dogné, J. M. et al. [2001],24 but using a primary amine (4-
bromoaniline) instead of a sulfonamide. The reaction was conducted as described in the 
literature, but none of the desired product (sulfonylcyanoguanidine) was obtained (Scheme 
4.3.2). Only starting material was recovered after the reaction was worked up. This may be a 








Due to the lack of success using the first approach to obtain the sulfonylcyanoguanidine 
compounds, an alternate strategy was pursued. In this strategy dimethyl N-
cyanodithioiminocarbonate was first coupled with the primary aniline. The resulting iso-
thiourea would then be coupled with the easily deprotonated sulfonamide (using a weak base; 
K2CO3). The deprotonation of the sulfonamide with K2CO3 results in a more nucleophilic 
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Second approach: 
The synthesis of the sulfonylcyanoguanidine compounds (RKG139F3 and RKG151 respectively) 
was performed as described by Dogné, J. M. et al. [2001]24 and Yokoyama, M. et al. [1981].41 
The first step involves the coupling of the primary amine with dimethyl N-
cyanodithioiminocarbonate, by refluxing them together in ethanol for 4 hours. After isolation 
and purification of the iso-thiourea (RKG136A and RKG150A), the intermediate product is 
added to solution of 4-chlorobenzenesulfonamide and K2CO3 dissolved in DMF. The reaction 
mixture is stirred under reflux for 20 hours, and then allowed to cool to room temperature. The 
reaction is worked-up as described in the experimental section, and the precipitate is recovered 
by filtration. The isolated precipitate is dried in vacuo, and recrystallized from boiling methanol 


































O OEtOH, 80 oC, 4h K2CO3, DMF, reflux, 20h
where R = 4-bromophenyl  (RKG136A, 61%)
            R = iso-propyl             (RKG150, quantitative)
where R = 4-bromophenyl  (RKG139F3, 32%)
             R = iso-propyl             (RKG151A, 50%)














Synthetically, acylthioureas have been widely used as the starting block for various 
transformations; examples include the preparation of four-,42 five-,43-49 six-, 45,50,51 and seven-52 
membered heterocyclic ring systems. In industry, the efficient ligand characteristics of N,N-
dialkyl-N’-acyl(aroyl)thioureas with platinum group metals, makes them useful for the 
separation and refinement of platinum, palladium, rhodium, ruthenium, iridium and 
osmium.53,54 
 
From a pharmaceutical perspective, acylthioureas have shown a wide range of promising 
activities and uses, and have been patented due to their observed antidiabetic,55 antiarthritic,56 
antineoplastic,57 local anaesthetic,58 antihyperlipidemic,58 antiproliferative58 (including 
antitumour platinum acylthiourea complexes,59 and quinoline- and quinazoline-acylthiourea 
inhibitiors of PDGF receptor autophosphorylation60), anticoagulant61 (in treatment of cognitive 
problems61 and prostate disorder63,64) and antiviral (inhibition of Hepatitis C virus replication)65 
activities. Other interesting areas of activity of acylthioureas include; herbicidal,66,67 fungicidal,66 
bactericidal,66 insecticidal68 and plant growth regulator69 activities. 
 
An exploratory group of four acylthiourea analogues of previously synthesized sulfonyl urea 
derivatives (RKG1491, RKG1492, RKG1493 and RKG1531) for comparative in vitro testing 
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4.4.1 Proposed synthetic routes 
 
There are many published routes in the literature which describe the synthesis of acylthioureas. 
Katritzky, A. R. et al. [2004]69 have comprehensively reviewed and summarized the synthesis of 















To synthesize the envisaged acylthiourea derivatives, route (vi) (from Figure 4.4.1.1) was 
chosen. This involved reacting an in situ generated acyl isothiocyanate, derived from an acid 
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chloride, with the appropriate primary amine.70,71 This reaction scheme and mechanism is 







The synthesis is described as a 2 step, 1 pot, protocol. The procedure starts with the conversion 
of an aryl acid chloride to the reactive acyl isothiocyanate with ammonium thiocyanate. The 
precipitated salt (ammonium chloride) is filtered off, and the primary amine is added to the 
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Briefly, the first step, in the mechanism, involves a substitution reaction of the chloride with the 
thiocyanate to form an acyl isothiocyanate intermediate in situ. The acyl isothiocyanate is 
extremely reactive and not isolated. The addition of an amine, results in a nucleophilic attack of 
the lone pair of electrons on the amine nitrogen onto the acyl isothiocyanate carbon. The 
electrons flow though the conjugated π-system, resulting in the formation of the enolate. A 
proton transfer takes place to form the hydrogen-bond stabilized enol derivative. Tautomerism 
occurs, and the enol derivative is converted to the more favored amide derivative, the 
acylthiourea. 
 
4.4.2. Synthesis of Acylthioureas 
 
The synthesis of four acylthioureas was initially envisaged. The reaction proceeded by the 
addition of the 4-chlorobenzoyl chloride to a solution of ammonium thiocyanate dissolved in 
acetone. The reaction mixture was stirred under reflux for 30 min, and allowed to cool to room 
temperature. The precipitated salt (ammonium chloride) was filtered off, and the amine added 
to the filtered solution of the acyl isothiocyanate dissolved in the acetone. The reaction mixture 
was stirred under reflux for a further 2 hours and allowed to cool to room temperature 











R(i) NH4SCN, acetone, 30min, reflux
(ii) H2N-R, acetone, 2h, reflux
where R = 4-bromophenyl                          (RKG1541, 72%)
             R = 5-bromopyridin-2-yl                 (RKG1542, 80%)
             R = 4,6-dimethoxypyrimidin-2-yl  (RKG1543, 43%)
             R = iso-propyl                                   (RKG162A, 83%)
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residue, resulting in the formation of a precipitate. The precipitate was filtered off and 



























The envisaged sulfonyl ureas, sulfonylcyanoguanidines, imidazolinones and acylthioureas, as 
well as phthalimides, were successfully synthesized and characterized. All respective target 
compounds, including isolated and pure intermediate compounds, were evaluated for anti-TB 
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Chapter 5 
 New Synthesis of Sulfonyl Ureas 
 
One of the main aims of this project, besides the synthesis of compounds to target new 
permeability pathways and acetolactate synthase in the search of new leads in the attempt to 
treat both malaria and tuberculosis respectively, is to develop efficient synthetic technologies 
for the synthesis of the target compounds.  
 
5.1 Commonly used Methodology 
 
There are several approaches that can be followed in order to generate arenesulfonyl urea 





















































di and trisubstituted sulfonyl ureaarenesulfonyl isocyanates














This method is possibly the most common approach for the synthesis of disubstituted 
arenesulfonyl ureas. The advantage of this method lies in the large number of commercially 
available isocyanates and sulfonamides. However, a major disadvantage is the need for a 
second supplementary step in order to access tri- and tetra-substituted arenesulfonyl ureas. 
Further drawbacks of this approach include the poor solubility of arenesulfonamides in most 
organic solvents, and the fact that arenesulfonamides are less reactive towards isocyanates 
than amines. Hence, a catalyst like cuprous chloride,1 or Lewis acid like boron trifluoride diethyl 




This approach of coupling a highly reactive arenesulfonyl isocyanate with a primary or 
secondary amine appears to be the most straight forward method of preparing both di- and 
trisubstituted arenesulfonyl ureas. However, while the technique and chemistry is simple and 
efficient, this approach is hindered by the limited number of commercially available 
arenesulfonyl isocyanates.  
 
There are, as highlighted and described, limitations to each approach, and so the need for 
developing novel synthetic routes to create diverse arenesulfonyl urea libraries should be 
continually investigated and further developed. A method that generates a vast selection of 
arenesulfonyl isocyanates from a range of commercially available starting materials could, 
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5.2 Proposed Novel Synthetic Route 
 
Another approach to the synthesis of sulfonyl ureas was envisaged. This strategy involves the 
use of 1,2,4-dithiazolidine-3,5-dione,3-5 which should provide an alternative route to the 













The first step involves reacting the 1,2,4-dithiazolidine-3,5-dione with an arenesulfonyl chloride 
in the presence of a weak base. Wood, M. E. et al. [2003]6 observed that the hydrogen on the 
nitrogen of the 1,2,4-dithiazolidine-3,5-dione scaffold is remarkably acidic with a pKa of 2.85 ± 
0.002. This is attributed to the ability of the negative charge created on deprotonation to be 
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will have to be determined; NaHCO3 was determined to be the base of choice in acetonitrile for 
the N-alkylation using alkyl halides of 1,2,4-dithiazolidine-3,4-dione, and pyridine was 
determined to be the base and solvent of choice for N-benzoylation with benzoyl chloride (acid 
chloride).6 The intermediate product is converted to the corresponding arenesulfonyl 
isocyanate in the presence of triphenylphosphine. The mechanism of the conversion from the 













The arenesulfonyl isocyanate is not isolated, and is reacted in situ with a primary or secondary 
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5.3 Methodology Development to Synthesize Sulfonyl Ureas 
 
5.3.1 Synthesis of 1,2,4-Dithiazolidine-3,5-dione 
 
O-Ethyl thiocarbamate (RKG101) (a. k. a. ethyl xanthamidate) is synthesized as detailed by 
Davies, W. et al. [1951],3 and then reacted with (chlorocarbonyl)sulfenyl chloride in a solution 
of triethylamine in diethyl ether to give the cyclized 3-ethoxy-1,2,4-dithiazolin-5-one (RKG104). 
3-Ethoxy-1,2,4-dithiazolin-5-one is coverted to 1,2,4-dithiazolidine-3,5-dione (RKG121A) by 
reaction with concentrated HCl (Scheme 5.4). The yields obtained are comparable to, if not 








5.3.2 Attempted Synthesis of 4-Benzenesulfonyl-1,2,4-dithiazolidine-3,5-dione 
 
The reaction of 1,2,4-dithiazolidine-3,5-dione with commercially available benzene sulfonyl 
chloride was attempted (Scheme 5.5). The reaction was carried out at room temperature (25 



















RKG104, 56% RKG121A, 57%
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Due to the acidity of the proton of 1,2,4-dithiazolidine-3,5-dione, various weak bases were 
utilized (namely pyridine, pyridine with a catalytic amount of DMAP, DMAP, NaHCO3 and K2CO3) 
in DCM or DMF. Comparison studies of using both NaHCO3 and pyridine at 0 
oC was also 
attempted due to the belief that the desired intermediate product (4-benzenesulfonyl-1,2,4-
dithiazolidine-3,5-dione) is unstable at room temperature. Thin layer chromatography 
investigation of the reactions showed the development of new products. However, upon 
isolation using preparation thin layer chromatography, none of the new products could be 








Due the possibility of (further) decomposition of the desired intermediate product while 
separating using column chromatography, toluene and triphenylphosphine were added to the 
reaction mixtures and refluxed. The reactions were monitored again via TLC, and a number of 
new spots appeared. After refluxing for 24 hours, the reactions were quenched and products 
isolated via column chromatography. However, none of the isolated samples could be identified 
as the desired sulfonyl urea product. 
 
Other than the proposal that the intermediate 4-arenesulfonyl-1,2,4-dithiazolidine-3,5-dione 
products may be very unstable and easily decomposed, there are several other observations 




















where base = NaHCO3 or K2CO3; solvent = CH3CN, CH2Cl2 or DMF
             base = pyridine, DMAP or pyridine + DMAPcat; solvent = pyridine, CH2Cl2 or DMF
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Decomposition of 1,2,4-dithiazolidine-2,5-dione in reactions with alkyl halides using DMF or 
DMSO as solvent, as well as at elevated temperatures (40 oC and higher), was observed and 
documented by Wood, M. E. et al. [2003].6 The reactivity and decomposition of 1,2,4-
dithiazolidine-2,5-diones in the presence of amines (and amine bases), respectively, is also well-
documented in the literature by Barany, G. et al. [1980].7 
 
5.3.3 Alternate New Synthetic Route to Sulfonyl Ureas 
 
During attempts to synthesize sulfonyl ureas (above), another, alternative, route to synthesize 
sulfonyl ureas was envisaged. The reaction of 1,2,4-dithiazolidine-2,5-dione (RKG121A) with 































where   X = Cl, Br, I
              R1 = alkyl, aryl
              R2 = alkyl, aryl
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given. The resulting N-alkyl-1,2,4-dithiazolidine-2,5-dione, in the presence of 
triphenylphosphine, were converted to isocyanates and reacted with amines to give the 
corresponding ureas. It was, hence, envisaged that these N-alkyl-1,2,4-dithiazolidine-2,5-diones 
would be converted to their corresponding isocyanates, and reacted with sulfonamides in the 
place of amines.6 This could provide a new synthesis to sulfonyl ureas, and would provide an 
alternative route to more diverse sulfonyl urea libraries, as the initial starting reagents are 
commercially available alkyl halides. 
 
5.3.3.1 Synthesis of Sulfonyl Ureas using Alternate Route 
 
Following the protocol described by Wood, M. E. et al. [2003],6 (3,5-dioxo-1,2,4-dithiazolidin-4-
yl)acetic acid ethyl ester (RKG2661) was synthesized as described using NaHCO3 in CH3CN giving 
a 65% yield (literature: 86%). Another seven alkyl bromides were also reacted with 1,2,4-

























where R = CO2Et                        (RKG2661, 65%)
             R = phenyl                      (RKG318, 74%)
             R = 2-bromophenyl      (RKG319, 94%)
             R = 3-bromophenyl      (RKG317, 79%)
             R = 4-bromophenyl      (RKG315, 92%)
             R = CH=CH2                    (RKG425B, 68%)
             R = 3-methoxyphenyl  (RKG425C, 76%)
             R = biphenyl-2-yl          (RKG425D, 78%)
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The reaction was attempted using a sulfonamide (4-chlorobenzene sulfonamide), in the 



























where R = CO2Et                        (RKG267F4, 48%)
             R = phenyl                      (RKG331, 65%)
             R = 2-bromophenyl      (RKG334, 49%)
             R = 3-bromophenyl      (RKG330, 52%)
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Based on the success of this reaction with 4-chlorobenzene sulfonamide, the reaction was 

























where X = Br, Y = H, Z = H, R = phenyl                                         (RKG357, 79%)
             X = Br, Y = H, Z = H, R = 2-naphthyl                                  (RKG360, 67%)
             X = H, Y = OCH3, Z = H, R = 4-chlorophenyl                    (RKG426A, 67%)
             X = H, Y = OCH3, Z = H, R = 2,4,5-triisopropylphenyl    (RKG426B, 32%)
             X = phenyl, Y = H, Z = H, R = 4-chlorophenyl                  (RKG427A, 71%) 
             X = Br, Y = H, Z = H, R =     
                                                                                                            (RKG359, 80%)
            X = H, Y = H, Z = Br, R =       
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5.3.4 Attempted Synthesis of Sulfonyl Ureas using a Key Metal-Catalyzed Step 
 
The efficient amination and amidation of aryl halides using metals, such as palladium,8-15 
nickel16-18 and copper,19-33 as a catalyst is extensively represented in the literature. While the 
palladium-catalyzed C-N bond formation has been studied extensively over the past few years, 
both the Ullmann and Goldberg reactions (copper-catalyzed N-arylation of amines and amides, 
respectively) predate the palladium-catalyzed amination methodology by almost a hundred 
years. A simplistic schematic representation of the transition metal catalyzed amidation is 











The limitation of the alternate new synthetic route to sulfonyl ureas described in Chapter 5.3.3 
is the need for the halogen (leaving group) to be attached to a (-CH2-) carbon unit. Therefore, 
starting materials and precursors are limited to halogenated alkyl- and benzyl–type moieties. 













where   R1 = alkyl, aryl, H
               R2 = alkyl, aryl, H
               R3 = alkyl, aryl, H
               Y = CH2, CO
               X = Cl, Br, I
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would include aryl halides as starting precursors, would be via a key transition metal catalyzed 










5.3.4.1 Attempted Pd-Catalyzed In ermolecular Amidation  
 
Based on the observations by Buchwald, S. L. et al. [2002],15 a Xantphos/Pd complex proved to 
be an active and efficient catalyst (1-4 mol % of Pd catalyst) for the amidation of both activated 
and unactivated aryl halides. The active catalyst is easily formed in situ by the addition of 
Xantphos ((9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine)), a ligand developed by 
van Leeuwen, P. W. N. M. et al. [1995],34 to Pd(OAc)2 or Pd(dba)3. Buchwald, S. L. et al. [2002]
15 
established, after a study of a variety of ligands and reaction variables, that the most successful 
catalytic system was obtained using Xantphos as the ligand, Cs2CO3 as the base, THF or 1,4-
dioxane as the solvent and temperatures varying from 45 – 100 oC. Using the optimized 
protocol described in the literature,15 the coupling of two different aryl halides with 1,2,4-
dithiazolidine-3,5-dione was attempted as detailed below (Scheme 5.12): 
X
transition metal






























where R1 = alkyl, aryl, H
            R2 = alkyl, aryl
            X = Cl, Br, I






















Monitoring the reactions at temperatures in the range 45 - 80 oC with TLC showed varying 
results. In both cases, a new distinct spot f rmed as the 1,2,4-dithiazolidine-3,5-dione spot 
disappeared on reaction. However, upon isolation using column chromatography, NMR analysis 
of the separated new product did not show the correct desired 1H aromatic signals in 
conjunction with the desired carbonyl peak in the 13C spectrum. Hence, it could not be 
concluded that the desired intermediate product had been formed. Further analysis of the NMR 
spectra seemed to suggest the formation of two inseparable products with similar Rf values. 
 
Not surprisingly it is known that the 1,2,4-dithiazolidine-3,5-dione scaffold decomposes in the 
presence of triphenylphosphine. Presumably because Xantphos (a phosphorous ligand) was 
used in our reactions, this may have led to the apparent decomposition. If the desired product 
did initially form, the present phosphorous ligand could react with it, converting it to the highly 
reactive and unstable isocyanate. This would also result in no active catalyst being present as 








45-80 oC, 24 h
R
X
where  X = I, R = NO2
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5.3.4.2 Attempted Cu-Catalyzed Intermolecular Amidation 
 
Extensive studies by Klapars, A. et al. [2002]33 revealed a simple and inexpensive catalyst 
system for the amidation of aryl halides using 0.2 – 10 mol % of CuI, 5 – 20 mol % of a 1,2-
diamine ligand, and CsCO3, K2CO3 or K3PO4 as the base. Studying a variety of 1,2-diamine 
ligands, using N,N’-dimethylethylenediamine or trans-N,N’-dimethyl-1,2-cyclohexanediamine 
proved to result in the most active catalyst systems, although several other 1,2-diamine ligands 
were also sufficiently active. This catalyst system effectively amidated aryl iodides, bromides, 
and in several cases, aryl chlorides, and showed tolerance to a number of diverse functional 
groups present on reactants that were not compatible with the Pd-catalyzed amination and 
amidation protocols. Using the optimized methodology developed by Klapars, A. et al. [2002],33 
the coupling of 1-iodo-4-nitrobenzene with 1,2,4-dithiazolidine-3,5-dione was attempted as 
detailed below (Scheme 5.13): 
 
Commercially available N,N’-dimethylethylenediamine (Sigma-Aldrich) was chosen to be the 
ligand and potassium carbonate was chosen as the base. Initial studies at 60 and 110 oC using 
three different solvents, namely 1,4-dioxane, toluene and DMF (all three solvents proved to be 
effective for the amidation of different aryl halides in the copper catalyzed coupling system33), 
and 1-iodo-4-nitrobenzene as the aryl halide were carried out.  
 
Thin layer chromatography was used to monitor all the systems, and as observed while 
attempting the Xantphos/Pd reactions, a new product was forming as the 1,2,4-dithiazolidine-
3,5-dione was being consumed. At 60 and 110 oC using both 1,4-dioxane and toluene as the 
solvent system, the separated new product appeared to be again a mixture of two new 
products (with corresponding Rf values) with similar 
1H NMR profiles (only the intensity of the 
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solvent, the 1H NMR seemed to suggest the formation of one new product (EI-MS: m/z = 275.98 
[M+]). At 110 oC using DMF as the solvent, again, the 1H NMR seemed to suggest the formation 
of one new product. However, this time, it appears to be another new product (EI-MS: m/z = 
307.95 [M+]), which was previously inseparable for all Pd catalyzed systems, and Cu catalyzed 
systems using toluene or 1,4-dioxane as the solvent systems. It must be noted that these mass 
spectra were recorded using EI-MS, and the m/z values recorded may have been either an 
abundant large molecular fragment or parent ion. Neither of the two compound’s mass spectra 
agree with the desired intermediate product (4-(4-nitrophenyl)-1,2,4-dithiazolidine-3,5-dione) 
which would be expected to have a m/z value of 255.96. Another possible product which could 
have formed, and is documented in the literature,33 is the coupling of the aryl halide to another 
molecule of aryl halide. In this case, the coupling of two 1-iodo-4-nitrobenzene molecules 











Other possible reasons for the failure of the Cu-catalyzed system may be the presence of the 
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documented in the literature by Wood, M, E, et al. [2003]6 and Barany, G. et al. [1980],7 that 
the susceptibility to decomposition of 1,2,4-dithiazolidine-3,5-dione is high in the presence of 































Following the literature, the 1,2,4-dithiazolidine-3,5-dione “scaffold” was successfully 
synthesized. The envisaged new methodology for the synthesis of sulfonyl ureas required the 
coupling of 1,2,4-dithiazolidine-3,5-dione with a sulfonyl chloride. This coupling step was 
attempted under a range of conditions, including varying the base, solvent, temperature etc. It 
was also attempted in order to allow the desired intermediate to remain in solution without 
isolation, and perform the following step with triphenylphosphine and amine. Presumably the 
key 4-(arylsulfonyl)-1,2,4-dithiazolidine-3,5-dione intermediate may be too unstable under the 
experimental conditions attempted. All attempts to synthesize sulfonyl ureas using the initial 
new methodology were, unfortunately, unsuccessful. 
 
However, another new route to sulfonyl ureas was envisaged using similar chemistry, but 
starting with N-alkyl-1,2,4-dithiazolidine-2,5-dione intermediates. Wood, M. E. et al. [2003]6 
had already developed this protocol to react the N-alkyl-1,2,4-dithiazolidine-2,5-dione with 
amines in the presence of triphenylphosphine to give ureas. It was, hence, envisaged that the 
reaction of N-alkyl-1,2,4-dithiazolidine-2,5-dione intermediates with sulfonamides in the 
presence of a weak base (i.e. potassium carbonate) and triphenylphosphine would give the 
expected products. This alternate method was successful, and eleven sulfonyl ureas were 
synthesized to demonstrate the success of this method. Yields ranged from 32 - 79%, and the 
purification of the final sulfonyl ureas was occasionally problematic due to poor solubility of the 
target sulfonyl urea in a range of solvents.  
 
The alternate new method, too, has its limitations, as only the synthesis N-alkyl-1,2,4-
dithiazolidine-2,5-dione intermediates has been developed. Thus, the synthesis of N-aryl-1,2,4-
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amidation methodology was envisaged. The formation of two new inseparable products under 
both Pd- and Cu-catalyzed methodology, in low yields, was observed. By varying the 
temperature of the Cu-catalyzed system, both new products were obtained individually. Their 
NMR spectra agree with what could be expected for the desired N-aryl-1,2,4-dithiazolidine-2,5-
dione intermediates, as well as for another bis-aryl byproduct. Mass spectroscopy was obtained 
on both samples, but the measured molecular ion for both new products do not agree with the 
N-aryl-1,2,4-dithiazolidine-2,5-dione intermediate, nor the bis-aryl byproduct. It is suspected 
that the N-aryl-1,2,4-dithiazolidine-2,5-dione may have decomposed under the conditions of 
the catalytic systems as phosphine (Pd-catalyzed) and amine (Cu-catalyzed) ligands are 
required. Although the two “new” unidentified products mass spectra did not agree with the 
desired target molecule, further investigation of these products could be carried out with x-ray 
crystallography, as well as, softer MS techniques, including chemical ionization (CI) or fast-atom 
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Chapter 6 
 Biological Results and Discussion 
 
6.1 New Permeability Pathways 
 
All synthesized potential NPP inhibitors and their intermediates (Chapter 2), as well as, all 
available potential ALS inhibitors and their respective intermediates (Chapter 4) were 
submitted in order to test their effect on the uptake of sorbitol, a known NPP substrate. The 
unpublished assaying method used was developed by N. Spillman (The Australian National 
University) (experimental details discussed in 6.1.5 Experimental Protocol). The assay involves 
the monitoring (using a fluorometer) of sorbitol uptake via the NPP of P. falciparum infected 
erythrocytes. The uptake of sorbitol causes haemolysis of the erythrocytes which results in a 
change in absorbance. The presence of a NPP inhibitor would result in the reduction or 
prevention of sorbitol uptake. Therefore, if the test compound is an effective NPP inhibitor, the 
absorbance will remain constant.  
 
6.1.1 Effect of Controls on Transmission 
 
Figure 6.1.1.1 shows the time course of transmission for infected cells with added isosmotic 
sorbitol. The uptake of sorbitol via the NPP is depicted by the increase in transmission seen 
over time. As the sorbitol is taken up, haemolysis of the erythrocytes occurs, and once a 
majority of the cells have lysed, the transmission reaches a plateau. The further addition of 
saponin (shown by an arrow) causes the haemolysis of all remaining cells, and is observed by 





















Figure 6.1.1.2 shows the time course transmission for infected cells with added furosemide (a 
potent NPP inhibitor) (a similar graph is observed if H157 is used as the control). The presence 
of the NPP inhibitor results in the blocking of sorbitol uptake, and subsequently prevents the 
haemolysis of the erythrocytes. A relatively constant transmission is the result, and the addition 
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6.1.2 Effect of Test Compounds on Transmission 
The following figures (6.1.2.1 – 6.1.2.8) show all compounds and intermediate products that 
had little effect, with the exception of the known NPP inhibitor RKG256 (H157), on the 
haemolysis time course. All samples were tested at a concentration of 50 µM and positive 
















Figure 6.1.2.1: Transmission of solution containing infected cells, sorbitol and test compounds 
































Figure 6.1.2.3: Transmission of solution containing infected cells, sorbitol and test compounds 
































Figure 6.1.2.5: Transmission of solution containing infected cells, sorbitol and test compounds 






























Figures 6.1.2.1 – 6.1.2.4 represent the assays that were conducted using the trophozoite stage 
of the FAF6 strain of P. falciparum (performed by collaborators from The Australian National 
Figure 6.1.2.7: Transmission of solution containing infected cells, sorbitol and test compounds 
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University, June 2007 – K. Easton and K. Kirk). Figures 6.1.2.5 – 6.1.2.8 represent the assays that 
were conducted using the trophozoite stage of the D10 strain of P. falciparum (performed by 
collaborators from The Australian National University, May 2006 – N. Spillman and K. Kirk). 
 
Of the 55 compounds tested, only four compounds showed pronounced inhibition of the 
sorbitol-induced haemolysis. One of these four compounds was RKG256 (H157), and effective 
inhibition was expected, and is graphically represented and confirmed in Figure 6.1.2.7. The 
other three inhibitory compounds were RKG4042P, RKG340 and RKG359. The following three 
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Both times courses for RKG4042P and RKG340 show a slight decrease in transmission over 
time, and this is likely the result of cells settling over time. The small increase in transmission 
over time observed for RKG359 is a result of incomplete inhibition of the sorbitol uptake. The 
large increase in transmission observed for all three compounds at around 30 minutes of 
elapsed time is due to the addition of saponin. 
 
All three compounds were further tested at concentrations of 22.5, 9 and 4.5 µM. RKG359 
showed good, but incomplete inhibition at all the concentrations. Almost complete inhibition at 
9 µM and some inhibition at 4.5 µM was observed for RKG340. RKG4042P proved be the most 
effective inhibitor of the three, and proved an approximately constant complete inhibition at all 
concentrations. 
 
6.1.3 Dose Response for RKG4042P  
 
Transmission time courses for concentrations of 45, 22.5, 9, 4.5, 1.8, 0.9, 0.45 and 0.09 µM of 
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From the graph (Figure 6.1.3.1), the IC50 (concentration required to reduce sorbitol uptake to 




From the library of 55 compounds that were tested for the inhibition of sorbitol uptake by 
parasitized erythrocytes, four compounds proved to show a significant inhibitory effect. These 






























































Figure 6.1.4.1: The four compounds that showed significant inhibition of sorbitol uptake by 
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RKG256 (H157) was demonstrated to inhibit parasite-induced choline transport by Staines, H. 
M. et al. [2004]1 and has an IC50 of 0.44 µM. It was synthesized for comparison purposes, and to 
use as a control in the screening of other test compounds. The IC50 was, hence, not determined, 
but it did show significant inhibition of sorbitol uptake as expected. RKG340 (an extended ‘side-
chain’ derivative of H157) showed almost complete inhibition at 9 µM, and although its IC50 was 
not precisely determined, this result is comparable to that of H157. It can further be concluded 
that the extension of the ‘side chain’ by one methylene unit did not affect the inhibitory 
effectiveness of this class of piretanide-like compounds. The extension of this ‘side chain’ by 
more than one methylene unit may be considered for future SAR studies. 
 
All compounds bearing an amide moiety in the ‘side-chain,’ ester derivatives of H157 and other 
ester intermediates, as well as those bearing heterocyclic and heteroaromatic groups on the 
‘side-chain’ showed little or no inhibition at all. It can be concluded that the secondary amine 
(anilinic) and carboxylic acid moieties are important for the activity of piretanide-like class of 
compounds. All acylthioureas, imidazolinone, phthalimide and sulfonylcyanoguanidine 
analogues showed little or no inhibition of sorbitol uptake. 
 
The IC50 of RKG359 was not determined, but it did show inhibition at concentrations as low as 
22.5 and 9 µM. A small collection of eleven sulfonyl ureas (including those synthesized in the 
sulfonyl urea methodology development) were sent for testing, and only RKG359 demonstrated 
any significant inhibition of sorbitol uptake. When analyzing the structure of RKG359, it was 
later found to be an analogue of the known classical Cl- channel blocker, glibenclamide.2   
 
The most active compound tested was RKG404P2, which gave an IC50 of approximately 1.2 µM. 
This result is consistent with that obtained for H157.1 Although RKG404P2 is the hydroxamic 
acid bioisostere of H157, an important observation is that the hydroxamic acid functionality is 
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furosemide-like NPP inhibitors are anionic. It would, therefore, be important to synthesize 
more hydroxamic acid derivatives of known piretanide-like and furosemide-like NPP inhibitors 
for further investigation. This may lead to the development of novel hydroxamate NPP 
blockers. 
 
For more conclusive results, the compounds that have shown effective inhibition of sorbitol 
uptake by parasitized erythrocytes should be investigated for their effect on the uptake of 
other known substrates believed to enter via the induced NPP. The inhibition of the uptake of 
substrates like pantothenate or choline could also be assayed. 
 
6.1.5 Experimental Protocol 
 
Parasites cultures: 
Assays were conducted using the trophozoite stage of the D10 and FAF6 strains of Plasmodium 
falciparum.  P. falciparum (strain D10) were cultured in group O erythrocytes by Dr Richard 
Allen (Postdoctoral research fellow, ANU). Parasites (strain FAF6) were synchronised and 
provided in human blood (from the Canberra branch of the Australian Red Cross Blood Service) 
by Natalie Spillman.  The parasite sample was washed three times in 50 ml ice cold, 
bicarbonate-free RPMI.   
Washing performed by centrifugation for 5 minutes at 1500 x g, 4C. 300 l of uninfected 
human blood was also obtained and centrifuged for 1 minute at 14000 x g.  The supernatant 
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Preparation of cells: 
Cells were washed in ice cold RPMI before magnetic enrichment of infected cells using a 21G 
needle on the Vario MACS column. Enriched infected cells and uninfected RBC were 
sedimented by centrifugation at 1550rpm (4ºC) and pellets transferred to microcentrifuge 
tubes. The uninfected RBC were resuspended at a dilution of 1/10, such that 100μL of the pellet 
was resuspended in 900μL of phosphate-buffered saline using a positive displacement pipette. 
The infected RBC were resuspended at a concentration of 2.175x108 cells/mL. Cell counts were 
performed using an improved Neubauer counting chamber at an appropriate cell dilution. The 
parasitemia was calculated using methanol-fixed, Giemsa-stained smear, counting a minimum 
of 650 cells. 
 
Isosmotic Haemolysis: 
A BMG Labtechnologies 96 well plate was loaded with 4uL aliquots of the uRBC and 20uL 
aliquots of the iRBC, which gave appropriate initial absorbance levels. At time zero, an eight-
lane multichannel pipettor was used to add 200uL of the isosmotic sorbitol (supplemented with 
inhibitor/control) to each well. The change in absorbance (A) corresponding to the lysis of the 
cells was measured using the HAEMOLYSISEXP-NJS program on the FLUOstar OPTIMA BMG 
LABTECH reader 413-1042. The experiment was performed at 700nm (37ºC) with orbital or 
double orbital shaking for up to 5 seconds before each cycle. Cycle times (depending on the 
number of wells utilised) varied from 34 to 95 seconds. After lysis had stopped for most 
samples the program was paused and 10μL of the plant-derived detergent Saponin (10%w/v) 
was added to each well. The absorbance measurements then resumed for another 10 cycles. All 
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6.2 In Vitro Testing against Plasmodium falciparum Strains 
 
The induction of the NPP into the host erythrocyte is very important for the growth of the 
malaria parasite P. falciparum. Based on work done by Staines, H. M. et al. [2004],1 even when 
the NPP operate at levels only a fraction of the norm, they still allow sufficient flux of solutes to 
allow the parasite to survive. Compounds that show the inhibition of NPP at nanomolar 
concentration ranges lack the potential of becoming antimalarial candidates if they have little 
effect on the growth of the parasite. In this regard, the antiplasmodial in vitro activities of all 
available synthesized compounds were determined. The antiplasmodial activity against the 
chloroquine-sensitive D10 strain of P. falciparum was determined in the laboratories of P. J. 
Smith (Division of Pharmacology, University of Cape Town). The antiplasmodial activity against 
the chloroquine-resistant W2 strain of P. falciparum was carried out by the collaborating group 
of P. J. Rosenthal (Department of Medicine, San Francisco General Hospital, University of 
California at San Francisco, UCSF)). Table 6.2.1 shows the antiplasmodial activities of 
compounds that were determined at the two different laboratories against both the 
chloroquine-sensitive (CQS) D10 and chloroquine-resistant (CQR) W2 strains. 
 
6.2.1 Results and Discussion 
 
Compound RKG303A, a chloroquine-based structure, was the only compound active against the 
(CQR) W2 and (CQS) D10 strains of P. falciparum (highlighted in blue in Table 6.2.1) with 
IC50(W2) = 0.89 ± 0.07 µM and IC50(D10) = 0.693 µM respectively. This activity, however, is more 
likely attributed to the compound following the 4-aminoquinoline-type mechanism of action, as 
opposed to the activity being a result of the inhibition of NPP. The rest of the compounds did 
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Compound IC50   IC50 
ID µM SD µg/ml µM 
RKG315 26.19 0.68 39 128.21 
RKG354 49.26 2.12 11.7 38.46 
RKG332 >50 - >100 - 
RKG345 >50 - 28.7 102.97 
RKG333 39.39 0.32 >100 - 
RKG346 20.21 0.86 >100 - 
RKG364 19.70 0.26 12.8 29.50 
RKG252COL1 44.31 5.42 9.8 23.39 
RKG404P2 17.70 0.29 7.1 16.91 
RKG335F2 36.47 0.36 >100 - 
RKG331 >50 - >100 - 
RKG328 >50 - 95.3 236.08 
RKG330 >50 - >100 - 
RKG357 >10 - >100 - 
RKG360 >50 - >100 - 
RKG359 >50 - 53.3 91.76 
RKG351 >10 - 42.5 64.50 
RKG1493A >50 - >100 - 
RKG1531 >50 - >100 - 
RKG1532 >50 - >100 - 
RKG1533PC >50 - >100 - 
RKG1541 >50 - 10.4 28.13 
RKG1542 >10 - 32.2 86.87 
RKG1543 >10 - 33.8 95.80 
RKG139F3 >50 - 86.1 208.13 
RKG151A >50 - >100 - 
RKG303A 0.89 0.07 0.693 1.28 
RKG1491 - - 61.8 158.60 
RKG162A - - 8.9 34.66 
RKG340 - - 53.3 127.24 
RKG256 >20 - 6.34 17.87 
RKG414F2 >20 - >10 - 
RKG409 >20 - >10 - 
RKG442 >20 - >10 - 
Chloroquine 0.091 0.024 0.015 0.048 
 
The four compounds that showed effective inhibition of sorbitol uptake (Chapter 6.1) are 
highlighted in orange in Table 6.2.1. Compounds RKG359 and RKG340 were found to have little 
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higher than the tested limit for the CQR W2 strain. Both RKG256 (H157), IC50(D10) = 17.9 µM, 
and bioisosteric analogue RKG4042P demonstrated the highest activites. The IC50 values were 
constant through both strains for RKG4042P, IC50(W2) = 17.7 ± 0.3 µM and IC50(D10) = 16.9 µM. 
Although, this activity is not as potent when compared to the control chloroquine (which IC50 
values are in the nanomolar ranges), it still presents the possibility that RKG4042P and RKG256 
moderate activities may be a result of NPP inhibition. This can be further concluded as the 
activities found in both the antiplasmodial assays and sorbitol uptake assays are all in the 
equivalent micromolar ranges. To be more conclusive, future testing of a bigger range of 
compounds showing good NPP inhibition should be carried out for antiplasmodial in vitro 
activity. 
 
6.2.2 Experimental Protocol 
 
In vitro testing against chloroquine-sensitive D10 P. falciparum 
The test compounds were tested in duplicate on one occasion against chloroquine sensitive 
(CQS) strain of Plasmodium falciparum (D10). Continuous in vitro cultures of asexual 
erythrocyte stages of P.falciparum were maintained using a modified method of Trager, W. J. 
and Jensen, B. [1976].3 Quantitative assessment of antiplasmodial activity in vitro was 
determined via the parasite lactate dehydrogenase assay using a modified method described by 
Makler, M. T. et al. [1993].4 
 
The compounds were prepared to a 2 mg/ml stock solution in 10% DMSO or 10% methanol and 
were sonicated to enhance solubility. Compounds were tested as a suspension if not 
completely dissolved. Stock solutions were stored at -20 oC. Further dilutions were prepared on 
the day of the experiment. Chloroquine (CQ) was used as the reference drug in all experiments. 
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inhibiting 50% of parasite growth (IC50 – value). Test compounds were tested at a starting 
concentration of 10 μg/ml (December 2007) and 100 μg/ml (May 2007), which was then serially 
diluted 2-fold in complete medium to give 10 concentrations; with the lowest concentration 
being 0.2 μg/ml. The same dilution technique was used for all samples. CQ was tested at a 
starting concentration of 100 ng/ml. Compound RKG303A was tested at a starting 
concentration of 1000 ng/ml. The highest concentration of solvent to which the parasites were 
exposed to had no measurable effect on the parasite viability (data not shown). The IC50-values 
were obtained using a non-linear dose-response curve fitting analysis via GraphPad Prism v.4.0 
software. 
 
In vitro testing against chloroquine-resistant W2 P. falciparum 
The protocol to carrying out the in vitro testing was performed as described by Rosenthal, P. J. 
et al. [1996].5 Synchronized W2 strain P. falciparum par sites are cultured with test compounds 
(added from 1000x stocks in DMSO) for 48 hours, beginning at the ring stage. After 24 hours, 
the medium is changed while maintaining appropriate inhibitor concentration. Giemsa-stained 
smears are made after 48 hours, when control cultures contained nearly all parasites in the 
ring-stage.  The number of new ring forms per 500 erythrocytes are counted, and compared 
with those of controls cultured in 0.1% DMSO. IC50’s for growth inhibition are determined with 
GraphPad Prism software from plots of percentages of the level of parasitemia of the control 
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6.3 In Vitro Testing against Mycobacterium tuberculosis Strains 
 
In 2005, all sulfonyl ureas, imidazolinones, phthalimides, sulfonylcyanoguanidines, 
acylthioureas, intermediate compounds, and the commercially available herbicides were sent 
to the Tuberculosis Antimicrobial Acquisition & Coordianting Facility (TAACF, USA) for 
antimicrobial assessment against Mycobacterium tuberculosis. Compounds were further 
evaluated at the Department of Medical Biochemistry (UCT) in the M. tuberculosis Resazurin 
assay.  
 
6.3.1 Primary Screening Results (TAACF) 
 
Primary screening results are shown in Table 6.3.1.1. The primary screening is done at the test 
concentration of 6.25 µg/mL on the Alamar blue assay.6,7 The Alamar assay makes use of the 
indicator dye resazurin to measure the metabolic capacity of cells. Viable cells retain the ability 
to reduce resazurin into the highly fluorescent resorufin. Non-viable cells lose their metabolic 
capacity to reduce the indicator dye, and thus do not generate a fluorescent signal. Only if 
compounds show greater than 90% inhibition of the Mycobacterium tuberculosis H37Rv strain 
(hence, prevent the reduction of resazurin to resorufin), are they retested and the cytotoxicity 
evaluated. If the compound has a determined minimum inhibitory concentration (MIC) of > 
6.25 µg/mL it is usually not evaluated further. Table 6.3.1.1 reveals that only RKGC5Et showed 
inhibition of greater than 90% in the initial primary screening. Compounds RKG162A, RKG1541, 
RKGC11Tria, RKG1542, RKG1543, RKGC12Th and RKGAS4ELEU showed lower to moderate 
inhibition ranging from 21 – 41 % at the concentration of 6.25 µg/mL. Compounds RKGC3Ci, 
RKGAS4EVAL and RKGC3Ch showed only traces of inhibition. Due to the good inhibitory activity 
of 96% of RKGC5Et against the M. tuberculosis H37Rv strain at 6.25 µg/mL, cytotoxicity studies 
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RKGC5Et Alamar <6.25 96 + 
RKG162A Alamar >6.25 41 - 
RKG1541 Alamar >6.25 40 - 
RKGC11Tria Alamar >6.25 38 - 
RKG1542 Alamar >6.25 37 - 
RKG1543 Alamar >6.25 28 - 
RKGC12Th Alamar >6.25 24 - 
RKGAS4ELEU Alamar >6.25 21 - 
RKGC4Ci Alamar >6.25 7 - 
RKGAS4EVAL Alamar >6.25 3 - 
RKGC3Ch Alamar >6.25 1 - 
RKGAS4ELGY Alamar >6.25 0 - 
RKG1492 Alamar >6.25 0 - 
RKG1491 Alamar >6.25 0 - 
RKG1533PC Alamar >6.25 0 - 
RKGANT3 Alamar >6.25 0 - 
RKGAS4EPA Alamar >6.25 0 - 
RKGC13Trib Alamar >6.25 0 - 
RKGC14Trif Alamar >6.25 0 - 
RKG150A Alamar >6.25 0 - 
RKGC9Py Alamar >6.25 0 - 
RKGC10Ri Alamar >6.25 0 - 
RKG151A Alamar >6.25 0 - 
RKGC2Be Alamar >6.25 0 - 
RKG1531 Alamar >6.25 0 - 
RKG1532 Alamar >6.25 0 - 
RKGC1Im Alamar >6.25 0 - 
RKG114A Alamar >6.25 0 - 
RKG161A Alamar >6.25 0 - 
RKG136A Alamar >6.25 0 - 
RKG147A Alamar >6.25 0 - 
RKG139F3 Alamar >6.25 0 - 
RKG125A Alamar >6.25 0 - 
RKG123A Alamar >6.25 0 - 










Chapter 6 Biological Results and Discussion | 135  
 
RKGC5Et, and it was found to have a cytotoxicity IC50 of > 62.5 µg/mL, and further concurrent 
studies proved RKGC5Et to have a MIC of > 6.25 µg/mL. It was not evaluated further by TAACF 
and, therefore, the IC50 against M. tuberculosis was not determined. 
 




6.3.2 Primary Screening Results (UCT) 
 
The Resazurin assay is based on the ability of living cells to convert a redox dye (resazurin) into 
a fluorescent end product (resorufin). Resazurin has been identified as the main component of 
Alamar blue.8 A color change from blue to pink indicates the growth of the bacteria. The MIC is 
defined as the lowest concentration of drug or test sample to prevent the color change. The 
Figures 6.3.2.1 – 6.3.2.4 represents the primary screening of compounds, and depicts the 
reduction of percentage of resazurin due to inhibition by the compound. Primary-line 
antituberculosis drugs rifampicin (RIF) and isoniazid (INH) are used as controls. The bar graph 
representations indicate the percentage of resazurin reduced over a period of 5 days.  
Compound ID % Inh Assay 
MIC 
(µg/mL) IC50 
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Figure 6.3.2.1: Resazurin assay of test compounds 
Figure 6.3.2.2: Resazurin assay of test compounds 
Resazurin Assay of Test Compounds 
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Figure 6.3.2.3: Resazurin assay of test compounds 
Figure 6.3.2.4: Resazurin assay of test compounds 
Resazurin Assay of T st Compounds 
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Good activity is defined by a low percentage of resazurin reduced, and is observed in Figures 
6.3.2.1 – 6.3.2.4 for the measurements taken for the controls RIF and INH. Of the compounds 
submitted for evaluation, only RKG162A (Figure 6.3.2.1) and RKG1541 (Figure 6.3.2.4) were 
found to show good inhibition for the reduction of resazurin. The minimum inhibitory 
concentrations (MIC) were then evaluated for each of these two active compounds (Figure 
















































Figure 6.3.2.5: Studies to determine the MIC of RKG1541 











































Chapter 6 Biological Results and Discussion | 139  
 
Based on the MIC studies, RKG1541 was found to have an approximate IC50 of 10.7 µM, and 
RKG162A an approximate IC50 of 16.9 µM. 
 
6.3.3 Conclusion  
 
Based on the primary screening by TAACF, the only compound that showed good inhibition of 
the Mycobacterium tuberculosis H37Rv strain was the commercially available sulfonyl urea, 
RKGC5Et (Ethoxysulfuron), and showed an inhibition of 96% in the initially primary screening. It 
was further evaluated for mammalian cell cytotoxicity studies and found to have an IC50 of > 
62.5 µg/mL. In further evaluation it was found to have an MIC of > 6.25 µg/mL, and, hence, was 
not evaluated further. Compounds demonstrating inhibition at the concentration of 6.25 µg/mL 
include RKG162A (41%), RKG1541 (40%), RKGC11Tria (38%), RKG1542 (37%), RKG1543 (28%), 
RKGC12Th (24%) and RKGAS4ELEU (21%). Compounds RKGC3Ci, RKGAS4EVAL and RKGC3Ch 
showed only traces of inhibition. 
 
From the screening conducted at UCT, compounds RKG1541 and RKG162A demonstrated 
moderate inhibition in the resazurin assay, with IC50 values of 10.7 µM and 16.9 µM 
respectively.It is important to note that both compounds are of the acylthiourea class, and 
were the only two compounds to show activity in both separate (TAACF and UCT) primary 
screenings. The two active compounds were compared structurally with the two acylthioureas, 
namely RKG1542 and RKG1543, which only showed low inhibition in the TAACF assay. It is 
noteworthy that RKG1542 and RKG1543 are more hydrophilic compounds, bearing pyridinyl 
and dimethoxypyrimidinyl moieties respectively, as opposed to the more hydrophobic 
acylthioureas, RKG1541 and RKG162A, which bear phenyl and alkyl (iso-propyl) groups. It may 
be suggested that the more hydrophobic substituent is important for the compounds activity. 
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Unfortunately, all synthesized imidazolinones, phthalimides, sulfonylcyanoguanidines, sulfonyl 
ureas and commercial herbicides (including Imazapyr, RKGC1Im) showed little or no inhibitory 
activity at the concentration ranges used in both primary screenings. 
 
6.3.4 Experimental Protocol  
 
In vitro Evaluation at Tuberculosis Antimicrobial Acquisition & Coordinating Facility (TAACF, 
USA) 
1. Primary screening is conducted at 6.25 µg/mL against Mycobacterium tuberculosis H37Rv 
(ATCC 27294) in BACTEC 12B medium using a broth microdilution assay, the Microplate 
Alamar Blue Assay (MABA).6 Compounds exhibiting fluorescence are tested in the 
BACTEC 460 radiometric system.6 Compounds effecting <90% inhibition in the primary 











































Chapter 6 Biological Results and Discussion | 141  
 
2. Compounds demonstrating at least 90% inhibition in the primary screen are retested at 
lower concentrations against M. tuberculosis H37Rv to determine the actual minimum 
inhibitory concentration (MIC) using MABA. The MIC is defined as the lowest 
concentration effecting a reduction in fluorescence of 90% relative to controls. 
3. Concurrent with the determination of MICs, compounds are tested for cytotoxicity (IC50) 
in VERO cells at concentrations ≤ 62.5 µg/mL or 10x the MIC for M. tuberculosis H37Rv 
(solubility in media permitting). After 72 hours exposure, viability is assessed on the 
basis of cellular conversion of MTT into a formazan product using the Promega CellTiter 
96 Non-radioactive Cell Proliferation Assay. 
 
In vitro Evaluation at Department of Medical Biochemistry (UCT) 
 
The Resazurin Microtiter Assay plate was carried out as described by Martin, A. et al. [2003]9 
and Palomino, J.-C. et al. [2002].10 
 
100 µL of 7H9-S broth (Middlebrook 7H9 supplemented with 0.1% Casitone, 0.5% glycerol, and 
10% OADC [oleic acid, albumin, dextrose, and catalase]; Becton-Dickinson) is dispensed in each 
well of a sterile flat-bottom 96-well. Serial twofold dilutions of each compound were prepared 
directly in the plate. Isolates were freshly subcultured on LJ medium. A further 100 µL of 
inoculums standard (prepared in 7H9-S broth, spectrophotometrically adjusted to a no. 1 
McFarland tube and diluted to 1:10 in 7H9-S broth for test) is added to each well. Both growth 
and sterile controls are also included for each isolate. Isolates were freshly subcultured on LJ 
medium. Sterile water is added to all perimeter wells to prevent evaporation while incubation 
takes place. The plate is covered, and sealed in a plastic bag. The plate is incubated at 37 oC for 










Chapter 6 Biological Results and Discussion | 142  
 
prepared at 0.02% (wt/vol) in distilled water, sterilized by filtration, and stored at 4 oC for 
approximately a week) added, and the plate is reincubated overnight. The change in color from 
blue to pink indicates the growth of the bacteria. The MIC is defined as the lowest test sample 
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Chapter 7 




All successfully synthesized H157 derivatives, including relevant intermediate compounds and 
H157 respectively, and available potential acetolactate synthase inhibitors, and their respective 
intermediates, were tested in the sorbitol uptake inhibition (NPP) assay as well as for in vitro 
activity against both chloroquine sensitive and resistant strains of Plasmodium falciparum. Four 
compounds demonstrated significant inhibition of the sorbitol uptake, namely RKG256 
(synthesized H157), RKG340 (an extended ‘side-chain’ derivative of H157), RKG4042P 
(hydroxamic bioisostere of H157) and RKG359 (sulfonyl urea, and analogue of glibenclamide). 
Almost complete inhibition at the concentration of 9 µM was observed for both RKG359 and 
RKG340. RKG4042P proved to be the most active with an IC50 value of 1.2 µM. Against the 
chloroquine-sensistive D10 and chloroquine-resistant W2 strains, the most active compound 
was found to be RKG303A, a 7-chloroquinoline bearing H157 derivative [D10 (IC50 = 1.28 µM) 
and W2 (IC50 = 0.89 µM)]. From the four compounds that showed good new permeability 
pathways inhibition, only compounds RKG256 (H157) [D10 (IC50 = 17.9 µM)] and RKG4042P 
[D10 (IC50 = 16.9 µM) and W2 (IC50 = 17.7 µM)] showed notable in vitro activity. This activity is 
not as potent as the chloroquine controls but presents the possibility of the activity being a 
result of the inhibition of the NPP. 
 
All successfully synthesized sulfonyl ureas, imidazolinones, sulfonylcyanoguanidines, 
acylthioureas, phthalimides, intermediate compounds, and a collection of 13 commercially 
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Alamar blue assay, as well as in the Mycobacterium tuberculosis Resazurin assay. Only 
commercially available ethoxysulfuron (RKGC5Et) showed inhibition of greater than 90% in the 
primary screening against the H37Rv strain at the concentration of 6.25 µg/ml. Other 
compounds that showed low to moderate inhibition (21-41%) at the concentration 6.25 µg/ml 
were acylthioureas: RKG162A, RKG1541, RKG1542 and RKG1543; and commercially available 
sulfonyl ureas: triasulfuron (RKGC11Tria) and thifensulfuron-methyl (RKGC12Th). From the 
primary screening in the resazurin assay, only acylthioureas RKG162A and RKG1541 showed 
good inhibition of the reduction of resazurin [approximate (IC50 = 16.9 µM) and (IC50 = 10.7 
µM)].  
 
The new synthesis of sulfonyl ureas envisaged using 1,2,4-dithiazolidine-3,5-dione as the 
starting scaffold, which was proposed to work via a 4-arenesulfonyl-1,2,4-dithiazolidine-3,5-
dione intermediate, was unsuccessful. The coupling of 1,2,4-dithiazolidine-3,5-dione with a 
sulfonyl chloride was attempted under a variety of conditions, however, the 4-arenesulfonyl-
1,2,4-dithiazolidine-3,5-dione intermediate could not be isolated or confirmed. Another new 
route to sulfonyl ureas was envisaged involving the reaction of N-alkyl-1,2,4-dithiazolidine-3,5-
dione with sulfonamides in the presence of triphenylphosphine and a weak base. This alternate 
method was successful, and eleven sulfonyl ureas were synthesized to demonstrate the success 
of the method with yields ranging from 32 – 79%. Due to this new method being initially limited 
to N-alkyl-1,2,4-dithiazolidine-3,5-diones, broadening this new synthetic method to include N-
aryl-1,2,4-dithiazolidine-3,5-diones was envisaged. Transition metal-catalyzed (Pd and Cu) 
amidation methodology was used in an attempt to couple 1,2,4-dithiazolidine-3,5-dione with 
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7.2 Future Work 
 
The generation of more H157 derivatives based on the initial in-depth SAR studies (Chaper 2.3) 
could be synthesized in order to investigate the activity of these piretanide-like molecules 
against the new permeability pathways. Due to the observed activity of RKG4042P in both the 
sorbitol uptake NPP assay and both P. falciparum in vitro assays, further hydroxamic acid 
bioisosteres as well as the tetrazole biosisostere of H157 and other active piretanide-like 
molecules should be synthesized and biologically evaluated. 
 
Based on the initial studies of the potential acetolactate synthase inhibitors, libraries of 
acylthioureas using RKG162A and RKG1541 as starting precursors for SAR studies could be 
initiated. This could be done in order to potentially find a new acylthiourea anti-tuberculosis 
compound class, as well as determine whether the inhibition of acetolactate synthase is the 
target of this active class of compounds. 
 
Like the commonly used protocols, the alternate new route to sulfonyl ureas too has its 
limitations. The inclusion of aryl halides to the starting material repertoire for the new alternate 
methodology would be most beneficial. Further investigations using alternate reactions 
conditions and catalyst ligands could be performed in order to potentially develop this method 
to include aryl halide precursors. X-ray crystallography investigation of the “unknown” products 
isolated from the Cu and Pd-catalyzed systems would be of interest, and could help in 





























8.1 Experimental: Chapter 2 
 
Synthesis of 3-amino-4-chloro-sulfamoylbenzoic acid (RKG211) 
 
A solution of 4-chloro-3-nitro-5-sulfamoylbenzoic acid (2.82 g, 10.0 
mmol) dissolved in EtOAc (120 ml) was treated with SnCl2.2H2O 
(11.3 g, 50.0 mmol), and heated with stirring at 65 – 70 °C for 1 h. 
The reaction mixture was allowed to cool to room temperature, and diluted further with more 
EtOAc (100 ml). A 10% Na2CO3 aqueous solution (~150 ml) was added until no more 
precipitation occurred, and the reaction mixture was filtered twice through Celite to remove 
the gelatinous precipitate. (The Celite® cake was washed thoroughly with more EtOAc and 
aqueous 10% Na2CO3 solution). The aqueous layer of the filtrate was separated from the 
organic layer, and the organic layer was washed further with 10% Na2CO3 aqueous solution (30 
ml). The aqueous layer and aqueous washing were combined and the pH was adjusted from 
basic to acid (pH ~ 1.5) with conc. HCl (10.18M). The acid aqueous phase was extracted with 
EtOAc (1 x 300 ml, then 1 x 200 ml). The combined organic extractions were washed with 1M 
HCl (50 ml), dried over anhydrous Na2SO4 and filtered. The solvent was then removed under 
reduced pressure, and the final residue was dried further in vacuo. 
White powder (2.10 g, 84%); m.p. 244 - 247 °C; IR (NaCl) vmax (cm
-1) 3380 (br s) (N-H), 2521 (br 
w) (O-H), 1687 (s) (C=O), 1632 (s) (N-H), 1530 (m) (C=C), 1325 (s) (S=O), 1270 (s) (C-O) and 1152 
(s) (S=O); 1H NMR (300MHz; d6-DMSO) δ 7.70 (d, 1H, J 2.1, Ar-H1), 7.58 (d, 1H, J 2.1, Ar-H2), 7.48 
(s, 2H, -SO2NH2) and 5.93 (s, 2H, Ar-NH2); 
13C NMR (75.5 MHz; d6-DMSO) δ 166.96, 147.43, 
142.38, 129.95, 119.18, 117.63, and 116.78; LRMS (EI): m/z = 250.0 [M+]; Anal. Calc. (Found C, 
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General procedure for the synthesis of esters (RKG262 and RKG345) 
 
The 3-amino-4-chloro-sulfamoylbenzoic acid (2.00 mmol) was dissolved in a mixture of 
methanol (6.0 ml) (ethanol in the case of RKG345) and conc. H2SO4 (3.00 mmol). The mixture 
was stirred under reflux for 5 hrs, and then allowed to cool to room temperature. The solvent 
was removed under reduced pressure, and deionised H2O (10 ml) was added to the residue. 
The aqueous phase was extracted with EtOAc (1 x 40ml, then 1 x 20 ml). The organic extracts 
were combined and washed with deionised H2O (20 ml), saturated NaHCO3 solution (20 ml), 
deionised H2O (20 ml), brine (20 ml), deionised H2O (20 ml), and finally dried over anhydrous 
Na2SO4. The organic phase was filtered, the solvent was removed under reduced pressure, and 
the residue was dried further in vacuo. 
 
1. (O-Methyl)-3-amino-4-chloro-sulfamoylbenzoate (RKG262) 
 White solid (0.431g, 81%); m.p. 175 - 178 °C; IR (NaCl) vmax (cm
-
1) 3402 (br s) (N-H), 1719 (s) (C=O), 1626 (s) (N-H), 1537 (m) 
(C=C), 1323 (s) (S=O), 1260 (s) (C-O) and 1155 (s) (S=O); 1H NMR 
(400 MHz; d6-DMSO) δ 7.66 (d, 1H, J 2.0, Ar-H1), 7.56 (d, 1H, J 
2.1, Ar-H2), 7.50 (s, 2H, -SO2NH2), 6.01 (s, 2H, Ar-NH2) and 3.80 (s, 3H, -OCH3); 
13C NMR (75.5 
MHz; d6-DMSO) δ 165.19, 146.83, 141.83, 127.98, 118.12, 117.53, 115.68 and 52.33; LRMS 
(EI): m/z = 264.0 [M+]; Anal. Calc. (Found C, 36.3; H, 3.33; N, 9.70; S, 11.8. C8H9ClN2O4S 
requires C, 36.3; H, 3.43; N, 10.6; S, 12.1%);  
 
2.  (O-Ethyl)-3-amino-4-chloro-sulfamoylbenzoate (RKG345) 
White, fine, needle-like crystals (3.11g, 93%) (12.0 mmol scale); 
m.p. 169 - 172 °C; ; IR (NaCl) vmax (cm
-1) 3361 (s) (N-H), 3272 (N-
H), 2985 (w) (C-H), 1705 (s) (C=O), 1593 (m) (C=C), 1565 (m) 
(C=C), 1531 (s) (C=C), 1481 (w) (C=C), 1327 (s) (S=O), 1304 (s) 
(C-N), 1264 (s) (C-O), 1146 (s) (S=O) and 769 (C-Cl); 1H NMR (400 MHz; d6-DMSO) δ 7.69 (d, 
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2H, J 7.1, -OCH2CH3) and 1.29 (t, 3H, J 7.1, -CH2CH3); 
13C NMR (100.6 MHz; d6-DMSO) δ 
165.47, 147.58, 142.51, 129.02, 118.85, 118.04, 116.43, 61.85 and 14.81; HRMS (EI): m/z = 
278.01235 [M+]; Anal. Calc. (Found C, 38.7; H, 3.81; N, 9.83; S, 11.6. C9H11ClN2O4S requires 
C, 38.8; H, 3.98; N, 10.1; S, 11.5%);  
 
Synthesis of phosphorane (RKG218) via the phosphonium salt (RKG217)  
 
Ethyl bromoacetate (0.333 ml, 3.00 mmol) was added dropwise to a cooled 
solution of PPh3 (944 mg, 3.60 mmol) dissolved in toluene (8.0 ml). The 
reaction mixtures temperature was allowed to warm up to room 
temperature (~19 °C), and the mixture was allowed to stir for 8 hrs under N2. The reaction 
mixture was placed in the fridge over night, and the white precipitate was collected via 
filtration, washed with cold toluene, and dryed in vacuo. 
White solid (1.30 g, quantitative); 
 
Method A: The phosphonium salt (750 mg, 1.75 mmol) was crushed into a 
fine powder and added to a solution of K2CO3 (2.42 g, 17.5 mmol) dissolved 
in deionised H2O (15ml). The reaction was stirred overnight (20 hrs) at 18 °C 
(room temperature), and the white precipitate that formed was filtered off, washed with 
deionised H2O, and dryed in vacuo. 
White solid (566 mg, 93%); 
 
Method B: The phosphonium salt (1.31 g, 3.00 mmol) was dissolved in deionised H2O (5 ml), 
and was titrated with an aqueous NaOH solution (120 mg NaOH dissolved in 5 ml deionised 
H2O). As soon as the mixture turned basic, it was placed in the fridge and left overnight. The 
white precipitate was filtered off, washed with deionised H2O, and dryed in vacuo. 
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White solid (961 mg, 92%); 1H NMR (300MHz; d1-CDCl3) δ 7.69-7.42 (m, 15H, Ar-H), 3.96 (q, 2H, 
J 7.1, CH2), 2.87 (s, 1H, P=CH) and 1.04 (m, 3H, CH3); 
13C NMR (75.5MHz; d1-CDCl3) δ 133.06, 
132.93, 131.86, 128.75, 128.58, 57.82 and 14.78; 
 
Synthesis of (2E)-3-(1-naphthalenyl)-2-propenoic acid ethyl ester (RKG327) 
 
The phosphorane (RKG218) (2.79 g, 8.01 mmol) was dissolved in toluene (25 ml). 1-
Naphthaldehyde (1.02 ml, 7.50 mmol) was added dropwise to the mixture, and the reaction 
mixture was refluxed at 120 °C for 20 hrs. The reaction was allowed to cool 
to room temperature, and the toluene was removed under reduced 
pressure. The resulting orange residue was flash column chromatographed 
(5:95, EtOAc:hexane) to isolate the alkene as a clear oil. 
Clear, pale yellow oil (1.79 mg, quantitative); Rf = 0.18; 
 
Synthesis of 3-(1-naphthalenyl)-2-propenoic acid ethyl ester (RKG329) 
 
Ester (RKG327) (1.00 g, 4.42 mmol) was dissolved in a 1:1 mixture of 
EtOH and EtOAc (10 ml). A catalytic amount of 10% Pd/C (~20 mg) was 
added, and H2 gas was bubbled through the solution for 20 min. The 
reaction was left to stir for a further 48 hrs under an atmosphere of H2 
gas. The reaction mixture was filtered through Celite®, and the Celite® 
cake was washed thoroughly with EtOAc (~200 ml).  The filtrate solvent 
was removed under reduced pressure, and an oil was obtained.  
Clear, pale orange oil (959 mg, 95%); 1H NMR (400 MHz; d1-CDCl3) δ 8.05 (d, 1H, J 8.1, Ar-H
9), 
7.86 (d, 1H, J 7.3, Ar-H6), 7.74 (d, 1H, J 8.0, Ar-H5), 7.53 (t, 1H, J = 8.1, Ar-H8), 7.49 (t, 1H, J 8.1, 
Ar-H7), 7.40 (t, 1H, J 7.1, Ar-H4), 7.36 (d, 1H, J 7.0), Ar-H3), 4.16 (quar, 2H, J 7.1, -OCH2CH3), 3.43 
(t, 2H, J 8.1, CH2
2), 2.76 (t, 2H, J 8.1, CH2
1) and 1.25 (t, 3H, J 7.1, -CH2CH3); 
13C NMR (100.6 MHz; 
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123.42, 60.49, 35.29, 28.15 and 14.22; LRMS (EI): m/z = 228.1 [M+]; Anal. Calc. (Found C, 78.7; 
H, 7.01. C15H16O2 requires C, 78.9; H, 7.06%); 
 
Synthesis of (2E)-3-(1-naphthalenyl)-2-propenoic acid (RKG259) 
 
Sodium hydroxide (353 mg, 8.83 mmol) was dissolved in a mixture of 
EtOH (5.0 ml) and deionised H2O (1.0 ml). The basic solution was added 
with stirring to a solution of ester (RKG327) (799 mg, 3.53 mmol) 
dissolved in EtOH (15 ml). The mixture was stirred under reflux (~85 °C) 
for 2 hrs [OBSERVATION: reaction mixture turned from yellow to dark 
orange in colour]. The reaction was allowed to cool to room 
temperature, and chloroform (20 ml) and deionised H2O (20 ml) were added. The layers were 
separated, and the organic layer was washed with aqueous 10% Na2CO3 solution (20 ml). The 
aqueous layers were combined and washed with chloroform (20 ml). The aqueous layer pH was 
adjusted from basic to acidic (pH ~ 1.5) with 6M HCl (added dropwise). A pale orange 
precipitate formed, and was filtered off and washed with deionised H2O.  
Light pale orange solid (601 mg, 86%); m.p. 173 - 177 °C; IR (NaCl) vmax (cm
-1) 3046 (m) (C-H), 
2835 (br m) (O-H), 1682 (s) (C=O), 1617 (s) (C=C), 1296 (s) (C-O), 790 and 766 (s) (C-H); 1H NMR 
(300MHz; d6-DMSO) δ 8.37 (d, 1H, J 15.8, C=CH2), 8.18 (d, 1H, J 8.1, Ar-H9), 8.01-7.90 (m, 3H, Ar-
H6+7+8), 7.64-7.52 (m, 3H, Ar-H3+4+5) and 6.57 (d, 1H, J 15.7, C=CH1); 13C NMR (75.5 MHz; d6-
DMSO) δ 167.23, 140.02, 133.18, 130.92, 130.64, 130.20, 128.58, 126.99, 126.14, 125.58, 
125.09, 122.85 and 121.88; LRMS (EI): m/z = 198.1 [M+]; Anal. Calc. (Found C, 78.4; H, 5.01. 
C13H10O2 requires C, 78.8; H, 5.09%); 
 
Synthesis of 3-(1-naphthalenyl)-2-propenoic acid (RKG332) 
 
Sodium hydroxide (394 mg, 9.85 mmol) was dissolved in deionised H2O (2.0 ml). The basic 
solution was added with stirring to a solution of ester (RKG329) (900 mg, 3.94 mmol) dissolved 
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allowed to cool to room temperature, and chloroform (35 ml) and 
deionised H2O (40 ml) were added. The layers were separated, and the 
organic layer was washed with aqueous 2M NaOH solution (20 ml). The 
basic aqueous layers were combined and washed with chloroform (20 
ml). The basic aqueous layers pH was adjusted from basic to acidic (pH ~ 
1.5) with 6M HCl (added dropwise), and a white precipitate formed. The 
precipitate was filtered off and washed with aqueous 1M HCl solution and deionised H2O.  
White powder (728 mg, 92%); m.p. 143 - 146 °C; IR (NaCl) vmax (cm
-1) 3048 (m) (C-H), 2924 (m) 
(C-H), 2638 (m) (O-H), 1704 (s) (C=O), 1598 (m) (C=C), 1508 (m) (C=C), 1438 (s) (C=C) and 1225 
(s) (C-O); 1H NMR (d1-CDCl3) δ 7.83 (dd, 1H, J 8.2, 1.3, Ar-H
9), 7.63 (dd, 1H, J 7.9, 1.6, Ar-H6), 7.50 
(dd, 1H, J 7.4, 2.0, Ar-H5), 7.30 (dt, 1H, J  6.8, 1.5, Ar-H8), 7.25 (dt, 1H, J 6.8, 1.3, Ar-H7), 7.16 (m, 
2H, Ar-H3+4), 3.19 (t, 2H, J 8.2, CH2
2) and 2.50 (t, 2H, J 8.1, CH2
1); HRMS (EI): m/z = 200.08318 
[M+]; Anal. Calc. (Found C, 77.1; H, 5.93. C13H12O2 requires C, 78.0; H, 6.04%);  
 
Synthesis of (2E)-3-(1-naphthalenyl)-2-propenoyl chloride and 3-(1-naphthalenyl)-2-propenoyl 
chloride 
 
An excess of freshly distilled SOCl2 was added in a 
dropwise manner to the carboxylic acid (RKG259 or 
RKG332) (700 mg, 3.53 mmol) with stirring. The 
mixture was heated gently for 1 hr at 100 °C under 
N2 (a further 1ml of SOCl2 was added after the first 
20 min to make a clear solution). The reaction was 
allowed to cool to room temperature (~20 oC), and then distilled at atmospheric pressure to 
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Synthesis of 4-chloro-3-(3-naphthalen-1-yl-acryloylamino)-5-sulfamoyl-benzoic acid (RKG223) 
 
Acetone (1.5 ml) was added to the unpurified acid 
chloride, and the resulting solution was added 
dropwise to a solution of 3-amino-4-chloro-
sulfomoylbenzoic acid (RKG211) (875 mg, 3.53 mmol) 
(assuming that the formation of the acid chloride was 
quantitative) dissolved in acetone (4.0 ml). The 
reaction mixture was stirred at room temperature (19 °C) for 6 hrs. The reaction vessel was 
cooled down on ice, and the cooled reaction mixture was added to 1M HCl (30 ml). A white 
precipitate formed, and was filtered off. The precipitate was recrystallized from MeOH to give a 
pure white product.  
White solid (1.21 g, 80% over two steps); m.p. 298 - 302 °C; IR (NaCl) vmax (cm
-1) 3359 (s) (N-H), 
3112 (m) (C-H), 2866 (br m) (O-H), 1696 (s) (C=O), 1677 (s) (C=O), 1619 (s) (N-H), 1529 (s) (C=C), 
1347 (s) (S=O),  1251 (s) (C-O) and 1160 (s) (S=O); 1H NMR (300MHz; d6-DMSO) δ 10.09 (s, 1H, 
CONH), 8.74 (d, 1H, J 2.0, Ar-H1), 8.45 (d, 1H, J 15.6, C=CH4), 8.36 (d, 1H, J 2.1, Ar-H2), 8.28 (d, 
1H, J 8.4, Ar-H11), 8.02 (m, 2H, 2 x Ar-H7+8), 7.92 (d, 1H, J 7.2, Ar-H5), 7.80 (s, 2H, -SO2NH2), 7.72-
7.58 (m, 3H, 3 x Ar-H6+9+10) and 7.23 (d, 1H, J 15.5, C=CH3); 13C NMR (100.6 MHz; d6-DMSO) δ 
165.49, 164.23, 142.19, 138.03, 137.22, 133.34, 131.44, 130.79, 130.18, 129.33, 128.68, 128.57, 
127.34, 127.06, 126.28, 125.69, 125.01, 124.98, 124.04 and 123.09; LRMS (EI): m/z = 430.2 
[M+]; Anal. Calc. (Found C, 55.1; H, 3.51; N, 6.11; S, 6.88. C20H15ClN2O5S requires C, 55.8; H, 3.51; 
N, 6.50; S, 7.44%); 
 
Synthesis of 4-chloro-3-(3-naphthalen-1-yl-acryloylamino)-5-sulfamoyl-benzoic acid methyl 
ester (RKG260)  
(NOTE: the acid chloride was synthesized as discussed above, except on a 3.00 mmol scale) 
 
Acetone (2.0 ml) was added to the unpurified acid chloride, and the resulting solution was 
added dropwise to a solution of (O-methyl)-3-amino-4-chloro-sulfomoylbenzoate (RKG262) 
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dissolved in acetone (3.0 ml). The reaction mixture 
was stirred at room temperature (19 °C) for 6 hrs 
(more acetone was added periodically to aid stirring 
due to the formation of a precipitate). The reaction 
mixture was added to 1M HCl (30 ml). A white 
precipitate formed, and was filtered off and washed 
with 1M HCl and cold acetone, to afford a white product.  
White solid (869 mg, 71% over two steps); m.p. 271 - 275 °C; IR (NaCl) vmax (cm
-1) 3267 (s) (N-H), 
3015 (m) (C-H), 1715 (s) (C=O), 1656 (s) (C=O), 1628 (s) (N-H), 1524 (s) (C=C), 1343 (s) (S=O),  
1253 (s) (C-O) and 1160 (s) (S=O); 1H NMR (400 MHz; d6-DMSO) δ 10.12 (s, 1H, CONH), 8.78 (d, 
1H, J 2 .1, Ar-H1), 8.45 (d, 1H, J 15.6, C=CH4), 8.35 (d, 1H, J  2.1, Ar-H2), 8.26 (d, 1H, J 8.4, Ar-H11), 
8.01 (m, 2H, 2 x Ar-H7+8), 7.91 (d, 1H, J 7.1, Ar-H5), 7.84 (s, 2H, -SO2NH2), 7.67-7.52 (m, 3H, 3 x 
Ar-H6+9+10), 7.23 (d, 1H, J 15.5, C=CH3) and 3.92 (s, 3H, -CO2CH3); 
13C NMR (100.6 MHz; d6-
DMSO) δ 164.52, 164.27, 142.37, 138.14, 137.40, 133.34, 131.43, 130.79, 130.20, 128.68, 
128.19, 128.04, 127.60, 127.06, 126.27, 125.68, 124.98, 124.69, 123.99, 123.10 and 52.76; 
LRMS (EI): m/z = 444.1 [M+]; Anal. Calc. (Found C, 56.5; H, 3.77; N, 5.51; S, 6.66. C21H17ClN2O5S 
requires C, 56.7; H, 3.85; N, 6.30; S, 7.21%);  
 
Synthesis of 4-chloro-3-(3-naphthalen-1-yl-propionylamino)-5-sulfamoyl-benzoic acid methyl 
ester (RKG333)  
(NOTE: the acid chloride was synthesized as discussed above, except on a 1.50 mmol scale) 
 
Acetone (2.0 ml) was added to the unpurified acid 
chloride, and the resulting solution was added 
dropwise to a solution of (O-methyl)-3-amino-4-
chloro-sulfomoylbenzoate (RKG262) (384 mg, 1.45 
mmol) (assuming that the formation of the acid 
chloride was quantitative) dissolved in acetone (2.0 
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added periodically to aid stirring due to the formation of a precipitate). The reaction mixture 
was added to 1M HCl (20 ml). A white precipitate formed, and was filtered off and washed with 
1M HCl and acetone, to afford a white product.  
White solid (378 mg, 58% over two steps); m.p. 237 - 239 °C; IR (NaCl) vmax (cm
-1) 3399 (s) (N-H), 
3274 (s) (CON-H), 3006 (w) (C-H), 1733 (s) (C=O), 1669 (s) (C=O), 1597 (m) (C=C), 1567 (m) 
(C=C), 1521 (s) (C=C), 1335 (s) (S=O), 1241 (s) (C-O), 1164 (s) (S=O) and 769 (s) (C-Cl); 1H NMR 
(400 MHz; d6-DMSO) δ 9.87 (s, 1H, CONH), 8.46 (d, 1H, J 2.0, Ar-H1), 8.31 (d, 1H, J 2.0, Ar-H2), 
8.14 (d, 1H, J 8.3, Ar-H11), 7.92 (d, 1H, J 7.9, Ar-H8), 7.78 (m, 3H, Ar-H7 and –SO2NH2), 7.57 (t, 1H, 
J 8.1, Ar-H10), 7.52 (t, 1H, J 7.9, Ar-H9), 7.43 (m, 2H, 2 x Ar-H5+6), 3.90 (s, 3H, -CO2CH3), 3.42 (t, 
2H, J 8.0, CH2
4) and 2.89 (t, 2H, CH2
3); 13C NMR (100.6 MHz; d6-DMSO) δ 172.10, 165.22, 143.06, 
138.11, 137.62, 134.14, 132.01, 129.74, 129.31, 129.15, 128.65, 127.41, 126.79, 126.51, 126.31, 
126.28, 125.60, 124.29, 53.47, 37.34 and 28.44; HRMS (EI): m/z = 446.06974 [M+]; Anal. Calc. 
(Found C, 55.9; H, 4.15; N, 5.77; S, 7.16. C21H19ClN2O5S requires C, 56.4; H, 4.29; N, 6.27; S, 
7.17%); 
 
Synthesis of 4-chloro-3-(3-naphthalen-1-yl-propylamino)-5-sulfamoyl-benzoic acid methyl ester 
(RKG335F2) 
 
RKG333 (250 mg, 0.56 mmol) was added to dried 
(anhydrous) THF (2.5 ml). The resulting suspension 
was cooled to 0 °C, and the borane-THF complex 
(1.0M in THF) (1.2 ml, 1.19 mmol) was added 
dropwise and was stirred for 15 minutes. The 
mixture was heated and refluxed for 21 hrs under 
an atmosphere of N2. After cooling to room temperature, the reaction mixture was quenched 
with glacial acetic acid (~10 ml). The apparatus was rearranged for distillation, and the THF was 
distilled off (distillation was aided by the application of a slight vacuum). The resulting acidic 
solution was cooled to 0 °C and aqueous 10% Na2CO3 solution was added until a pH of 6-7 was 
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(2 x 20 ml). The organic layer was washed with deionized H2O (20 ml), and dryed over 
anhydrous Na2SO4, filtered, and the solvent was removed under reduced pressure. The brown 
residue was dryed further in vacuo and column chromatographed (2.5:97.5, MeOH:DCM), 
yielding RKG355F2. 
Clear, pale yellow oil (51.3 mg, 21%); Rf = 0.56; 
1H NMR (400 MHz; d4-MeOD) δ 8.01 (m, 2H, 2 x 
Ar-H1+12), 7.86 (d, 1H, J 8.3, Ar-H9), 7.74 (d, 1H, J 8.1, Ar-H8), 7.49 (m, 2H, 2 x Ar-H10+11), 7.47 (d, 
1H, J 1.8, Ar-H2), 7.41 (t, 1H, J 8.1, Ar-H7), 7.34 (d, 1H, J 7.0, Ar-H6), 3.91 (s, 3H, -CO2CH3), 3.36 (t, 
2H, J 7.0, N-CH2
3), 3.24 (t, 2H, J 7.4, Ar-CH2
5) and 2.18 (quin, 2H, J 7.0, CH2
4); 13C NMR (100.6 
MHz; d4-MeOD) δ 165.68, 145.40, 140.05, 136.94, 134.03, 131.70, 129.56, 128.95, 127.10, 
126.11, 126.03, 125.56, 123.76, 123.42, 117.54, 115.30, 52.59, 43.58, 30.27 and 29.77; LRMS 
(EI): m/z = 432.0 [M+]; Anal. Calc. (Found C, 58.1; H, 4.65; N, 6.17; S, 7.67. C21H21ClN2O4S 
requires C, 58.3; H, 4.89; N, 6.47; S, 7.41%); 
 
Synthesis of 4-chloro-3-(3-naphthalen-1-yl-propylamino)-5-sulfamoyl-benzoic acid (RKG340) 
 
Sodium hydroxide (18.9 mg, 0.47 mmol) was 
dissolved in a mixture of MeOH (1.1 ml) and 
deionized H2O (0.2 ml), and added to a stirring 
solution of RKG335F2 (51.3 mg, 0.12 mmol) 
dissolved in MeOH (1.0 ml). The reaction mixture 
was stirred under reflux (~80 °C) for 2 hrs. The 
reaction was allowed to cool to room temperature, and chloroform (10 ml) and deionized H2O 
(5.0 ml) were added, followed by 10% Na2CO3 aqueous solution (5.0 ml). The layers were 
separated, and the organic phase was washed with 10% Na2CO3 aqueous solution (10 ml). The 
aqueous layers were combined and washed with chloroform (10 ml). The aqueous layer pH was 
adjusted from basic to neutral (6/7). A white precipitate formed and was filtered off, washed 
with deionized H2O, and finally dried in vacuo. 
White powder (28.6 mg, 58%); m.p. 248 - 250 °C; IR (NaCl) vmax (cm
-1) 3379 (m) (N-H), 2891 (w) 
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(S=O), 1246 (m) (C-O), 1154 (s) (S=O) and 795 (s) (C-Cl); 1H NMR (300 MHz; d6-DMSO) δ 8.04 (m, 
1H, Ar-H12), 7.89 (m, 1H, Ar-H9), 7.76 (d, 1H, J = 1.9, Ar-H1), 7.74 (m, 1H, Ar-H8), 7.54 (s, 2H, -
SO2NH2), 7.48 (m, 2H, 2 x Ar-H
10+11), 7.40 (m, 2H, 2 x Ar-H6+7), 7.38 (d, 1H, J 2.0, Ar-H2), 6.05 (t, 
1H, J 5.6, NH), 3.35 (m, 2H, N-CH2
3), 3.14 (t, 2H, J 7.6, Ar-CH2
5) and 1.99 (quin, 2H, J 7.4, CH2
4); 
13C NMR (75.5 MHz; d6-DMSO) δ 166.33, 145.55, 141.71, 137.67, 133.40, 131.23, 129.84, 
128.49, 126.36, 125.79, 125.74, 125.49, 125.43, 123.50, 118.14, 115.65, 113.59, 42.68, 29.50 
and 29.16; HRMS (EI): m/z = 418.07491 [M+]; Anal. Calc. (Found C, 57.0; H, 4.44; N, 6.22; S, 6.96. 
C20H19ClN2O4S requires C, 57.3; H, 4.57; N, 6.69; S, 7.65%); 
 
General procedure for the synthesis of amides (RSON104, RSON105, RSON106, RSON112 and 
RKG303A) 
 
A mixture (suspension) of amide (RKG251) (500 mg, 1.57 mmol) in methanol (20 ml) was placed 
in a reaction tube. The amine (3.5 equivalents, 5.50 mmol) was added dropwise with stirring (if 
the amine is a liquid), and the reaction was left to stir for 20 hrs at room temperature (~19 °C) 
[OBSERVATION: the suspension of amide disappeared over time, later followed by the 
formation of another precipitate]. The precipitate was filtered off, washed with cold methanol 
and dried in vacuo. 
 
1. 4-Chloro-3-(3-morpholin-4-yl-propionylamino)-5-sulfamoyl-benzoic acid methyl ester 
RSON104 
White solid (394 mg, 62%) (0.31 mmol scale: 78%); 
m.p. 195 - 199 °C; IR (NaCl) vmax (cm
-1) 3341 (m) 
(N-H), 2811 (m) (C-H), 1722 (s) (C=O), 1678 (s) 
(C=O), 1574 (s) (N-H), 1531 (s) (C=C), 1348 (s) 
(S=O), 1229 (s) (C-O) and 1161 (s) (S=O); 1H NMR 
(300 MHz; d6-DMSO) δ 10.48 (s, 1H, CONH), 8.77 (d, 1H, J 2.2, Ar-H1), 8.27 (d, 1H, J 2.0, 
Ar-H2), 7.77 (s, 2H, -SO2NH2), 3.89 (s, 3H, -CO2CH3), 3.63 (t, 4H, J 4.7, 2 x CH2
6-O), 2.63 
(m, 4H, 2 x CH2
3+4) and 2.48 (m, 4H, 2 x CH2
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164.50, 142.11, 137.51, 128.02, 126.87, 126.09, 123.91, 65.92 (2C), 53.73, 52.76 (2C), 
52.66 and 32.67; LRMS (EI): m/z = 405.1 [M+]; Anal. Calc. (Found C, 44.0; H, 4.79; N, 
10.2; S, 7.24. C15H20ClN3O6S requires C, 44.4; H, 4.97; N, 10.4; S, 7.90%); 
 
2. 4-Chloro-3-(3-piperidin-1-yl-propionylamino)-5-sulfamoyl-benzoic acid methyl ester 
(RSON106) 
White solid (503 mg, 79%); m.p. 200 - 202 °C; IR (NaCl) vmax (cm
-1) 3357 (m) (N-H), 2783 
(m) (C-H), 1728 (s) (C=O), 1662 (s) (C=O), 1574 (s) (N-H), 1533 (s) (C=C), 1351 (s) (S=O), 
1229 (s) (C-O) and 1159 (s) (S=O); 1H NMR (300 
MHz; d6-DMSO) δ 10.85 (s, 1H, CONH), 8.85 (d, 
1H, J 2.1, Ar-H1), 8.25 (d, 1H, J 2.1, Ar-H2), 7.77 (s, 
2H, -SO2NH2), 3.89 (s, 3H, -CO2CH3), 2.60 (m, 4H, 
2 x CH2
3+4), 2.45 (t, 4H, J 5.0, 2 x CH2
5-N), 1.56 
(quin, 4H, J 5.1, 2 x CH2
6) and 1.42 (quin, 2H, 
CH2
7); 13C NMR (75.5 MHz; d6-DMSO) δ 171.32, 164.53, 142.06, 137.63, 128.03, 126.40, 
125.52, 123.66, 53.88, 53.39 (2C), 52.64, 32.81, 25.16 (2C) and 23.79; LRMS (EI): m/z = 
403.1 [M+]; Anal. Calc. (Found C, 47.1; H, 4.95; N, 10.4; S, 8.25. C16H22ClN3O5S requires C, 
47.6; H, 5.49; N, 10.4; S, 7.94%);  
 
3. 4-Chloro-3-[3-(4-methyl-piperidin-1-yl)-propionylamino]-5-sulfamoyl-benzoic acid methyl 
ester (RSON105) 
White solid (527 mg, 80%); m.p. 207 – 209 °C; 
IR (NaCl) vmax (cm
-1) 3357 (m) (N-H), 2835 (m) 
(C-H), 1720 (s) (C=O), 1671 (s) (C=O), 1575 (s) 
(N-H), 1539 (s) (C=C), 1348 (s) (S=O), 1233 (s) 
(C-O) and 1160 (s) (S=O); 1H NMR (300 MHz; 
d6-DMSO) δ 10.83 (s, 1H, CONH), 8.85 (d, 1H, 
J 2.0, Ar-H1), 8.25 (d, 1H, J = 2.0, Ar-H2), 7.79 (s, 2H, -SO2NH2), 3.89 (s, 3H, -CO2CH3), 2.99 
(d, 2H, J 11.2, 2 x CH5H-N), 2.61 (m, 4H, 2 x CH2
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(d, 2H, J 12.3, 2 x CHH6), 1.37 (m, 1H, CH7), 1.19 (quar, 2H, J 12.1, CH6H) and 0.90 (d, 3H, 
CH3
8); 13C NMR (100.6 MHz; d6-DMSO) δ 171.39, 164.59, 142.10, 137.70, 128.07, 126.44, 
123.71 (2C), 53.56, 52.84 (2C), 52.71, 33.58 (2C), 32.96, 30.12 and 21.69; LRMS (EI): m/z 
= 417.1 [M+]; Anal. Calc. (Found C, 48.5; H, 5.62; N, 9.84; S, 6.88. C17H24ClN3O5S requires 
C, 48.9; H, 5.79; N, 10.1; S, 7.67%);  
 
4. 3-[3-(4-Benzyl-piperidin-1-yl)-propionylamino]-4-chloro-5-sulfamoyl-benzoic acid methyl 
ester (RSON112) 
White solid (633 mg, 82%); m.p. 127 
- 131 °C; IR (NaCl) vmax (cm
-1) 3316 
(m) (N-H), 2832 (m) (C-H), 1722 (s) 
(C=O), 1678 (s) (C=O), 1575 (s) (N-
H), 1533 (s) (C=C), 1347 (s) (S=O), 
1240 (s) (C-O) and 1181 (s) (S=O); 1H 
NMR (300 MHz; d6-DMSO) δ 10.78 (s, 1H, CONH), 8.84 (d, 1H, J 2.1, Ar-H1), 8.26 (d, 1H, J 
2.1, Ar-H2), 7.79 (s, 2H, -SO2NH2), 7.29-7.14 (m, 5H, 5 x Ar-H), 3.89 (s, 3H, -CO2CH3), 2.97 
(d, 2H, J 11.5, 2 x CHH5-N), 2.60 (m, 4H, 2 x CH2
3+4), 2.51 (d, 2H, J 6.4, CH2
8), 1.90 (t, 2H, J 
11.7, 2 x CH5H-N), 1.57 (m, 3H, CH7 and 2 x CHH6) and 1.25 (quar, 2H, 2 x CH6H); 13C NMR 
(100.6 MHz; d6-DMSO) δ 171.36, 164.56, 142.08, 140.23, 137.66, 128.82 (2C), 128.06 
(2C), 126.48, 125.67, 125.57, 123.70, 53.53, 52.74 (2C), 52.69, 42.27, 37.24, 33.00 and 
31.46 (2C); LRMS (EI): m/z = 493.1 [M+]; Anal. Calc. (Found C, 55.8; H, 5.70; N, 8.21; S, 
5.93. C23H28ClN3O5S requires C, 55.9; H, 5.71; N, 8.51; S, 6.49%); 
 
5. 4-Chloro-3-{3-[2-(7-chloro-quinolin-4-ylamino)-ethylamino]-propionylamino}-5-
sulfamoyl-benzoic acid methyl ester (RKG303A) 
White powder (246 mg, 72%) (0.63 mmol scale); m.p. 127 - 131 °C; IR (NaCl) vmax (cm
-1) 
3394 (m) (N-H), 2837 (m) (C-H), 1717 (s) (C=O), 1671 (s) (C=O), 1575 (s) (C=C), 1534 (s) 
(C=C), 1334 (s) (S=O), 1220 (s) (C-O), 1160 (s) (S=O) and 764 (s) (C-Cl); 1H NMR (300 MHz; 
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8.24 (d, 1H, J 9.1, Ar-H11), 7.78 (d, 
1H, J 2.2, Ar-H9), 7.42 (dd, 1H, J 9.0, 
2.3, Ar-H10), 7.23 (t, 1H, J 4.8, NH), 
6.54 (d, 1H, J 5.5, Ar-H7), 3.92 (s, 
3H, -CO2CH3), 3.45 (quar, 2H, J 6.0, 
CH2
6-N), 2.96 (m, 4H, 2 x CH2
4+5) 
and 2.60 (t, 2H, J 6.0, CH2
3); 13C NMR (75.5 MHz; d6-DMSO) δ 171.68, 164.58, 151.85, 
150.10, 148.95, 142.13, 137.72, 133.33, 128.00, 127.37, 126.58, 126.04, 123.95 (2C), 
123.78, 117.39, 98.66, 52.69, 46.72, 44.45, 42.19 and 35.93; LRMS (EI): m/z = 539.03 
[M+]; Anal. Calc. (Found C, 48.1; H, 4.27; N, 12.8; S, 5.63. C22H23Cl2N5O5S requires C, 48.9; 
H, 4.29; N, 13.0; S, 5.93%);  
 
General procedure for the synthesis of amines (RSON108 and RSON109) 
 
The amide (400 mg) is added to anhydrous THF (2.5 ml). The suspension was cooled to 0 °C and 
the borane-THF complex (3.0 equiv) was added dropwise under N2. The reaction mixture was 
stirred for a further 15 min at 0 °C, and then heated and stirred under reflux for 20 hrs under 
N2. After cooling to room temperature, the reaction mixture was quenched with dried glacial 
acetic acid (~10 ml). The apparatus was rearranged for distillation, and the THF was distilled off. 
The pH of the reaction mixture was adjusted to 6-7 using a 10% Na2CO3 aqueous solution. A 
brown residue formed, and was extracted from the aqueous solution with EtOAc. The organic 
extracts were combined and dried over anhydrous Na2SO4, filtered and dried under reduced 
pressure. The brown residue was dried further in vacuo and column chromatographed (1:9, 
MeOH:EtOAc). 
 
1. 4-Chloro-3-[3-(4-methyl-piperidin-1-yl)-propylamino]-5-sulfamoyl-benzoic acid methyl 
ester (RSON108) 
White powder (68 mg, 17%); 1H NMR (400 MHz; d4-MeOD) δ 7.93 (d, 1H, J 1.9, Ar-H1), 
7.47 (d, 1H, J 1.8, Ar-H2), 3.91 (s, 3H, -CO2CH3), 3.33 (t, 2H, J 6.4, N-CH2
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12.0, 2 x CHH6), 2.49 (t, 2H, J 7.1, N-CH2
5), 1.99 
(td, 2H, J 11.9, 2.1, 2 x CH6H), 1.88 (quin, 2H, J 
7.0, CH2
4), 1.66 (d, 2H, J 12.9, 2 x CHH7), 1.40 
(m, 1H, CH8), 1.28 (quar-d, 2H, J 12.1, 3.6, 2 x 
CH7H) and 0.94 (d, 3H J 6.3, CH3
9); 13C NMR 
(100.6 MHz; d4-MeOD) δ 167.46, 147.50, 142.82, 130.34, 117.60, 115.11, 58.05, 55.14 
(2C), 53.00, 43.58, 35.03 (2C), 31.92, 26.36 and 22.16; LRMS (EI): m/z = 403.1 [M+]; Anal. 
Calc. (Found C, 50.1; H, 6.48; N, 9.79; S, 7.31. C17H26ClN3O4S requires C, 50.6; H, 6.49; N, 
10.4; S, 7.94%); 
 
2. 4-Chloro-3-(3-piperidin-1-yl-propylamino)-5-sulfamoyl-benzoic acid methyl ester 
(RSON109) 
White powder (141 mg, 36%); 1H NMR (400 MHz; 
d4-MeOD) δ 7.73 (d, 1H, J 2.0, Ar-H1), 7.32 (d, 1H, 
J 2.0, Ar-H2), 3.85 (s, 3H, -CO2CH3), 3.24 (quar, 2H, 
J 6.5, N-CH2
3), 2.48 (quin, 2H, J 1.9, 2 x CHH6), 
2.37 (t, 2H, J 6.3, N-CH2
5), 2.34 (m, 2H, 2 x CH6H), 
1.75 (quin, 2H, J 6.3, CH2
4), 1.53 (m, 4H, 2 x CH2
7) and 1.39 (m, 2H, CH2
8); 13C NMR (100.6 
MHz; d4-MeOD) δ 165.35, 146.01, 141.75, 128.44, 118.48, 115.15, 113.00, 57.33, 54.22 
(2C), 52.44, 42.92, 25.36 (2C), 24.27 and 24.01; LRMS (EI): m/z = 389.1 [M+]; Anal. Calc. 
(Found C, 48.9; H, 6.13; N, 9.98; S, 8.01. C16H24ClN3O4S requires C, 49.3; H, 6.20; N, 10.8; 
S, 8.22%); 
 
General procedure for the synthesis of amides (RKG2432, RKG2431, RKG2441, RKG2471, 
RKG2461 and RKG2462) 
 
A mixture (suspension) of amide (RKG209) (200 mg, 0.66 mmol) in methanol (5.0 ml) was 
placed in a reaction tube. The amine (3.5 equivalents, 2.30 mmol) was added dropwise with 
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was removed under reduced pressure, and the obtained residue was dissolved in deionized H2O 
(~10 ml). The pH of the aqueous solution was adjusted to neutral, and a precipitate formed. The 
precipitate was filtered off, washed with deionized H2O and dried in vacuo. 
 
1. 4-Chloro-3-(3-pyrrolidin-1-yl-propionylamino)-5-sulfamoyl-benzoic acid (RKG2432) 
White solid (29.1 mg, 12%); m.p. 202 - 206 °C; IR 
(NaCl) vmax (cm
-1) 3295 (m) (N-H), 2883 (m) (C-H), 
2434 (br m) (O-H), 1676 (s) (C=O), 1562 (s) (N-H), 
1540 (s) (C=C), 1373 (s) (S=O), 1282 (s) (C-O) and 1154 
(s) (S=O); 1H NMR (400 MHz; d6-DMSO) δ 10.3 (s, 1H, 
CONH), 8.50 (d, 1H, J 1.9, Ar-H1), 8.29 (d, 1H, J 2.0, Ar-
H2), 7.62 (s, 2H, -SO2NH2), 3.27 (t, 2H, J 6.8, CH2
4), 3.12 (m, 4H, 2 x CH2
5), 2.89 (t, 2H, J 
7.0, CH2
3) and 1.88 (m, 4H, 2 x CH2
6); 13C NMR (100.6 MHz; d6-DMSO) δ 168.89, 165.76, 
141.53, 136.25, 130.87, 129.49, 127.76, 125.70, 53.65 (2C), 49.81, 31.40 and 22.42 (2C); 
LRMS (EI): m/z = 375.0 [M+]; Anal. Calc. (Found C, 44.3; H, 4.73; N, 10.5; S, 8.00. 
C14H18ClN3O5S requires C, 44.7; H, 4.83; N, 11.2; S, 8.53%); 
 
2. 4-Chloro-3-(morpholin-4-yl-propionylamino)-5-sulfamoyl-benzoic acid (RKG2431) 
White solid (53.1 mg, 21%); m.p. 172 - 176 °C; IR 
(NaCl) vmax (cm
-1) 3429 (m) (N-H), 3015 (m) (C-H), 
2425 (br m) (O-H), 1682 (s) (C=O), 1558 (s) (N-H), 
1528 (s) (C=C), 1375 (s) (S=O), 1265 (s) (C-O) and 
1160 (s) (S=O); 1H NMR (400 MHz; d6-DMSO) δ 
10.2 (s, 1H, CONH), 8.53 (d, 1H, J 1.8, Ar-H1), 8.31 (d, 1H, J 1.9, Ar-H2), 7.71 (s, 2H, -
SO2NH2), 3.59 (t, 4H, J 4.6, 2 x CH2
6), 2.60 (m, 4H, 2 x CH2
3+4) and 2.49 (m, 4H, 2 x CH2
5); 
13C NMR (100.6 MHz; d6-DMSO) δ 170.97, 165.56, 141.86, 137.27, 129.79, 127.28, 
125.60, 124.26, 65.89 (2C), 53.74, 52.75 (2C) and 32.65; LRMS (EI): m/z = 391.2 [M+]; 
Anal. Calc. (Found C, 41.1; H, 4.84; N, 9.67; S, 7.60. C14H18ClN3O6S requires C, 42.9; H, 
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3. 4-Chloro-3-(3-piperidin-1-yl-propionylamino)-5-sulfamoyl-benzoic acid (RKG2441) 
White solid (108 mg, 42%); m.p. 221 - 224 °C; IR 
(NaCl) vmax (cm
-1) 3390 (m) (N-H), 2949 (m) (C-H), 
2309 (br m) (O-H), 1682 (s) (C=O), 1638 (m) 
(C=O), 1563 (s) (N-H), 1368 (s) (S=O), 1268 (m) 
(C-O) and 1156 (s) (S=O); 1H NMR (400 MHz; d6-
DMSO) δ 10.0 (s, 1H, CONH), 8.40 (d, 1H, J 2.0, 
Ar-H1), 8.30 (d, 1H, J 2.1, Ar-H2), 7.64 (s, 2H, -SO2NH2), 3.37 (t, 2H, J 10.8, 2 x CHH
5), 3.31 
(t, 2H, J 7.1, CH2
4), 2.93 (t, 2H, J 7.1, CH2
3), 2.86 (t, 2H, J 10.6, 2 x CH5H), 1.76-1.66 (m, 
5H, 2 x CH2
6 and CHH7) and 1.37 (m, 1H, CH7H); 13C NMR (100.6 MHz; d6-DMSO) δ 
168.82, 165.26, 141.99, 136.61, 132.72, 129.22, 128.26, 125.54, 52.45 (2C), 51.59, 
29.99, 22.34 (2C) and 20.93; LRMS (EI): m/z = 389.0 [M+]; Anal. Calc. (Found C, 45.8; H, 
5.16; N, 10.4; S, 7.81. C15H20ClN3O5S requires C, 46.2; H, 5.17; N, 10.8; S, 8.22%); 
 
4. 4-Chloro-3-[3-(4-methyl-piperidin-1-yl)-propionylamino]-5-sulfamoyl-benzoic acid 
(RKG2471) 
White solid (87.3 mg, 65%) (0.33 mmol scale); 
m.p. 219 - 222 °C; IR (NaCl) vmax (cm
-1) 3388 
(m) (N-H), 2925 (m) (C-H), 2350 (br m) (O-H), 
1686 (s) (C=O), 1637 (m) (C=O), 1565 (s) (N-H), 
1373 (s) (S=O), 1275 (m) (C-O) and 1157 (s) 
(S=O); 1H NMR (400 MHz; d6-DMSO) δ 10.6 (s, 
1H, CONH), 8.66 (d, 1H, J 2.0, Ar-H1), 8.23 (d, 1H, J 2.0, Ar-H2), 7.69 (s, 2H, -SO2NH2), 3.05 
(d, 2H, J 11.6, 2 x CHH5), 2.75 (t, 2H, J 6.4, CH2
4), 2.63 (t, 2H, J 6.5, CH2
3), 2.12 (t, 2H, J 
11.5, CH5H), 1.62 (t, 2H, J 12.4, 2 x CHH6), 1.39 (m, 1H, CH7), 1.21 (dquar, 2H, J 12.5, 2 x 
CH6H) and 0.86 (d, 3H, J 6.5, CH3
8); 13C NMR (100.6 MHz; d6-DMSO) δ 169.70, 166.39, 
141.01, 136.03, 134.82, 129.03, 125.47, 52.16 (3C), 31.48 (2C), 31.09, 28.41 and 20.86; 
LRMS (EI): m/z = 403.1 [M+]; Anal. Calc. (Found C, 46.9; H, 5.49; N, 10.1; S, 6.95. 
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5. 4-Chloro-3-[3-(4-methyl-piperazin-1-yl)-propionylamino]-5-sulfamoyl-benzoic acid 
(RKG2461)  
White solid (41.8 mg, 31%) (0.33 mmol scale); 
m.p. 179 - 183 °C; IR (NaCl) vmax (cm
-1) 3311 (m) 
(N-H), 2900 (m) (C-H), 2427 (br m) (O-H), 1698 
(s) (C=O), 1689 (m) (C=O), 1565 (s) (N-H), 1520 
(s) (C=C), 1373 (s) (S=O), 1286 (m) (C-O) and 
1156 (s) (S=O); 1H NMR (400 MHz; d6-DMSO, 
d2-D2O wash) δ 10.0 (s, 1H, CONH), 8.52 (d, 1H, J 1.8, Ar-H
1), 8.25 (d, 1H, J 1.9, Ar-H2), 
7.73 (s, 2H, -SO2NH2), 2.73 (t, 4H, J 6.5, 2 x CH2
6), 2.67 (s, 3H, CH3
7), 2.59 (t, 4H, J 6.5, 2 x 
CH2
5) and 2.49 (m, 4H, 2 x CH2
3+4); 13C NMR (100.6 MHz; d6-DMSO) δ 170.83, 165.45, 
141.75, 136.90, 136.26, 129.57, 128.58, 124.99, 52.52 (2C), 52.26, 49.12 (2C), 42.38 and 
32.88; LRMS (EI): m/z = 404.0 [M+]; Anal. Calc. (Found C, 44.0; H, 5.00; N, 12.3; S, 7.78. 
C15H21ClN4O5S requires C, 44.5; H, 5.23; N, 13.8; S, 7.92%); 
 
6. 3-[3-(4-Benzyl-piperidin-1-yl)-propionylamino]-4-chloro-5-sulfamoyl-benzoic acid 
(RKG2462)  
White solid (8.8 mg, 6%) (0.33 mmol 
scale); m.p. 179 - 183 °C; IR (NaCl) vmax 
(cm-1) 3311 (m) (N-H), 2900 (m) (C-H), 
2427 (br m) (O-H), 1698 (s) (C=O), 
1689 (m) (C=O), 1565 (s) (N-H), 1520 
(s) (C=C), 1373 (s) (S=O), 1286 (m) (C-O) and 1156 (s) (S=O); 1H NMR (300 MHz; d6-
DMSO, d2-D2O wash) δ 10.19 (s, 1H, CONH), 8.45 (d, 1H, J 2.0, Ar-H
1), 8.27 (d, 1H, J 2.1, 
Ar-H2), 7.74 (s, 2H, -SO2NH2), 7.24 (t, 2H, J 7.8, 2 x ArH), 7.14 (t, 3H, J 7.7, 3 x ArH
+11), 
3.33 (m, 2H, CHH5), 2.88, (m, 4H, 2 x CHH6 and CH2
4), 2.52 (m, 4H, 2 x CH6H and CH2
8), 
1.75 (m, 2H, 2 x CH5H) and 1.43 (m, 1H, CH7); 13C NMR (75.5 MHz; d6-DMSO) δ 169.30, 
165.71, 142.21, 139.65, 136.89, 130.21, 129.46, 129.26 (2C), 128.54 (2C), 126.31, 
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[M+]; Anal. Calc. (Found C, 54.6; H, 5.00; N, 8.32; S, 6.07. C22H26ClN3O5S requires C, 55.1; 
H, 5.46; N, 8.75; S, 6.68%); 
 
Synthesis of (1-Naphthalenyl)-2-ethanoyl chloride 
 
Freshly distilled SOCl2 (0.560 ml, 7.62 mmol) was added in a dropwise 
manner to 1-naphthalene acetic acid (1.18 g, 6.35 mmol) with stirring. The 
mixture was heated gently for 1 h at 100 °C under N2 (a further 1.0 ml of 
SOCl2 was added after the first 20 min to make a clear solution). The 
reaction was allowed to cool to room temperature, and then distilled at 
atmospheric pressure to remove the excess SOCl2, affording a dark brown residue. The acid 
chloride was not isolated or purified. 
 
Synthesis of RKG248 and RKG346 
(NOTE: the acid chloride was used as obtained above) 
 
Acetone (4.0 ml) was added to the unpurified acid chloride, and the resulting solution was 
added dropwise to a solution of (O-alkyl)-3-amino-4-chloro-sulfomoylbenzoate (RKG262 and 
RKG345) (1.40 g, 5.29 mmol) (assuming that the formation of the acid chloride was 
quantitative) dissolved in acetone (6.0 ml). The reaction mixture was stirred at room 
temperature (19 °C) for 6 hrs (more acetone was added periodically to aid stirring due to the 
formation of a precipitate). The precipitate was filtered off and washed with cold acetone and 
deionized H2O, and dried in vacuo. 
 
4-Chloro-3-(2-naphthalen-1-yl-acetylamino)-5-sulfamoyl-benzoic acid methyl ester (RKG248) 
Pale pink solid (1.80 g, 79% over two steps); m.p. 222-225 °C; IR (NaCl) vmax (cm
-1) 3240 (s) (N-
H), 3009 (m) (C-H), 1734 (s) (C=O), 1669 (s) (C=O), 1599 (s) (N-H), 1520 (s) (C=C), 1335 (s) (S=O),  
1239 (s) (C-O) and 1163 (s) (S=O); 1H NMR (300 MHz; d6-DMSO) δ 10.08 (s, 1H, CONH), 8.47 (d, 
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(d, 1H, J 7.9, ArH6), 7.77 (s, 2H, -SO2NH2), 7.59-7.46 (m, 
4H, 4 x ArH4+5+8+9), 4.31 (s, 2H, CH2
3) and 3.85 (s, 3H, -
CO2CH3); 
13C NMR (75.5 MHz; d6-DMSO) δ 169.93, 
164.37, 142.32, 137.20, 133.33, 131.85, 131.80, 128.47, 
128.37, 128.18, 128.01, 127.98, 127.36, 126.08, 125.67, 
125.46, 124.87, 124.04, 52.66 and 39.98; LRMS (EI): m/z = 
432.0 [M+]; Anal. Calc. (Found C, 55.2; H, 3.86; N, 6.01; S, 6.91. C20H17ClN2O5S requires C, 55.5; 
H, 3.96; N, 6.47; S, 7.41%); 
 
4-Chloro-3-(2-naphthalen-1-yl-acetylamino)-5-sulfamoyl-
benzoic acid ethyl ester (RKG346) 
White solid (2.03 g, 76% over two steps); m.p. 222 - 225 
°C; IR (NaCl) vmax (cm
-1) 3353 (s) (N-H), 3262 (s) (CON-H), 
2975 (w) (C-H), 1714 (s) (C=O), 1674 (s) (C=O), 1595 (m) 
(C=C), 1568 (m) (C=C), 1512 (s) (C=C), 1464 (w) (C=C), 
1359 (s) (S=O), 1300 (s) (C-N), 1249 (s) (C-O), 1162 (s) 
(S=O) and 783 (s) (C-Cl); 1H NMR (400 MHz; d6-DMSO) δ 10.10 (s, 1H, CONH), 8.46 (d, 1H, J 2.1, 
Ar-H1), 8.30 (d, 1H, J 2.1, Ar-H2), 8.14 (d, J 8.3, ArH10), 7.93 (d, 1H, J 7.7, ArH7), 7.85 (d, 1H, J 8.0, 
ArH6), 7.78 (s, 2H, -SO2NH2), 7.52 (m, 4H, 4 x ArH
4+5+8+9), 4.31 (m, 4H, CH2
3 and –OCH2-) and 1.28 
(t, 3H, J 7.1, -CH2CH3); 
13C NMR (100.6 MHz; d6-DMSO) δ 170.73, 164.64, 143.03, 137.97, 
134.10, 132.62, 132.57, 129.31, 129.16, 129.05, 129.01, 128.83, 128.15, 126.86, 126.46, 126.25, 
125.68, 124.81, 62.31, 40.75 and 14.74; HRMS (EI): m/z = 446.06977 [M+]; Anal. Calc. (Found C, 
55.2; H, 4.24; N, 5.76; S, 6.53. C21H19ClN2O5S requires C, 56.4; H, 4.29; N, 6.27; S, 7.17%); 
 
Synthesis of 4-chloro-3-(2-naphthalen-1-yl-ethylamino)-5-sulfamoyl-benzoic acid methyl ester 
(RKG252COL1) 
 
RKG248 (422 mg, 1.00 mmol) was added to anhydrous THF (2.5 ml). The resulting suspension 
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dropwise [OBSERVATION: color change from pink to 
yellow] and was stirred for 15 minutes. The mixture was 
heated and refluxed for 21 hrs under an atmosphere of 
N2. After cooling to room temperature, the reaction 
mixture was quenched with glacial acetic acid (~10 ml). 
The apparatus was rearranged for distillation, and the 
THF was distilled off (distillation was aided by the application of a slight vacuum). The resulting 
acidic solution was cooled to 0 °C and aqueous 10% Na2CO3 solution was added until a pH of 6-7 
was obtained. A brown sticky residue formed, and the aqueous solution was extracted with 
EtOAc (2 x 20 ml). The organic layer was washed with deionized H2O (20 ml), and dried over 
anhydrous Na2SO4, filtered, and the solvent was removed under reduced pressure. The brown 
residue was dried further in vacuo and column chromatographed (2:3, EtOAc:hexane), yielding 
RKG252COL1 (Rf = 0.42; 2:3, EtOAc:hexane) and RKG252COL3 (Rf = 0.13; 2:3, EtOAc:hexane); 
 
4-Chloro-3-(2-naphthalen-1-yl-ethylamino)-5-sulfamoyl-benzoic acid methyl ester 
(RKG252COL1) 
Pale yellow solid (115 mg, 27%) (larger 2.0 mmol scale (132 mg, 16%)); m.p. 119 - 123 °C; IR 
(NaCl) vmax (cm
-1) 3267 (s) (N-H), 2950 (m) (C-H), 1707 (s) (C=O), 1595 (s) (N-H), 1571 (s) (C=C), 
1344 (s) (S=O),  1263 (s) (C-O) and 1158 (s) (S=O); 1H NMR (300 MHz; d6-DMSO) δ 8.20 (d, 1H, J 
7.5, Ar-H11), 7.92 (dd, 1H, J 7.8, 1.7, Ar-H8), 7.79 (dd, 1H, J 7.2, 2.2, Ar-H7), 7.74 (d, 1H, J 1.9, Ar-
H1), 7.55 (m, 4H, 2 x Ar-H9+10 and -SO2NH2), 7.43 (m, 2H, Ar-H
5+6), 7.36 (d, 1H, J 1.9, Ar-H2), 6.17 
(t, 1H, J 5.8, -NH-), 3.84 (s, 3H, -CO2CH3), 3.57 (m (quar), 2H, J 6.6, 5.8, N-CH2
3) and 3.37 (t, 2H, J 
6.5, Ar-CH2
4); 13C NMR (75.5 MHz; d6-DMSO) δ 165.21, 145.47, 141.90, 135.15, 133.41, 131.47, 
128.52, 128.36, 126.79, 126.59, 126.03, 125.57, 125.49, 123.49, 118.59, 115.40, 113.24, 52.40, 
43.82 and 31.51; LRMS (EI): m/z = 418.0 [M+]; Anal. Calc. (Found C, 57.5; H, 4.77; N, 5.98; S, 






























White solid (110 mg, 28%) (larger 2.0 mmol scale (444 mg, 
57%)); m.p. 119 - 123 °C; IR (NaCl) vmax (cm
-1) 3267 (s) (N-
H), 2950 (m) (C-H), 1707 (s) (C=O), 1595 (s) (N-H), 1571 (s) 
(C=C), 1344 (s) (S=O),  1263 (s) (C-O) and 1158 (s) (S=O); 1H 
NMR (300 MHz; d6-DMSO) δ 8.21 (d, 1H, J 8.1, Ar-H11), 
7.93 (dd, 1H, J 7.7, 1.7, Ar-H8), 7.80 (m, 1H, Ar-H9), 7.59-
7.43 (m, 4H, 4 x Ar-H5+6+7+10), 7.34 (s, 2H, -SO2NH2), 7.20 (d, 1H, J 1.9, Ar-H
1), 6.93 (d, 1H, J 1.8, 
Ar-H2), 5.75 (t, 1H, J 5.6, -NH-), 5.28 (s (not well resolved t), 1H, -OH), 4.45 (s, 2H, CH2
12-O), 3.51 
(m (quar), 2H, J 6.5, 5.5, N-CH2
3) and 3.36 (t, 2H, J 6.6, Ar-CH2
4); 13C NMR (100.6 MHz; d6-DMSO) 
δ 144.96, 142.05, 141.11, 135.40, 133.43, 131.54, 128.54, 126.78, 126.60, 126.05, 125.61, 
125.54, 123.68, 113.37, 112.10, 111.60, 62.31, 43.99 and 31.64; LRMS (EI): m/z = 390.1 [M+]; 
Anal. Calc. (Found C, 58.0; H, 5.06; N, 6.80; S, 7.61. C19H19ClN2O3S requires C, 58.4; H, 4.90; N, 
7.17; S, 8.20%); 
 
Synthesis of 4-chloro-3-(2-naphthalen-1-yl-ethylamino)-5-sulfamoyl-benzoic acid (RKG256) 
(H157) 
 
Sodium hydroxide (20 mg, 0.48 mmol) was dissolved in a 
mixture of MeOH (1.0 ml) and deionized H2O (0.2 ml), and 
added to a stirring solution of RKG252COL1 (50 mg, 0.12 
mmol) dissolved in MeOH (1.0 ml). The reaction mixture 
was stirred under reflux (~80 °C) for 2 hrs. The reaction 
was allowed to cool to room temperature, and chloroform 
(10 ml) and deionized H2O (5 ml) were added, followed by 10% Na2CO3 aqueous solution (5 ml). 
The layers were separated, and the organic phase was washed with 10% Na2CO3 aqueous 
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aqueous layer pH was adjusted from basic to neutral (6/7). A white precipitate formed and was 
filtered off, washed with deionized H2O, and finally dried in vacuo. 
White solid (37.2 mg, 77%); m.p. 266 - 270 °C; IR (NaCl) vmax (cm
-1) 3378 (s) (N-H), 2950 (m) (C-
H), 1642 (s) (C=O), 1557 (s) (N-H), 1490 (m) (C=C), 1367 (s) (S=O),  1269 (s) (C-O) and 1159 (s) 
(S=O); 1H NMR (400 MHz; d6-DMSO) δ 8.23 (d, 1H, J 8.3, Ar-H11), 7.92 (d, 1H, J 7.9, Ar-H8), 7.80 
(m, 2H, Ar-H1+7), 7.60-7.41 (m, 5H, 5 x Ar-H2+5+6+9+10), 7.29 (s, 2H, -SO2NH2), 5.56 (t, 1H, J 5.7, Ar-
NH-), 3.52 (m (quar), 2H, J 6.7, 5.60, N-CH2
3) and 3.36 (t, 2H, J 6.6, Ar-CH2
4); 13C NMR (100.6 Mz; 
d6-DMSO) δ 167.61, 144.14, 140.22, 138.03, 135.45, 133.44, 131.55, 128.54, 126.78, 126.48, 
126.14, 125.62, 125.56, 123.73, 116.92, 114.67, 114.01, 44.12 and 31.59; HRMS (EI): m/z = 
404.05921 [M+]; Anal. Calc. (Found C, 56.0; H, 4.07; N, 5.95; S, 7.22. C19H17ClN2O4S requires C, 
56.4; H, 4.23; N, 6.92; S, 7.92%); 
 
Synthesis of 4-chloro-N-hydroxy-3-(2-naphthalen-1-yl-acetylamino)-5-sulfamoyl-benzamide 
(RKG364) 
 
Methyl ester (RKG262) (500 mg, 1.16 mmol) was 
dissolved in a 1:1 mixture of THF and MeOH (7.5 ml). An 
aqueous hydroxylamine solution (50% w/w) (1.07 ml, 
17.4 mmol) was added to the mixture, immediately 
followed by the addition of a catalytic amount of KCN 
(25 mg, 0.38 mmol). The reaction was allowed to stir at 
room temperature (~23 oC), and was monitored by TLC at 12 hour intervals. To drive the 
reaction to completion, further amounts of aqueous hydroxylamine solution (0.5 ml) and KCN 
(10 mg) were added at the 12 hour intervals. This technique was pursued until TLC showed no 
more ester (RKG262) to be present. The reaction appeared complete after 3 days. A white 
precipitate formed (hydroxylamine salt), and aqueous 3M HCl was added until an acidic pH was 
obtained. The resulting reaction mixture volume was reduced under reduced pressure, and the 
resulting residue was columned chromatographed (starting MeOH:EtOAc (1:49), gradually 
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Brown oil which crystallized to a white solid (322 mg, 64%); Rf  = 0.03 (5:95, MeOH:EtOAc); m.p. 
260 - 264 °C; IR (NaCl) vmax (cm
-1) 2856 (s) (C-H), 1700 (s) (C=O), 1668 (s) (C=O), 1567 (s) (C=C), 
1525 (s) (C=C), 1337 (s) (S=O), 1259 (s) (C-O), 1153 (s) (S=O) and 781 (s) (C-Cl); 1H NMR (400 
MHz; d4-MeOH) δ 8.58 (d, 1H, J 1.8, Ar-H1), 8.48 (d, 1H, J 1.9, Ar-H2), 8.13 (d, 1H, J 8.1, Ar-H10), 
7.91 (d, 1H, J 7.9, Ar-H7), 7.85 (d, 1H, J 8.2, Ar-H6), 7.71 (m, 2H, Ar-H8+9), 7.56 (m, 2H, Ar-H4+5) 
and 4.31 (s, 2H, CH2
3); 13C NMR (100.6 MHz; d6-DMSO) δ 170.04, 162.36, 141.44, 138.22, 
136.30, 134.07, 132.94, 132.65, 129.10, 128.66, 128.01, 127.13, 126.78, 126.40, 126.23, 124.89, 
123.50 and 40.80; LRMS (EI): m/z = 433.01 [M+]; Anal. Calc. (Found C, 52.1; H, 3.19; N, 10.2; S, 
6.89. C19H16ClN3O5S requires C, 52.6; H, 3.72; N, 9.69; S, 7.39%); 
 
Synthesis of 4-chloro-N-hydroxy-3-(2-naphthalen-1-yl-ethylamino)-5-sulfamoyl-benzamide   
(RKG404P2) 
 
Methyl ester (RKG252COL1) (79.5 mg, 0.190 mmol) was 
dissolved in a 1:1 mixture of THF and MeOH (1.5 ml). An 
aqueous hydroxylamine solution (50% w/w) (0.175 ml, 
2.85 mmol) was added to the mixture, immediately 
followed by the addition of a catalytic amount of KCN 
(3.71 mg, 0.0570 mmol). The reaction was allowed to 
stir at room temperature (~23 oC), and was monitored 
by TLC, at 12 hour intervals, until TLC showed no more ester (RKG252COL1) to be present. The 
reaction appeared complete after five days. The reaction mixture volume was reduced under 
reduced pressure, and the pH of the resulting aqueous residue was adjusted to neutral/slightly 
acidic with AcOH:H2O (1:1). The aqueous solution was extracted with EtOAc (2 x 50 ml). The 
combined organic extracts were washed with deionised H2O (2 x 20 ml) and dried over 
anhydrous Na2SO4. The dried organic extract was filtered and the solvent was removed in 
vacuo, resulting in a brown residue. The residue was columned chromatographed (starting 
2:98, EtOAc:hexane (1:49), gradually increasing to 100% EtOAc, then changing to MeOH:EtOAc 
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Brown oil (39.9 mg, 50%); Rf  = 0.03 (5:95, MeOH:EtOAc); 
1H NMR (400 MHz; d6-acetone) δ 8.24 
(t, 1H, J 8.6, Ar-H9), 8.00 (d, 1H, J 1.8, Ar-H1), 7.92 (d, 1H, J 8.1, Ar-H11), 7.81 (m, 2H, Ar-H8 and 
NH), 7.63 (d, 1H, J 1.7, Ar-H2), 7.58 - 7.43 (m, 6H, Ar-H5+6+7+10 and -SO2NH2), 3.74 (quar, 2H, J 7.3, 
N-CH2
3) and 3.52 (t, 2H, J 7.3, Ar-CH2
4); 13C NMR (100.6 Mz; d6-acetone) δ 166.27, 145.15, 
141.63, 135.30, 133.39, 131.61, 131.43, 128.52, 126.79, 126.52, 126.02, 125.57, 123.66, 123.53, 
115.79, 113.60, 111.34, 43.86 and 31.38; LRMS (EI): m/z = 419.0 [M+]; Anal. Calc. (Found C, 
53.9; H, 4.09; N, 9.79; S, 7.22. C19H18ClN3O4S requires C, 54.4; H, 4.32; N, 10.0; S, 7.64%); 
 
Synthesis of ethyl 3-(1-naphthamido)-4-chloro-5-sulfamoylbenzoate (RKG409) 
 
Naphthoyl chloride (188 mg, 0.99 mmol) was dissolved in 
acetone (1.0 ml),  and the resulting solution was added 
dropwise to a solution of (O-ethyl)-3-amino-4-chloro-
sulfomoylbenzoate (RKG345) (150 mg, 0.90 mmol) dissolved 
in acetone (1.5 ml). The reaction mixture was stirred at room 
temperature (19 °C) for 48 hrs (more acetone was added periodically to aid stirring due to the 
formation of a precipitate). The reaction mixture was cooled in an ice bath, and the precipitate 
was filtered off and washed with cold acetone. It was further dried in vacuo to yield a pure, 
white product. 
White solid (269 mg, 69%); Rf  = 0.28 (2:3, EtOAc:hexane); 
1H NMR (400 MHz; d6-DMSO, d2-D2O 
wash) δ 8.51 (d, 1H, J 2.0, Ar-H1), 8.45 (d, 1H, J 2.0, Ar-H2), 8.34 (d, 1H, J 7.6, Ar-H9), 8.12 (d, 1H, 
J 8.3, Ar-H3), 8.04 (d, 1H, J 7.4, Ar-H6), 7.93 (d, 1H, J 6.9, Ar-H5), 7.64 (m, 3H, 3 x Ar-H4+7+8), 4.41 
(quar, 2H, J 7.1, -OCH2CH3) and 1.36 (t, 3H, J 7.1, -CH2CH3); 
13C NMR (100.6 MHz; d6-DMSO) δ 
168.46, 164.67, 143.31, 138.21, 133.89, 132.08, 131.73, 131.46, 130.46, 129.07, 127.85, 127.14, 
126.97, 126.87, 125.82, 125.69, 118.83, 116.41, 62.41 and 14.81; HRMS (EI): m/z = 432.05410 
[M+]; Anal. Calc. (Found C, 55.1; H, 4.23; N, 6.19; S, 7.90. C20H17ClN2O5S requires C, 55.5; H, 3.96; 
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Synthesis of ethyl 4-chloro-3-(naphthalene-1-ylmethylamino)-5-sulfamoylbenzoate (RKG414F2) 
 
Sodium borohydride (17.7 mg, 0.47 mmol) is added to 
diglyme (0.9 ml), and the solution is added dropwise to a 
solution of ethyl 3-(1-naphthamido)-4-chloro-5-
sulfamoylbenzoate (RKG409) (150 mg, 0.38 mmol) in a 
mixture of BF3 ethyl etherate (0.080 ml, 89.6 mg, 0.63 mmol) 
and diglyme (1.4 ml). The reaction was stirred at room 
temperature (20 oC) for 4.5 hrs. The reaction progress was monitored by thin-layer 
chromatography (2:3, EtOAc:hexane). The reaction mixture is poured into ice-water. The oily 
precipitate is extracted with EtOAc (3 x 20 ml). The combined organic fractions were washed 
with deionised H2O (20 ml) and dried over anhydrous Na2SO4, filtered, and the solvent was 
removed under reduced pressure. The brown residue was dried further in vacuo and column 
chromatographed (1:9, EtOAc:hexane), yielding RKG414F2.  
White solid (43 mg, 27%); Rf = 0.31; (2:3, EtOAc:hexane); 
1H NMR (300 MHz; d6-acetone) δ 8.26 
(d, 1H, J 8.3, Ar-H10), 7.97 (m, 2H, 2 x Ar-H1+7), 7.87 (d, 1H, J 8.2, Ar-H6), 7.58 (m, 4H, 4 x Ar-
H2+4+8+9), 7.47 (t, 1H, J 8.1, Ar-H5), 6.75 (br s, 2H, -SO2NH2), 6.19 (m, 1H, NH), 5.10 (d, 2H, J 5.6, 
CH2
3), 4.27 (quar, 2H, J 7.1, -OCH2CH3) and 1.27 (t, 3H, J 7.1, -CH2CH3); 
13C NMR (100.6 MHz; d6-
acetone) δ 164.97, 146.12, 142.04, 134.34, 133.63, 131.65, 129.74, 128.00, 128.25, 126.51, 
126.07, 125.65, 125.22, 123.44, 119.37, 117.03, 114.85, 61.27, 45.37 and 13.76; HRMS (EI): m/z 
= 418.07484 [M+]; Anal. Calc. (Found C, 57.0; H, 4.19; N, 7.20; S, 7.05. C20H19ClN2O4S requires C, 
57.3; H, 4.57; N, 6.69; S, 7.65%); 
 
Synthesis of 4-chloro-3-(naphthalen-1-ylmethylamino)-5-sulfamoylbenzoic acid (RKG442)  
 
Sodium hydroxide (10 mg, 0.25 mmol) was dissolved in a mixture of MeOH (0.5 ml) and 
deionized H2O (0.2 ml), and added to a stirring solution of RKG414F2 (25.5 mg, 0.061 mmol) 
dissolved in MeOH (0.5 ml). The reaction mixture was stirred under reflux (~80 °C) for 2 hrs. The 
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(2/3) with 6M HCl. A white precipitate formed and was 
filtered off, washed with deionized H2O, and finally dried in 
vacuo. 
White solid (18.9 mg, 79%); 1H NMR (300 MHz; d6-DMSO) δ 
8.24 (d, 1H, J 7.8, Ar-H10), 7.96 (d, 1H, J 7.9, Ar-H7), 7.83 (d, 
1H, J 7.6, Ar-H6), 7.78 (d, 1H, J 1.9, Ar-H1), 7.63-7.38 (m, 6H, 4 
x Ar-H4+5+8+9 and –SO2NH2), 7.28 (d, 1H, J 1.9, Ar-H
2), 6.66 (t, 1H, J 5.7, Ar-NH-) and 4.98 (d, 2H, J 
5.7, CH2
3); 13C NMR (100.6 Mz; d6-DMSO) δ 166.12, 145.56, 141.67, 139.52, 133.37, 130.64, 
129.54, 128.57, 127.36, 126.17, 125.81, 125.36, 123.60, 123.13, 118.20, 115.94, 114.12 and 
44.24; HRMS (EI): m/z = 390.04357 [M+]; Anal. Calc. (Found C, 55.2; H, 3.96; N, 7.35; S, 7.75. 
C18H15ClN2O4S requires C, 55.3; H, 3.87; N, 7.17; S, 8.20%); 
 
General procedure for the synthesis of amides (RKG209, RKG204(ii) and RKG210) 
 
A mixture of acid chloride (1.1 equiv.) and acetone (1.0 ml) is added dropwise to a solution of 
amine (RKG211) (251 mg, 1.0 mmol) dissolved in acetone (4.0 ml). The reaction mixture is 
stirred at room temperature (20 oC) for 6 hrs. The cooled mixture was poured into aqueous 1M 
HCl (25 ml), and the white precipitate was filtered off, washed with aqueous 1M HCl and 
deionized H2O, and dried in vacuo.  
 
1. 3-Acryloylamino-4-chloro-5-sulfamoyl-benzoic acid (RKG209) 
White solid (90.7 mg, 30%) (larger 7.98 mmol scale (1.41 
g, 58%)); m.p. 238 - 241 °C; IR (NaCl) vmax (cm
-1) 3385 (s) 
(N-H), 2848 (m) (C-H), 2542 (m) (O-H), 1698 (s) (C=O), 
1670 (s) (C=O), 1598 (s) (N-H), 1529 (s) (C=C), 1321 (s) 
(S=O), 1253 (s) (C-O) and 1159 (s) (S=O); 1H NMR (400 
MHz; d6-DMSO) δ 10.0 (s, 1H, CONH), 8.52 (d, 1H, J 2.0, 
Ar-H1), 8.32 (d, 1H, J 2.1, Ar-H2), 7.77 (s, 2H, -SO2NH2), 6.65 (dd, 1H, J 17.0, 10.2, C=CH
3), 
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MHz; d6-DMSO) δ 165.39, 163.83, 142.20, 136.98, 130.87, 129.25, 129.11, 128.21, 
125.31 and 103.20; LRMS (EI): m/z = 304.0 [M+]; Anal. Calc. (Found C, 39.3; H, 2.92; N, 
8.40; S, 9.96. C10H9ClN2O5S requires C, 39.4; H, 2.98; N, 9.19; S, 10.5%); 
 
2. 4-Chloro-3-(3-chloro-propionylamino)-5-sulfamoyl-benzoic acid (RKG204(ii)) 
White solid (253 mg, 71%) (1.05 mmol amine scale); m.p. 
226 – 230 °C; IR (NaCl) vmax (cm
-1) 3385 (s) (N-H), 2849 
(m) (C-H), 2540 (m) (O-H), 1702 (s) (C=O), 1647 (s) (C=O), 
1596 (s) (N-H), 1523 (s) (C=C), 1355 (s) (S=O), 1242 (s) (C-
O) and 1161 (s) (S=O); 1H NMR (300 MHz; d6-DMSO) δ 
9.86 (s, 1H, CONH), 8.43 (d, 1H, J 2.0, Ar-H1), 8.34 (d, 1H, 
J 2.1, Ar-H2), 7.66 (s, 2H, -SO2NH2), 3.89 (t, 2H, J 6.4, Cl-CH2
4) and 2.97 (t, 2H, J 6.4, CH2
3
 ); 
13C NMR (75.5 MHz; d6-DMSO) δ 168.95, 165.40, 142.20, 136.92, 129.27 (2C), 128.05, 
125.33, 40.34 and 38.59; LRMS (EI): m/z = 340.0 [M+]; Anal. Calc. (Found C, 35.2; H, 2.88; 
N, 7.60; S, 8.98. C10H10Cl2N2O5S requires C, 35.2; H, 2.95; N, 8.21; S, 9.40%); 
 
3. 4-Chloro-3-(4-chloro-butyrylamino)-5-sulfamoyl-benzoic acid (RKG210) 
White solid (493 mg, 63%) (2.19 mmol amine scale); 
m.p. 210 - 214 °C; IR (NaCl) vmax (cm
-1) 3367 (s) (N-H), 
2916 (m) (C-H), 2540 (m) (O-H), 1693 (s) (C=O), 1670 
(s) (C=O), 1574 (s) (N-H), 1526 (s) (C=C), 1317 (s) 
(S=O), 1247 (s) (C-O) and 1160 (s) (S=O); 1H NMR (300 
MHz; d6-DMSO) δ 9.83 (s, 1H, CONH), 8.42 (d, 1H, J 
2.0, Ar-H1), 8.31 (d, 1H, J 2.1, Ar-H2), 7.74 (s, 2H, -SO2NH2), 3.70 (t, 2H, J 6.9, Cl-CH2
5), 
2.66 (t, 2H, J 7.0, CH2
3
 ) and 2.05 (quin, 2H, J 6.9, CH2
4); 13C NMR (100.6 MHz; d6-DMSO) 
δ 171.03, 165.43, 142.14, 137.14, 129.40, 129.17, 128.20, 125.20, 44.80, 32.81 and 
27.81; LRMS (EI): m/z = 354.0 [M+]; Anal. Calc. (Found C, 37.3; H, 3.38; N, 7.47; S, 9.41. 
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Chemical analysis of proposed macrocycle RKG214  
 
White solid (quantiative); 1H NMR (300 MHz; d6-DMSO) δ 8.47 (d, 
1H, J 2.1, Ar-H1), 8.13 (d, 1H, J 2.1, Ar-H2), 7.82 (s, 2H, -SO2NH2), 
3.72 (t, 2H, J 7.0, O-CH2
5), 2.45 (t, 2H, J 7.8, CH2
3
 ) and 2.16 (quin, 
2H, J 7.5, CH2
4); 13C NMR (100.6 MHz; d6-DMSO) δ 174.42, 165.08, 
142.73, 139.19, 133.68, 133.29, 130.19, 128.23, 48.24, 30.26 and 
18.78; LRMS (EI): m/z = 318.0 [M+]; Anal. Calc. (Found C, 41.2; H, 
3.49; N, 8.64; S, 9.96. C11H11ClN2O5S requires C, 41.5; H, 3.48; N, 8.79; S, 10.1%); 
 
General procedure for the synthesis of amides (RKG251 and RSON110) 
 
A mixture of acid chloride (1.2 equiv) and acetone (1.0 ml) is added dropwise to a solution of 
amine (RKG262) (400 mg, 1.5 mmol) dissolved in acetone (8.0 ml). The reaction mixture is 
stirred at room temperature (20 oC) for 20 hrs. The cooled mixture was poured into aqueous 
1M HCl (40 ml), and the white precipitate was filtered off, washed with aqueous 1M HCl and 
deionized H2O, and dried in vacuo. 
 
1. 3-Acryloylamino-4-chloro-5-sulfamoyl-benzoic acid methyl ester (RKG251) 
White solid (407 mg, 84%); m.p. 211 - 214 °C; IR (NaCl) 
vmax (cm
-1) 3397 (s) (N-H), 2840 (m) (C-H), 1733 (s) 
(C=O), 1663 (s) (C=O), ~1600 (s) (N-H), 1525 (s) (C=C), 
1336 (s) (S=O), 1244 (s) (C-O) and 1156 (s) (S=O); 1H 
NMR (300 MHz; d6-DMSO) δ 10.0 (s, 1H, CONH), 8.58 (d, 
1H, J 2.1, Ar-H1), 8.34 (d, 1H, J 2.1, Ar-H2), 7.80 (s, 2H, -SO2NH2), 6.62 (dd, 1H, J 17.0, 
10.2, C=CH3), 6.33 (dd, 1H, J 17.0, 1.9, C=CH5), 5.85 (dd, 1H, J 10.2, 1.8, C=CH4) and 3.90 
(s, 3H, -CO2CH3);
 13C NMR (75.5 MHz; d6-DMSO) δ 169.01, 164.43, 163.87, 142.37, 
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Anal. Calc. (Found C, 40.9; H, 3.42; N, 8.39; S, 9.67. C11H11ClN2O5S requires C, 41.4; H, 
3.48; N, 8.79; S, 10.1%); 
 
2. 4-Chloro-3-(2-chloro-acetylamino)-5-sulfamoyl-benzoic acid methyl ester (RSON110) 
White solid (579 mg, 90%) (1.89 mmol amine scale); m.p. 
205 - 209 °C; IR (NaCl) vmax (cm
-1) 3397 (s) (N-H), 2840 (m) 
(C-H), 1733 (s) (C=O), 1663 (s) (C=O), 1600 (s) (N-H), 1525 
(s) (C=C), 1336 (s) (S=O), 1244 (s) (C-O) and 1156 (s) (S=O); 
1H NMR (400 MHz; d4-MeOD) δ 8.48 (d, 1H, J 2.1, Ar-H1), 
8.36 (d, 1H, J 2.1, Ar-H2), 4.43 (s, 2H, CH2
3) and 3.91 (s, 3H, -CO2CH3);
 13C NMR (100.6 
MHz; d4-MeOD) δ 165.77, 164.34, 142.46, 136.72, 128.83, 128.74, 128.15, 125.45, 52.78 
and 42.96; LRMS (EI): m/z = 340.0 [M+]; Anal. Calc. (Found C, 35.5; H, 2.94; N, 8.01; S, 
9.03. C10H10Cl2N2O5S requires C, 35.2; H, 2.95; N, 8.21; S, 9.40%); 
 
Synthesis of (O-methyl)-3-bromo-4-chloro-benzoate (RKG236) 
 
3-Bromo-4-chloro-benzoic acid (1.00 g, 4.25 mmol) was dissolved in a 
mixture of methanol (12 ml) and conc. H2SO4 (0.350 ml, 6.37 mmol). 
The reaction mixture was stirred under reflux for 5 hrs. The reaction 
was allowed to cool, and the solvent was removed under reduced pressure. Deionized H2O (10 
ml) was added to the residue, and the resulting aqueous solution was extracted with EtOAc (2 x 
30 ml). The organic layer was separated and washed with deionized H2O (20 ml), saturated 
aqueous NaHCO3 solution (20 ml), deionized H2O (20 ml), brine (20 ml) and deionized H2O (20 
ml). After drying over anhydrous Na2SO4, the organic layer was filtered and the solvent was 
removed under reduced pressure. The residue was dried further in vacuo, giving a pale 
orange/white crystalline product.    
Pale orange/white solid (1.02 g, 96%); 1H NMR (400 MHz; d6-DMSO) δ 8.28 (d, 1H, J 2.0, Ar-H1), 
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8.2 Experimental: Chapter 4 
 
PLEASE NOTE:  
 
I. When d6-DMSO is used as the solvent for NMR, spectrums for sulfonyl ureas and acyl 
thioureas occasionally show duplication of peaks. The first set of peaks (usually the 
smaller of the pair) is due to strong intramolecular hydrogen bonding of molecule with 
itself, and the second set of peaks (usually the larger of the pair) is due to strong 
intermolecular hydrogen bonding of the compound with the DMSO, respectively. For the 
sake of differentiation between the two, the larger (i.e. has a larger integration) of the 
duplicated peaks has been marked with an asterisk (i.e. *).  
 
Synthesis of Sulfonyl Ureas 
 
General procedure for the synthesis of 1-(aryl/alkyl)-3-(p-chlorophenylsulfonyl)ureas (RKG1491; 
RKG1492; RKG1493A; RKG1531; RKG1532 and RKG1533PC) 
 
4-Chlorophenylsulfonyl isocyanate (1.00 mmol) is added dropwise to a solution of amine (1.00 
mmol) dissolved in dry THF (2.5 ml). The reaction is left stirring at room temperature (~20 oC) 
for 18 h under an atmosphere of N2. The solvent is then removed under reduced pressure, to 
afford a residue. The residue was column chromatographed (SiO2, EtOAc:hexane, 2:3) to give 
the sulfonyl urea.  
 
1. 1-(p-Bromophenyl)-3-(p-chlorophenylsulfonyl)urea (RKG1491) 
White powder (60 mg, 15%); m.p. 178 – 182 °C; 1H NMR 
(400 MHz; d6-acetone) δ 9.64 (br s, 1H, NH), 8.48 (br s, 
1H, NH), 8.07 (d, 2H, J 8.8, 2 x Ar-H2), 7.66 (2H, d, J 8.8, 2 
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MHz, d6-acetone) δ 149.24, 139.41, 139.30, 137.00, 131.91 (2C), 129.94 (2C), 129.35 (2C), 
121.42 (2C) and 115.79; LRMS (EI): m/z = 390.0 [M+]; Anal. Calc. (Found C, 40.6; H, 2.57; N, 
7.08; S, 8.14. C13H10N2O3SClBr requires C, 40.1; H, 2.59; N 7.19; S, 8.23%);  
 
2.   1-(p-Bromo-o-N-pyridinyl)-3-(p-chlorophenylsulfonyl)urea (RKG1492) 
White powder (23 mg, 6%); m.p. 170 – 174 °C; 1H NMR 
(300 MHz; d6-acetone) δ 11.52 (br s, 1H, NH), 9.15 (br s, 
1H, NH), 8.41 (d, 1H, J 2.6, Ar-H5), 8.09 (d, 2H, J 8.8, 2 x 
Ar-H2), 7.96 (dd, 1H, J  8.8, 2.6, Ar-H4), 7.67 (d, 2H, J 8.8, 
2 x Ar-H1) and 7.43 (d, 1H, J 8.8, Ar-H3); 13C NMR (75.5 MHz, d6-acetone) δ 147.76, 142.97, 
141.76, 139.58, 139.19, 138.91, 130.19 (2C), 129.33 (2C), 114.50 and 113.41; LRMS (EI): m/z 
= 389.0 [M+]; 
 
3.   1-(iso-Propyl)-3-(p-chlorophenylsulfonyl)urea (RKG1493A) 
White powder (55 mg, 45%); m.p. 140 – 144 °C; 1H NMR 
(300 MHz; d6-acetone) δ 9.30 (br s, 1H, NH), 8.01 (d, 2H, J 
8.9, 2 x Ar-H2), 7.65 (d, 2H, J 8.9, 2 x Ar-H1), 6.16 (d, 1H, J 
6.6, NH), 3.77 (oct, 1H, J 6.6, CH3) and 1.09 (d, 6H, J 6.6, 2 x CH3
4); 13C NMR (75.5 MHz, d6-
acetone) δ 150.35, 139.74, 139.11, 129.61 (2C), 129.31 (2C), 42.32, 22.06 and 22.04; LRMS 
(EI): m/z = 276.0 [M+]; Anal. Calc. (Found C, 43.1; H, 4.70; N, 9.39; S, 11.0. C10H13N2O3SCl 
requires C, 43.4; H, 4.73; N 10.1; S, 11.6%);  
 
4.   1-(m-Dimethoxy-o-N,N-pyrimidinyl)-3-(p-chlorophenylsulfonyl)urea (RKG1531) 
White flakes (298 mg, 80%); m.p. 184 - 187°C; IR 
(Thin film) νmax (cm
-1) 3399 (w) (N-H), 3232 (w) (N-H), 
3087-2935 (br m) (CH), 1718 (s) (C=O), 1610 (s) 
(C=C), 1577 (s) (C=C), 1491 (s) (C=C), 1451 (s) (C=C), 
1368 (s) (S=O), 1198 (s) (S=O), 1162 (s) (S=O); 1H 
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Ar-H2), 7.81 (d, 2H, J 8.8, 2 x Ar-H2), 7.70* (d, 2H, J 9.0, 2 x Ar-H1), 7.63 (d, 2H, J 8.8, 2 x Ar-
H1), 5.96* (s, 1H, Ar-H3), 5.32 (s, 1H, Ar-H3), 3.90* (s, 6H, 2 x -OCH3) and 3.74 (s, 6H, 2 x -
OCH3); 
13C NMR (100.6 MHz, d6-DMSO) δ 171.13 (2C), 155.90, 148.57, 138.75, 137.71, 
129.74* (2C), 129.24* (2C), 128.96 (2C), 127.52 (2C), 83.64*, 77.82, 54.53* (2C) and 53.05 
(2C); LRMS (EI): m/z = 372.0 [M+]; Anal. Calc. (Found C, 41.8; H, 3.35; N, 14.2; S, 8.37. 
C13H13N4O5SCl requires C, 41.9; H, 3.51; N 15.0; S, 8.60%);  
 
5. 1-(m-Methoxy-methyl-o-N,N-pyrimidinyl)-3-(p-chlorophenylsulfonyl)urea (RKG1532) 
White powder (240 mg, 67%); m.p. 179 – 183 °C; 1H 
NMR (400 MHz; d6-DMSO) δ 13.27* (br s, 1H, NH), 
10.55* (br s, 1H, NH), 7.99* (d, 2H, J 8.8, 2 x Ar-H2), 
7.81 (d, 2H, J 8.8, 2 x Ar-H2), 7.68* (d, 2H, J 8.5, 2 x 
Ar-H1), 7.63 (d, 2H, J 8.5, 2 x Ar-H1), 6.51* (s, 1H, Ar-
H3), 5.88 (s, 1H, Ar-H3), 3.90* (s, 3H, -OCH3), 3.76 (s, 3H, -OCH3), 2.34* (s, 3H, -CH3) and 2.12 
(s, 3H, -CH3); 
13C NMR (100.6 MHz, d6-DMSO) δ 170.25, 166.65, 156.22, 149.55, 138.42, 
138.31, 129.60* (2C), 129.14* (2C), 128.96 (2C), 127.53 (2C), 100.74, 54.18 and 22.63; LRMS 
(EI): m/z = 356.0 [M+]; Anal. Calc. (Found C, 43.8; H, 3.56; N, 15.7; S, 8.89. C13H13N4O4SCl 
requires C, 43.8; H, 3.67; N 15.7; S, 8.99%);  
 
6. 1-(m-Dimethyl-o-N,N-pyrimidinyl)-3-(p-chlorophenylsulfonyl)urea (RKG1533PC) 
White powder (259 mg, 76%); m.p. 196 – 199 °C; 1H 
NMR (400 MHz; d6-DMSO) δ 13.27* (br s, 1H, NH), 
10.51* (s, 1H, NH), 8.01* (d, 2H, J 8.8, 2 x Ar-H2), 7.83 
(d, 2H, J 8.8, 2 x Ar-H2), 7.70* (d, 2H, J 9.2, 2 x Ar-H1), 
7.65 (d, 2H, J 8.8, 2 x Ar-H1), 7.00* (s, 1H, Ar-H3), 6.33 
(s, 1H, Ar-H3), 2.40* (s, 6H, 2 x -CH3) and 2.08 (s, 6H, 2 x -CH3); 
13C NMR (100.6 MHz, d6-
DMSO) δ 167.65, 166.68, 156.37, 149.09, 142.95, 136.47, 129.64 (2C), 129.20 (2C), 128.96* 
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Calc. (Found C, 45.7; H, 3.78; N, 16.0; S, 9.20. C13H13N4O3SCl requires C, 45.8; H, 3.85; N 
16.4; S, 9.41%); 
 
Synthesis of Imidazolinone Derivatives 
 
General procedure for the synthesis of N-carbamoyl-alkyl/aryl-phthalamic acids (RKG114A; 
RKGANT3; RKG125A and RKG123A) 
 
The amino-amide hydrochloride (7.2 mmol) was dissolved in a mixture of triethylamine (14.2 
mmol) in deionised water (5 ml) and stirred vigorously for 10 - 15 minutes. This mixture was 
added to a solution of phthalic anhydride (1.05 g, 7.1 mmol) dissolved in dioxane (15 ml). The 
resulting solution was stirred at room temperature for 0.5 h, and then concentrated via 
removal of the solvent under reduced pressure, leaving a syrup/glassy residue. An aqueous 
solution of 1M HCl (60 ml) was added to the residue, and the mixture was stirred for 5 min. The 
mixture was placed in the fridge (~5 ºC) overnight, to allow precipitation. The precipitate was 
collected via filtration, and was washed successively with an aqueous solution of 1M HCl (3 x 
5ml), and cold diethyl ether (1 x 5ml). The collected solid was dried further in vacuo on a 
vacuum pump, affording the phthalamic acid. 
 
1.   N-Carbamoylmethyl-phthalamic acid monohydrate (RKG114A) 
White crystalline flakes (6.22g, 77%) (35.4 mmol scale); m.p. 
262 – 265 °C; IR (Thin film) νmax (cm
-1) 3536 (w) (COO-H), 
3435 (m) (N-H), 3391 (m) (N-H), 3203 (br m) (C-H), 1686 (s) 
(C=O), 1657 (s) (C=O), 1642 (s) (C=O), 1600 - 1530 (4 x s), 
(C=C) and 1263 (s) (C-N); 1H NMR (300 MHz; d6-DMSO) δ 13.18 (br s, 1H, COOH), 8.61 (t, 1H, 
J 5.9, CONH), 7.84 (dd, 1H, J 7.5, 1.1, Ar-H4), 7.61 (td, 1H J 7.5, 1.5, Ar-H2), 7.53 (td, 1H, J 7.5, 
1.5, Ar-H3), 7.48 (dd, 1H, J 7.5, 1.1, Ar-H1), 7.26 (s, 2H, CONH2), 3.74 (d, 2H, J 6.0, CH2
5) and 
3.33 (br s, H2O); 
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129.59, 129.37, 129.21, 127.82 and 42.73; LRMS (EI): m/z = 222.1 [M+]; Anal. Calc. (Found C, 
50.0; H, 4.77; N, 11.6. C10H10N2O4.H2O requires C, 50.0; H, 5.04; N 11.7%); 
 
2.   N-(1-Carbamoyl-2-phenyl-ethyl)-phthalamic acid (RKG123A) 
White powder (2.06 g, 93%); m.p. 190 – 193 °C; 1H NMR 
(400 MHz; d6-DMSO) δ 8.55 (br d, 1H, J 8.5, CONH), 7.81 (d, 
1H, J 7.7, Ar-H4), 7.53 (t, 1H, J 7.5, Ar-H2), 7.48 (t, 1H, J 7.5, 
Ar-H3), 7.28 (m, 7H, 5 x Ar-H7+8+9 and CONH2), 6.97 (d, 1H, J 
7.5, Ar-H1), 4.55 (m, 1H, CH5), 3.28 (d, 1H, J 14.1, CH6H) and 
2.81 (t, 1H, J 14.1, CHH6); 13C NMR (100.6 MHz, d6-DMSO) δ 
173.79, 169.14, 168.66, 139.48, 139.35, 132.38, 130.10, 130.06, 129.82, 129.73 (2C), 128.76 
(2C), 128.12, 126.86, 54.89 and 37.12; LRMS (EI): m/z = 312.1 [M+]; Anal. Calc. (Found C, 
65.4; H, 4.53; N, 8.79. C17H16N2O4 requires C, 65.4; H, 5.16; N 8.97%);  
 
3.   N-(1-Carbamoyl-3-methyl-butyl)-phthalamic acid (RKG125A or RKG166A) 
White powder; Yield: 1.95 g, (99%); m.p. 199 – 201 °C; IR 
(Thin film) νmax (cm
-1) 3540 (w) (COO-H), 3457 (m) (N-H), 
3333 (m) (N-H), 2949 (m) (C-H), 1700 (m) (C=O), 1642 (s) 
(C=O), 1628 (s) (C=O), 1530 (s) (C=C), 1451 (s) (C=C) and 
1274 (s) (C-N); 1H NMR (300 MHz; d6-DMSO) δ 13.20 (br s, 
1H, COOH), 8.45 (d, 1H, J 7.9, CONH), 7.84 (dd, 1H, J 7.9, 1.2, 
Ar-H4), 7.61 (td, 1H, J 7.3, 1.2, Ar-H2), 7.52 (td, 1H, J 7.3, 1.2, Ar-H3), 7.40 (dd, 1H, J 7.9, 1.2, 
Ar-H1), 7.28 (s, 1H, CONHH), 7.11 (s, 1H, CONHH), 4.31 (m, 1H, CH5), 1.72 (m, 1H, CH6H), 1.59 
(m, 2H, CHH6 and CH7) and 0.90 (dd, 6H, J 6.4, 1.9, 2 x CH3
8); 13C NMR (75.5 MHz, d6-DMSO) 
δ 174.31, 168.63, 167.94, 138.88, 131.71, 129.48, 129.37, 129.08, 127.84, 51.44, 39.91, 
24.37, 23.20 and 21.19; LRMS (EI): m/z = 278.1 [M+]; Anal. Calc. (Found C, 60.3; H, 6.47; N, 
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4.   N-(1-Carbamoyl-2-methyl-propyl)-phthalamic acid (RKGANT3) 
White flakes (1.95 g, 99%); m.p. 213 – 216 °C; IR (Thin film) 
νmax (cm
-1) 3573 (br w) (COO-H), 3406 (m) (N-H), 3312 (s) (N-
H), 2870 (s) (C-H), 1693 (s) (C=O), 1635 (s) (C=O), 1642 (s) 
(C=O), 1595 (s) (C=C), 1537 (s) (C=C), 1487 (s) (C=C) and 1263 
(C-N); 1H NMR (400 MHz; d6-DMSO) δ 8.19 (br d, 1H, J 8.8, 
CONH), 7.80 (dd, 1H, J 7.7, 1.1, Ar-H4), 7.58 (td, 1H, J 7.5, 1.3, Ar-H2), 7.50 (td, 1H, J 7.7, 1.5, 
Ar-H3), 7.38 (dd, 1H, J 7.7, 1.3, Ar-H1), 7.28 (s, 1H, CONHH), 7.09 (s, 1H, CONHH), 4.24 (dd, 
1H, J 8.8, 5.8, CH5), 2.16 (oct, 1H, J 6.0, CH6), 0.92 (d, 3H, J 6.8, CH3
7) and 0.87 (d, 3H, J 6.8, 
CH3
7); 13C NMR (100.6 MHz, d6-DMSO) δ 172.99, 168.81, 167.83, 138.72, 131.46, 129.73, 
129.19, 128.98, 127.86, 58.13, 29.59, 19.36 and 17.67; LRMS (EI): m/z = 264.1 [M+]; Anal. 
Calc. (Found C, 59.7; H, 6.20; N, 10.7. C13H16N2O4 requires C, 59.1; H, 6.10; N 10.6%);  
 
Synthesis of 3-(N-Carbamoylmethyl)carboxamide-nicotinic acids (RKG164A) 
 
Glycinamide hydrochloride (1.00 g, 9.05 mmol) was dissolved in 
a mixture of triethylamine (2.5 ml, 18.1 mmol) in deionised 
water (5 ml) and stirred vigorously for 10 - 15 minutes. This 
mixture was added to a solution of 2,3-pyridine dicarboxylic 
anhydride (1.35 g, 9.05 mmol) dissolved in dioxane (20 ml). The resulting solution was stirred at 
room temperature (~20 oC) for 1 h, and then concentrated via removal of the solvent under 
reduced pressure, leaving a syrup/glassy residue. An aqueous solution of 1M HCl (50 ml) was 
added to the residue, and the mixture was stirred for 5 min. The mixture was placed in the 
freezer (~ -12 ºC) overnight, to allow precipitation. The precipitate was collected via filtration, 
and was washed successively with an aqueous solution of cold 1M HCl (3 x 5ml), and cold 
diethyl ether (1 x 5ml). The collected solid was dried further in vacuo on vacuum pump, 
affording the nicotinic acid. 
Small white fluffy crystals; Yield: 0.430 g, (21%); m.p. 159 – 164 °C; IR (Thin film) νmax (cm
-1) 
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(s) (C=O), 1642 (s) (C=O), 1541 (s) (C=C), 1433 (s) (C=C), and 1263 (s) (C-N); 1H NMR (300 MHz; 
d6-DMSO) δ 8.79 (t, 1H, J 5.8, CONH), 8.71 (dd, 1H, J 4.9, 1.5, Ar-H1), 8.07 (dd, 1H, J 7.9, 1.5, Ar-
H3), 7.64 (dd, 1H, J 7.6, 4.6, Ar-H2), 7.37 (br s, 1H, CONHH), 7.18 (br s, 1H, CONHH) and 3.84 (d, 
2H, J 5.8, CH2
4); 13C NMR (100.6 MHz, d6-DMSO) δ 170.83, 167.91, 164.86, 149.86, 149.07, 
136.95, 128.57, 125.59 and 41.91; LRMS (EI): m/z = 223.0 [M+];  
 
General procedure for the synthesis of 2-[4,5-dihydro-4-alkyl/aryl-5-oxo-1H-imidazol-2-yl]-
benzoic acids (RKGAS4EGLY; RKGAS4ELEU; RKGAS4EPA and RKGAS4EVAL)  
 
The phthalamic acid (200 mg) is added to deionised water (2.5 ml). Four molar equivalents of 
NaOH is added to the mixture and stirred. The reaction vessel is sealed under N2, and the 
reaction is heated to reflux (~ 115 ºC) for 3 hrs. The reaction was then allowed to stand and 
cool down to room temperature. Concentrated HCl (10.18M) was added dropwise until a pH of 
between 2 – 3 was reached. The mixture was left to stand so that precipitation could occur. The 
precipitate was filtered off, and washed successively with cold aqueous 1M HCl, and cold 
deionised water. The resulting product was dried further in vacuo under vacuum, giving the 
pure benzoic acid. 
 
NOTE: when RKG123A and RKG125A were used as starting materials, the final product 
precipitated on the addition of the concentrated HCl. For RKG114A and RKGANT3, the reaction 
mixture (at pH of ~2) was placed in the fridge overnight. However, no precipitate was formed. 
The cooled mixture was left to warm up to room temperature, and a combination of being at 
room temperature and lots of scratching resulted in the product precipitating out.   
1.   2-[4,5-Dihydro-5-oxo-1H-imidazol-2-yl]-benzoic acid (RKGAS4EGLY)  
White powder (71.2 mg, 42%); m.p. 89 – 93 °C; 1H NMR (400 MHz; 
d4-MeOD) δ 7.94 (dd, 1H, J 7.7, 1.5), Ar-H4), 7.61 (td, 1H, J 7.7, 1.5, 
Ar-H2), 7.55 (m, 2H, J 1.5, Ar-H1 and Ar-H3) and 4.08 (s, 2H, CH2
5); 
13C NMR (100.6 MHz, d4-MeOD) δ 171.74, 171.68, 168.20, 138.16, 
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= 204.0 [M+]; 
 
2. 2-[4,5-Dihydro-4S-iso-propyl-5-oxo-1H-imidazol-2-yl]-benzoic acid (RKGAS4EVAL)  
White powder (84.7 mg, 45%); m.p. 167 – 171 °C; IR (Thin film) 
νmax (cm
-1) 3409 (br m) (COO-H), 3248 (br m) (N-H), 2961 (m) (C-
H), 1709 (s) (C=O), 1640 (s) (C=O), 1600 (s) (C=C), 1545 (s) (C=C) 
and 1275 (s) (C-N); 1H NMR (300 MHz; d4-MeOD) 7.95 (dd, 1H, J 
7.6, 1.5, Ar-H4), 7.61 (td, 1H, J 7.6, 1.6, Ar-H2), 7.53 (dt, 1H, J 7.6, 
1.5, Ar-H3), 7.48 (dd, 1H, J 7.6, 1.5, Ar-H1), 4.52 (d, 1H, J 5.8, 
CH5), 2.26 (m (oct), 1H, J 7.0, 5.8, CH6), 1.07 (d, 3H, J 7.0, CH3
7) and 1.04 (d, 3H, J 7.0, CH3
7); 
13C NMR (75.5 MHz, d4-MeOD) δ 174.70, 172.78, 169.24, 139.68, 132.98, 131.22, 130.80, 
130.54, 129.03, 59.70, 31.89, 19.63 and 18.66; LRMS (EI): m/z = 246.1 [M+]; 
 
3. 2-[4,5-Dihydro-4S-iso-butyl-5-oxo-1H-imidazol-2-yl]-benzoic acid (RKGAS4ELEU)  
White powder (101 mg, 54%); m.p. 149 – 153 °C; IR (Thin film) 
νmax (cm
-1) 3582 (w) (COO-H), 3248 (m) (N-H), 2955 (m) (C-H), 
2866 (m) (C-H), 1700 (s) (C=O), 1643 (s) (C=O), 1600-1551 (3 x 
s) (C=C) and 1278 (s) (C-N); 1H NMR (300 MHz; d6-DMSO) δ 
12.65 (br s, 1H, CO2H), 8.53 (s, 1H, NH), 7.78 (dd, 1H, J 7.6, 1.5, 
Ar-H4), 7.62 (td, 1H, J 7.6, 1.5, Ar-H2), 7.54 (dt, 1H, J 7.6, 1.5, 
Ar-H3), 7.44 (dd, 1H, J 7.6, 1.5, Ar-H1), 4.42 (m, 1H, CH5), 1.80 (m, 1H, CH7), 1.69 (m, 1H, 
CHH6), 1.55 (m, 1H, CH6H) and 0.93 (d, 6H, J 6.4, 2 x CH3
8); 13C NMR (75.5 MHz, d4-MeOD) δ 
173.97, 168.25, 167.82, 137.97, 130.96, 130.77, 129.13, 129.00, 127.70, 50.48, 39.75, 24.12, 
22.95 and 21.21; LRMS (EI): m/z = 260.1 [M+];  
 
4. 2-[4,5-Dihydro-4S-benzyl-5-oxo-1H-imidazol-2-yl]-benzoic acid (RKGAS4EPA)  
White powder (141 mg, 75%); m.p. 155 – 159 °C; IR (Thin film) νmax (cm
-1) 3409 (w) 
(COO-H), 3379 (m) (N-H), 3021 (m) (C-H), 2818 (br m) (C-H), 1706 (s) (C=O), 1670 (s) 
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MHz; d4-MeOD) δ 7.92 (dd, 1H, J 7.4, 1.6, Ar-H4), 7.55 
(td, 1H, J 7.5, 1.6, Ar-H2), 7.50 (dt, 1H, J 7.4, 1.6, Ar-
H3), 7.30 (m, 5H, 5 x Ar-H1+7+8), 7.21 (m, 1H, Ar-H9), 
4.89 (dd, 1H, J 6.0, 7.7, CH5), 3.26 (dd, 1H, J 13.9, 5.9, 
CHH6) and 3.12 (dd, 1H, J 13.9, 7.7, CH6H); 13C NMR 
(100.6 MHz, d4-MeOD) δ 173.23, 171.03, 168.10, 
138.17, 137.23, 131.71, 130.05, 129.71, 129.46, 129.30 (2C), 128.20 (2C), 127.70, 
126.58, 54.25 and 37.31; LRMS (EI): m/z = 294.1 [M+];  
 
General procedure for the synthesis of 1,3-dihydro-1,3-dioxo-α-alkyl/aryl-2H-isoindole-2-
acetamides (RKG119A; RKG145A; RKG131A and RKG133A)  
 
The phthalamic acid (0.500 g) and NaOH (0.4 molar equiv) were added to NMP (0.75 ml). The 
reaction mixture was heated with stirring to 130 - 140 °C for 18 hrs. The reaction mixture was 
then allowed to cool down to room temperature, and an aqueous solution of 1M HCl was 
added until a pH of 2 - 3 was obtained. The reaction mixture was column chromatographed 
(SiO2, Acetone:DCM, 30:70) to obtain the 2H-isoindole-2-acetamides. The product was further 
purified by recrystallization from acetone. 
 
1.   1,3-Dihydro-1,3-dioxo-2H-isoindole-2-acetamides (RKG119A)  
Small white fluffy crystals (1.13 g, 67%) (2.00g scale in 
deionsied H20 (3.0ml) at 100 
oC); m.p. 260 – 262 °C; 1H NMR 
(400 MHz; d6-DMSO) δ 7.87 (m, 4H, 4 x Ar-H1+2), 7.65 (br s, 1H, 
CONHH), 7.19 (br s, 1H, CONHH) and 4.14 (s, 2H, CH2
3); 13C 
NMR (100.6 MHz, d6-DMSO) δ 168.59 (2C), 168.22, 135.19 
(2C), 132.45 (2C), 123.83 (2C) and 40.65; LRMS (EI): m/z = 204.0 [M+]; Anal. Calc. (Found C, 
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2.   1,3-Dihydro-(αS)-(1-methylethyl)-1,3-dioxo-2H-isoindole-2-acetamides (RKG145A)  
White fluffy crystals (71.2 mg, 15%); m.p. 190 – 191 °C; 1H 
NMR (300 MHz; d6-acetone) δ 7.89 (m, 4H, 4 x Ar-H1+2), 7.01 
(br s, 1H, CONHH), 6.45 (br s, 1H, CONHH), 4.38 (d, 1H, J 9.6, 
CH3), 2.84 (m, 1H, CH4), 1.12 (d, 3H, J 6.7, CH3
5) and 0.85 (d, 
3H, J 6.7, CH3
5); 13C NMR (75.5 MHz, d6-acetone) δ 169.91, 
168.11 (2C), 134.64 (2C), 132.05 (2C), 123.35 (2C), 60.51, 27.74, 20.42 and 19.12; LRMS (EI): 
m/z = 246.1 [M+]; Anal. Calc. (Found C, 63.6; H, 5.35; N, 11.2. C13H14N2O3 requires C, 63.4; H, 
5.73; N 11.4%);  
 
3.   1,3-Dihydro-(αS)-(2-methylpropyl)-1,3-dioxo-2H-isoindole-2-acetamides (RKG131A)  
White powder (134 mg, 29%); m.p. 162 - 165°C; 1H NMR (400 
MHz; d6-acetone) δ 7.87 (m, 4H, 4 x Ar-H1+2), 7.09 (br s, 1H, 
CONHH), 6.48 (br s, 1H, CONHH), 4.85 (dd, 1H, J 11.7, 4.4, 
CH3), 2.39 (m, 1H, CHH4), 1.97 (m, 1H, CH4H), 1.47 (m, 1H, 
CH5), 0.93 (d, 3H, J 6.6, CH3
6) and 0.91 (d, 3H, J 6.8, CH3
6); 13C 
NMR (100.6 MHz, d6-acetone) δ 170.72, 168.06 (2C), 134.48 
(2C), 132.40 (2C), 123.20 (2C), 52.19, 37.27, 25.36, 22.94 and 20.60; LRMS (EI): m/z = 260.1 
[M+]; Anal. Calc. (Found C, 65.4; H, 6.33; N, 10.3. C14H16N2O3 requires C, 64.6; H, 6.20; N 
10.8%);  
 
4.   1,3-Dihydro-1,3-dioxo-(αS)-(phenylmethyl)-2H-isoindole-2-acetamides (RKG133A)  
Pale brown/white powder (173 mg, 37%); m.p. 230 – 233 °C; 
1H NMR (400 MHz; d6-acetone/d6-DMSO) δ 7.77 (m, 4H, 4 x 
Ar-H1+2), 7.65 (br s, 1H, CONHH), 7.21 (br s, 1H, CONHH), 
7.11 (m, 5H, 5 x Ar-H5+6+7), 4.93 (dd, 1H, J 12.0, 4.5, CH3), 
3.53 (dd, 1H, J 13.9, 4.5, CHH4) and 3.37 (dd, 1H, J 13.9, 12.0, 
CH4H); 13C NMR (100.6 MHz, d6-acetone/d6-DMSO) δ 170.27, 
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55.03 and 34.45; LRMS (EI): m/z = 294.1 [M+]; Anal. Calc. (Found C, 69.0; H, 4.79; N, 9.44. 
C17H14N2O3 requires C, 69.4; H, 4.79; N 9.52%);  
 
Synthesis of Sulfonylcyanoguanidines 
 
Synthesis of N-cyano-N'-(4-bromophenyl)-S-methyl-isothiourea (RKG136A) 
 
Dimethyl N-cyanodithioiminecarbonate (0.825 g, 5.64 mmol)  
and 4-bromoaniline (1.087 g, 6.31 mmol) were added to 
absolute ethanol (2.5 ml), and the mixture was refluxed at 80 ºC 
for 17 hrs. The reaction mixture was allowed to cool down to 
room temperature, and then placed in an ice bath. A white precipitate formed, and was filtered 
off. The white precipitate was recrystallized from absolute ethanol, and washed with cold 
absolute ethanol. 
White powder (0.933g, 61%); m.p. 193 – 195 °C; IR (Thin film) νmax (cm
-1) 3406 (br w) (N-H), 
3188 (w) (C-S), 3007 (w) (C-H), 2159 (s) (C≡N), 1585 (m) (C=N), 1509 (s) (C=C), 1487 (s) (C=C) and 
1285 (m) (C-N); 1H NMR (400 MHz; d6-DMSO) δ 10.15 (br s, 1H, NH), 7.57 (d, 2H, J 8.8, 2 x Ar-
H1), 7.42 (d, 2H, J 9.0, 2 x Ar-H2) and 2.70 (s, 3H, -SCH3); 
13C NMR (100.6 MHz, d6-DMSO) δ 
170.87, 137.37, 132.36 (2C), 126.63 (2C), 119.20, 115.24 and 15.59; LRMS (EI): m/z = 271.0 [M
+]; 
Anal. Calc. (Found C, 40.2; H, 2.69; N, 15.7; S, 11.7. C9H8N3SBr requires C, 40.0; H, 2.98; N 15.6; 
S, 11.9%);  
 
Synthesis of N-cyano-N'-iso-propyl-S-methyl-isothiourea (RKG150A)  
 
Dimethyl N-cyanodithioiminecarbonate (0.500 g, 3.42 mmol) and 
isopropylamine (0.298 ml, 207 mg, 3.50 mmol)were added to absolute 
ethanol (2 ml), and the mixture was refluxed at 80 oC for 4 hrs. The 
reaction mixture was allowed to cool down to room temperature, and then the solvent was 
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0.1M HCl (10 ml) was added, and the resulting solution was extracted with chloroform (3 x 
20ml). The combined organic washes were dried over anhydrous Na2SO4. The organic phase 
was filtered, and the solvent was removed under reduced pressure. The resulting product was 
dried further in vacuo.  
White powder (0.556 g, quantitative); m.p. 113 – 116 °C; 1H NMR (300 MHz; d6-DMSO) δ 8.04 
(br s, 1H, NH), 4.07 (br m, 1H, CH2), 2.57 (s, 3H, -SCH3) and 1.15 (d, 6H, J 6.6, 2 x CH3
1); 13C NMR 
(75.5 MHz, d6-DMSO) δ 168.60, 115.80, 45.57, 21.29 (2C) and 14.11; LRMS (EI): m/z = 157.0 
[M+]; 
 
Synthesis of N-[(cyanoamino)(alkyl/arylamino)methylene]-4-chloro-benzenesulfonamide 
(RKG139F3 and RKG151) 
 
The isothiourea (1.59 mmol) was added to a solution of 4-chloro-benzenesulfonamide (1.59 
mmol) and K2CO3 (1.59 mmol) in DMF (3 ml). The reaction was refluxed at 120 ºC for 20 hrs. 
The reaction mixture was allowed to cool down to room temperature and deionised H2O (12 
ml) was added, followed by an aqueous solution of 2.5M NaOH (1 ml). The solution was 
extracted with diethyl ether (3 x 15ml), and the resulting aqueous phase pH was adjusted to 1 
with an aqueous solution of 1M HCl. The precipitate was collected via filtration, and was 
washed with cold H2O. The precipitate was dryed in vacuo, and was further purified via 
recrystallization from methanol to obtain the sulfonamide (sulfonylcyanoguanidine). 
NOTE: for the synthesis of RKG139F3, the final product was obtained via column 
chromatography (SiO2, MeOH:DCM, 5:95 to 20:80) of the reaction mixture before the work-up 
stage as described above. 
 
1.   N-[(Cyanoamino)(p-bromophenylamino)methylene]-chloro-benzenesulfonamide (RKG139F3) 
Pale brown/white powder (195.1 mg, 32%) (1.48 
mmol scale); m.p. 192 – 195 °C; IR (Thin film) νmax 
(cm-1) 3319 (br w) (N-H), 2167 (s) (C≡N), 1603 (m) 
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(S=O) and 1133 (s) (S=O); 1H NMR (400 MHz; d6-DMSO) δ 8.91 (br s, 1H, NH), 7.76 (d, 2H, J 
8.5, 2 x Ar-H2), 7.53 (d, 2H, J 8.5, 2 x Ar-H1) and 7.39 (m (s), 4H, 4 x Ar-H3+4); 13C NMR (100.6 
MHz, d6-DMSO) δ 159.65, 144.85, 139.05, 136.20, 131.87 (2C), 129.33 (2C), 128.25 (2C), 
123.47 (2C), 118.88 and 115.23; LRMS (EI): m/z = 412.0 [M
+]; Anal. Calc. (Found C, 40.9; H, 
2.78; N, 14.0; S, 8.01. C14H10N4O2SClBr requires C, 40.7; H, 2.44; N 13.5; S, 7.75%); 
 
2.   N-[(Cyanoamino)(isopropyl)methylene]-chloro-benzenesulfonamide (RKG151A) 
White flake-like crystals (237.8 mg, 50%); m.p. 134 – 
138 °C; IR (Thin film) νmax (cm
-1) 3377 (m) (N-H), 3080 
(w) (N-H), 2971 (m) (CH), 2717 (br m) (CH), 2188 
(C≡N), 1617 (s) (C-N), 1559 (s) (C=C), 1440 (s) (C=C), 
1350 (s) (S=O) and 1162 (s) (S=O); 1H NMR (300 MHz; 
d6-DMSO) δ 7.89 (d, 2H, J 8.8, 2 x Ar-H2), 7.72 (d, 2H, J 9.0, 2 x Ar-H1), 7.63 (br s, 1H, NH), 
3.95 (m, 1H, CH3) and 1.14 (d, 6H, J 6.6, 2 x CH3
4); 13C NMR (75.5 MHz, d6-DMSO) δ 154.61, 
140.04, 137.59, 129.10 (2C), 128.56 (2C), 115.23, 44.28 and 21.98 (2C); LRMS (EI): m/z = 
300.0 [M+]; Anal. Calc. (Found C, 44.1; H, 4.57; N, 18.9; S, 10.8. C11H13N4O2SCl requires C, 
43.9; H, 4.36; N 18.6; S, 10.7%);  
 
Synthesis of Acylthioureas 
 
General procedure for the synthesis of 1-(p-chlorobenzoyl)-3-(alkyl/aryl)thioureas (RKG1541; 
RKG1542; RKG1543; RKG162A) 
 
4-Chlorobenzoyl chloride (2.33 mmol) was added dropwise to a solution of ammonium 
thiocyanate (NH4SCN) (2.85 mmol) dissolved in acetone (7.5 ml). The mixture was stirred for 30 
min under reflux (~60 °C) under N2, and after the reaction mixture was allowed to cool to room 
temperature, the inorganic salt (NH4Cl) was filtered off to yield a solution of 4-
chlorobenzoylisothiocyanate in acetone. The alkyl/aryl amine (2.33 mmol) was added to the 
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cool to room temperature, and the acetone was removed under reduced pressure. Cold 
deionised water was added to the residue with stirring, and the solid was collected by filtration. 
The solid was then recrystallized from 95% ethanol, resulting in the pure acylthiourea. 
 
1.  1-(p-Chlorobenzoyl)-3-(p-bromophenyl)thiourea (RKG1541) 
Pale yellow powder (621 mg, 72%); m.p. 194 – 197 °C; 
1H NMR (400 MHz; d1-CDCl3) δ 12.52 (br s, 1H, NH), 
9.06 (br s, 1H, NH), 7.84 (d, 2H, J 8.8, 2 x Ar-H2), 7.62 
(d, 2H, J 8.8, 2 x Ar-H4) and 7.53 (m (2d), 4H, J 8.8, 4 x 
Ar-H1+3); 13C NMR (100.6 MHz, d1-CDCl3) δ  178.11, 165.89, 140.54, 136.89, 132.01 (2C), 
129.84, 129.61 (2C), 128.89 (2C), 125.51 (2C) and 120.09; LRMS (EI): m/z = 368.0 [M+]; Anal. 
Calc. (Found C, 45.4; H, 2.52; N, 7.67; S, 8.79. C14H10N2OSClBr requires C, 45.5; H, 2.73; N 
7.58; S, 8.67%);  
 
2.   1-(p-Chlorobenzoyl)-3-(p-bromo-o-N-pyridinyl)thiourea (RKG1542) 
Very pale yellow feather-like crystals (692 mg, 80%); 
m.p. 203 – 205 °C; 1H NMR (300 MHz; d6-DMSO) δ 8.58 
(d, 1H, J 2.4,  Ar-H5), 8.16 (dd, 1H, J 9.0, 2.4,  Ar-H4), 7.99 
(d, 2H, J 8.6, 2 x Ar-H2), 7.63 (d, 2H, J 8.6, 2 x Ar-H1) and 
7.35 (d, 1H, J 8.9, Ar-H3); 13C NMR (75.5 MHz, d6-DMSO) δ 177.86, 150.13, 148.84, 140.64, 
138.06, 131.02, 130.56 (2C), 128.56 (2C), 128.38, 116.95 and 115.53; LRMS (EI): m/z = 370.9 
[M+]; Anal. Calc. (Found C, 42.3; H, 2.13; N, 11.4; S, 8.95. C13H9N3OSClBr requires C, 42.1; H, 
2.45; N 11.3; S, 8.65%);  
 
3. 1-(p-Chlorobenzoyl)-3-(m-dimethoxy-o-N,N-pyrimidinyl)thiourea (RKG1543) 
Yellow powder (355 mg, 43%); m.p. 178 – 180 °C; IR 
(Thin film) νmax (cm
-1) 3319 (w) (N-H), 3152 (w) (N-H), 
2899 (br m) (C-H), 1711 (m) (C=O), 1686 (m) (C=N), 
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1245 (br s) (C-O and C=S); 1H NMR (300 MHz; d6-DMSO) δ 12.86* (br s, 1H, NH), 12.11* (br 
s, 1H, NH), 11.28 (br s, 1H, NH), 9.65 (br d, 1H, NH), 8.01* (d, 2H, J 8.7, 2 x Ar-H2), 7.94 (d, 
2H, J 8.7, 2 x Ar-H2), 7.62* (d, 2H, J 8.7, 2 x Ar-H1), 7.57 (d, 2H, J 8.7, 2 x Ar-H1), 6.06 (s, 1H, 
Ar-H3) and 3.88 (s, 6H, 2 x -OCH3); 
13C NMR (75.5 MHz, d6-DMSO) δ 181.91, 177.73*, 171.44 
(2C), 166.66, 165.25*, 155.67, 137.92*, 137.72, 131.63*, 131.03, 130.42 (2C), 130.21* (2C), 
128.62* (2C), 128.33 (2C), 84.62 and 54.61 (2C); LRMS (EI): m/z = 352.0 [M+]; Anal. Calc. 
(Found C, 47.2; H, 3.57; N, 15.6; S, 9.77. C14H13N4O3SCl requires C, 47.7; H, 3.71; N 15.9; S, 
9.09%); 
 
4.   1-(p-Chlorobenzoyl)-3-(iso-propyl)thiourea (RKG162A) 
Pale yellow powder (496 mg, 83%); m.p. 98 – 103 °C; 1H NMR 
(300 MHz; d6-DMSO) δ 11.31* (br s, 1H, NH), 10.72* (d, 1H, J 
7.8), NH), 9.67 (br d, 1H, NH), 8.26 (br d, 1H, J 7.3, NH), 7.93* 
(d, 2H, J 8.7, 2 x Ar-H2), 7.86 (d, 2H, J 8.3, 2 x Ar-H2), 7.57* (d, 
2H, J 8.7, 2 x Ar-H1), 7.51 (d, 2H, J 8.7, 2 x Ar-H1), 4.43* (m (oct), 1H, J 7.8, 6.9, 6.4, CH3), 4.08 
(m (oct), 1H, J 7.8, 6.9, 6.4, CH3), 1.26 (d, 6H, J 6.4, 2 x CH3
4) and 1.16 (d, 6H, J 6.9, 2 x CH3
4); 
13C NMR (75.5 MHz, d6-DMSO) δ 181.92, 178.66*, 167.16*, 166.71, 137.73*, 135.65, 133.49, 
131.03*, 130.40* (2C), 129.08 (2C), 128.38* (2C), 128.11 (2C), 46.62*, 41.04, 22.20 (2C) and 
21.13* (2C); LRMS (EI): m/z = 256.0 [M+]; Anal. Calc. (Found C, 51.9; H, 5.45; N, 10.7; S, 11.6. 
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8.3 Experimental: Chapter 5 
 
Synthesis of O-ethyl thiocarbamate (ethyl xanthamidate) (RKG101) 
 
Ethanol (50 ml) and carbon disulfide (17.6 ml, 0.291 mol) were shaken up with 
a solution of sodium hydroxide (10 g) in deionised water (150 ml). The solution 
was then left to stir for 1 h at room temperature [OBSERVATION: the clear 
solution turned deep orange after the addition of the NaOH solution]. A solution of sodium 
hydroxide (10 g) in deionised water (100 ml) was neutralized with the slow addition of 
chloroacetic acid (23.66 g, 0.250 mol) in an ice bath, and the resulting solution was added to 
the solution obtained above. The mixture was then left to stir overnight at room temperature 
[OBSERVATION: the deep orange solution changed to deep yellow after the addition of the 
neutralized chloroacetic acid solution]. Concentrated ammonium hydroxide (46.8 ml, 25% NH3 
in water, ~13.36M, 0.625 mol) was added, and the stirring was continued at room temperature 
overnight. The solution was neutralized by the addition of glacial acetic acid (14.6 ml), and then 
extracted with diethyl ether (2 x 150 ml). The organic phase was washed with deionised water 
(100 ml), followed by 1M HCl (100 ml), and dried over MgSO4. The extract was filtered and 
concentrated in vacuo. The resulting oil (clear, colourless) was placed under n-hexane at -12 ºC, 
producing a white solid. The purification process was carried out to remove the S-ethyl isomer.  
White flake-like crystals (12.8 g, 49%); m.p. 35 – 37 oC (lit.1 40 - 41 oC; lit.2 m.p. 38 - 39 oC); 1H 
NMR (300 MHz; d1-CDCl3) δ 4.48 (q, 2H, J 7.1, CH2) and 1.33 (t, 3H, J 7.1, CH3) *no δ 2.90, 
characteristic of S-ethyl isomer];  
 
Synthesis of 3-ethoxy-1,2,4-dithiazolin-5-one (RKG104) 
 
O-Ethyl thiocarbamate (4.00 g, 0.038 mol) and Et3N (5.3 ml, 0.038 mol) were added 
to Et2O (20 ml). The resulting mixture was added dropwise over 1 h to a stirred and 
chilled solution of (chlorocarbonyl)sulfenyl chloride (3.3 ml, 5.0 g, 0.038 mol) in Et2O 
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temperature below 10 ºC. After the addition was complete, the reaction was allowed to stir for 
an additional 5.5 h at room temperature (~20 oC). The white precipitate (Et3N.HCl) was 
removed via filtration, and the resulting clear pale yellow solution concentrated. The resulting 
pale yellow oil was cooled to -12 °C providing a light yellow solid. n-Hexane (20 ml) was added, 
and the mixture was heated to allow the desired product to dissolve into the n-hexane 
[OBSERVATION: upon heating a yellow oil formed, which was immiscible in the n-hexane (2 
layers observed)]. The warm n-hexane layer was separated, and cooled to -12 oC producing off-
white (pale yellow) needle-shaped crystals (2.90 g). The crystals were isolated via filtration, 
washed with cold n-hexane, and dried in vacuo.  
Pale yellow, white needle-like crystals (2.90 g, 47%); m.p. 44 – 47 oC (lit.3 m.p. 56 – 57 oC); 1H 
NMR (400 MHz; d1-CDCl3) δ 4.68 (q, 2H, J 7.1, CH2) and 1.46 (t, 3H, J 7.1, CH3);  
 
Synthesis of 1,2,4-dithiazolidine-3,5-dione (RKG121A) 
 
A stirred suspension of 3-ethoxy-1,2,4-dithiazolin-5-one (2.01 g, 12.3 mmol) in 
concentrated aqueous 32% HCl (12 ml) was heated over 45 min to 110 °C. The 
solution was stirred for a further 10 min, and filtered through a Buchner funnel 
while hot to remove elemental sulphur. The filtrate was concentrated and dried to 
provide a solid, which was then recrystallized from toluene. 
White crystals (0.714 g, 43 %); m.p. 132 – 136 oC (lit.4 m.p. 141 oC; lit.3 m.p. 142 – 144 oC); 13C 
NMR (75.5 MHz, d3-CD3CN) δ 170.05 (2C);  
 
General procedure for the synthesis of compounds (RKG2661, RKG315, RKG317, RKG318, 
RKG319, RKG425B, RKG425C and RKG425D) 
 
1,2,4-Dithiazolidine-3,5-dione (RKG121) (100 mg, 0.74 mmol) was dissolved in CH3CN (1.5 ml). 
Sodium bicarbonate (120 mg, 1.43 mmol) was added with stirring to the solution at room 
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for 16 hrs. The solvent was removed under reduced pressure with adsorption of the residue 
onto silica gel for purification by flash chromatography (1:9, EtOAc:hexane); 
1. (3,5-Dioxo-[1,2,4]dithiazolidin-4-yl)-acetic acid ethyl ester RKG2661  
Yellow oil (106 mg, 65%); Rf = 0.26; 
1H NMR (400 MHz; d1-
CDCl3) δ 4.46 (s, 2H, CH2
1), 4.25 (q, 2H, J 7.1, CH2
2) and 1.29 (t, 





2. 4-(4-Bromo-benzyl)-[1,2,4]dithiazolidine-3,5-dione RKG315 
White crystals (207 mg, 92%); Rf = 0.21; m.p. 93 - 97 °C; IR (NaCl) 
vmax (cm
-1) 2995 (w) (C-H), 1645 (s) (C=O), 1486 (m) (C=C), 1301 (s) 
(C-N), 724 (s) (C-Br) and 525 (w) (S-S); 1H NMR (400 MHz; d1-
CDCl3) δ 7.47 (d, 2H, J 8.4, 2 x Ar-H
3), 7.29 (d, 2H, J 8.30, 2 x Ar-H2) 
and 4.85 (s, 2H, CH2
1); 13C NMR (100.6 MHz, d1-CDCl3) δ 167.38 
(2C), 133.08, 132.03 (2C), 130.86 (2C), 123.02 and 48.65; HRMS 
(EI): m/z = 302.90176 [M+]; Anal. Calc. (Found C, 35.1; H, 1.96; N, 4.09; S, 19.7. 
C9H6BrNO2S2 requires C, 35.5; H, 1.99; N, 4.60; S, 21.1%);  
 
3. 4-(3-Bromo-benzyl)-[1,2,4]dithiazolidine-3,5-dione RKG317 
White needle-like crystals (178 mg, 79%); Rf = 0.30; m.p. 95 - 97 
°C; IR (NaCl) vmax (cm
-1) 3000 (w) (C-H), 1652 (s) (C=O), 1572 (m) 
(C=C), 1474 (m) (C=C), 1303 (s) (C-N), 708 (s) (C-Br) and 544 (w) (S-
S); 1H NMR (400 MHz; d1-CDCl3) δ 7.56 (s, 1H, Ar-H
5), 7.47 (d, 1H, J 
7.8, Ar-H4), 7.34 (d, 1H, J 7.7, Ar-H2), 7.21 (t, 1H, J 7.8, Ar-H3) and 
4.86 (s, 2H, CH2
1); 13C NMR (100.6 MHz; d1-CDCl3) δ 167.34 (2C), 136.17, 132.03, 131.96, 
130.38, 127.73, 122.81 and 48.57; HRMS (EI): m/z = 302.90191 [M+]; Anal. Calc. (Found 
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4. 4-Benzyl-[1,2,4]dithiazolidine-3,5-dione RKG318 
White crystals (124 mg, 74%); Rf = 0.36; m.p. 87 - 91 °C; 
1H NMR 
(400 MHz; d1-CDCl3) δ 7.41 (m, 2H, 2 x Ar-H
3), 7.43 (m, 3H, 3 x Ar-
H2+4) and 4.91 (s, 2H, CH2
1); 13C NMR (100.6 MHz; d1-CDCl3) δ 
167.47 (2C), 136.18, 129.06 (2C), 128.82 (2C), 128.71 and 49.38; 
HRMS (EI): m/z = 224.99127 [M+]; Anal. Calc. (Found C, 47.8; H, 
3.14; N, 6.10; S, 28.0. C9H7NO2S2 requires C, 48.0; H, 3.13; N, 6.22; S, 28.5%); 
 
5. 4-(2-Bromo-benzyl)-[1,2,4]dithiazolidine-3,5-dione RKG319 
White needle-like crystals (211 mg, 94%); Rf = 0.21; m.p. 80 - 81 °C; 
IR (NaCl) vmax (cm
-1) 3060 (w) (C-H), 1655 (s) (C=O), 1603 (m) (C=C), 
1477 (m) (C=C), 1312 (s) (C-N), 749 (m) (C-Br) and 555 (m) (S-S); 1H 
NMR (400 MHz; d1-CDCl3) δ 7.59 (dd, 1H, J 7.8, 1.3, Ar-H
5), 7.29 
(td, 1H, J 7.6, 1.3, Ar-H3), 7.18 (td, 1H, J 7.8, 1.7, Ar-H4), 7.07 (dd, 
1H, J 7.7, 1.7, Ar-H2) and 5.05 (s, 2H, CH2
1); 13C NMR (100.6 MHz; 
d1-CDCl3) δ 162.77 (2C), 133.25, 132.78, 129.62, 127.86, 127.72, 122.85 and 49.21; 
HRMS (EI): m/z = 302.90180 [M+]; Anal. Calc. (Found C, 34.9; H, 1.86; N, 4.18; S, 20.0. 
C9H6BrNO2S2 requires C, 35.5; H, 1.99; N, 4.60; S, 21.1%); 
 
6. 4-Allyl-[1,2,4]dithiazolidine-3,5-dione RKG425B 
Clear, yellow oil (88 mg, 68%); Rf = 0.31 (1:19, EtOAc:hexane); 
1H 
NMR (400 MHz; d1-CDCl3) δ 5.79 (m, 1H, CH
c), 5.28 (m, 2H, CH2
a + 
b) and 4.33 (dt, 2H, J 6.0, 1.4, CH2); 
13C NMR (100.6 MHz; d1-
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7. 4-(4-Methoxybenzyl)-[1,2,4]dithiazolidine-3,5-dione RKG425C 
White, crystalline solid (143 mg, 76%); Rf = 0.23 (1:19, 
EtOAc:hexane); 1H NMR (300 MHz; d1-CDCl3) δ 7.26 (t, 1H, J 
8.3, Ar-H4), 6.97 (m, 2H, 2 x Ar-H2+5), 6.87 (d, 1H, J 8.3, Ar-
H3), 4.87 (s, 2H, CH2) and 3.80 (s, 3H, -OCH3); 
13C NMR (75.5 
MHz; d1-CDCl3) δ 167.42 (2C), 159.85, 135.53, 129.85, 
121.20, 114.51, 114.28, 55.27 and 49.27; HRMS (EI): m/z = 255.00182 [M+]; Anal. Calc. 
(Found C, 46.9; H, 3.60; N, 5.31; S, 24.9. C10H9NO3S2 requires C, 47.0; H, 3.55; N, 5.49; S, 
25.1%); 
 
8. 4-(Biphenyl-2-ylmethyl)-[1,2,4]dithiazolidine-3,5-dione RKG425D 
White, crystalline solid (174 mg, 78%); Rf = 0.38 (1:19, 
EtOAc:hexane); 1H NMR (400 MHz; d1-CDCl3) δ 7.43 – 7.14 
(m, 9H, 9 x Ar-H) and 4.88 (s, 2H, CH2); 
13C NMR (100.6 MHz; 
d1-CDCl3) δ 167.12 (2C), 141.87, 140.20, 131.27, 130.41, 
129.13 (2C), 128.40 (2C), 127.88, 127.85, 127.49, 126.49 and 
47.28; HRMS (EI): m/z = 301.02259 [M+]; Anal. Calc. (Found C, 59.9; H, 3.61; N, 4.58; S, 
21.1. C15H11NO2S2 requires C, 59.8; H, 3.68; N, 4.65; S, 21.3%); 
 
General procedure for the synthesis of compounds (RKG267F4, RKG328, RKG330 and RKG331) 
 
One equivalent of 4-chlorobenzene sulfonamide was added to a solution of alkylated 1,2,4-
dithiazolidine-3,5-dione (50 mg) and PPh3 (1 equiv.) dissolved in toluene (2.0 ml). K2CO3 (1 
equiv.) was added, and the reaction was stirred under reflux for 24 hrs. The reaction mixture 
was allowed to cool to room temperature. The suspended material was filtered off and washed 
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1. Ethyl 2-(3-(4-chlorophenylsulfonyl)ureido)acetate RKG2672F4 
Isolated using column chromatography (1:9, EtOAc:hexane; adjusting to 2:3, 
EtOAc:hexane); 
Yellow oil (30.6 mg, 48%); Rf = 0.05 (2:3, 
EtOAc:hexane); 1H NMR (400 MHz; d6-
DMSO) δ 8.17 (s, 1H, NH), 7.58 (m, 4H, 4 x 
ArH), 4.12 (q and s overlapping, 3H, J 7.1, 
CH2
2 and NH), 4.00 (s, 2H, CH2
1) and 1.18 (t, 3H, J 7.1, CH3
3); 13C NMR (100.6 MHz; d6-
DMSO) δ 171.43, 167.37, 131.45 (2C), 128.97, 128.72 (2C), 127.53, 45.99, 38.90 and 
13.90; LRMS (EI): m/z = 320.0 [M+]; 
 
2. N-(4-Bromobenzylcarbamoyl)-4-chlorobenzenesulfonamide RKG328 
White powder (51.5 mg, 58%); m.p. 243 - 
247 °C; IR (NaCl) vmax (cm
-1) 3378 (s) (N-H), 
3039 (w) (C-H), 2882 (w) (C-H), 1603 (s) 
(C=O), 1574 (m) (C=C), 1462 (s) (C=C), 
1343 (s) (S=O), 1218 (s) (C-O), 1133 (s) 
(S=O), 755 (s) (C-Cl) and 521 (s) (C-Br); 1H NMR (400 MHz; d6-DMSO) δ 7.70 (d, 2H, J 8.3, 
2 x ArH4), 7.38 (m, 4H, 4 x ArH3+5), 7.10 (d, 2H, J 8.0, 2 x Ar-H2) and 4.00 (s, 2H, CH2
1); 13C 
NMR (100.6 MHz; d6-DMSO) δ 160.75, 141.27, 133.70, 130.94, 130.62 (2C), 129.10 (2C), 
128.34 (2C), 127.39 (2C), 118.90 and 42.29; LRMS (EI): m/z = 400.9 [M+]; Anal. Calc. 
(Found C, 41.2; H, 2.44; N, 6.18; S, 7.57. C14H12BrN2O3SCl requires C, 41.7; H, 3.00; N, 
6.94; S, 7.94%); 
 
3. N-(3-Bromobenzylcarbamoyl)-4-chlorobenzenesulfonamide RKG330 
White powder (46.1 mg, 52%); m.p. 240 - 
244 °C; IR (NaCl) vmax (cm
-1) 3386 (s) (N-H), 
3022 (w) (C-H), 2933 (w) (C-H), 1599 (s) 
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(s) (C-O), 1130 (s) (S=O), 783 (s) (C-Cl) and 520 (s) (C-Br); 1H NMR (400 MHz; d6-DMSO) δ 
7.71 (d, 2H, J 8.2, 2 x ArH6), 7.36 (m, 4H, 4 x ArH2+3+7), 7.16 (m, 2H, 2 x Ar-H4+5) and 4.03 
(s, 2H, CH2
1); 13C NMR (100.6 MHz; d6-DMSO) δ 160.65, 145.08, 133.54, 130.28, 129.94, 
129.48, 128.74, 128.30 (2C), 127.35 (2C), 125.83, 121.35 and 42.32; LRMS (EI): m/z = 
400.9 [M+]; Anal. Calc. (Found C, 41.2; H, 2.69; N, 6.32; S, 7.18. C14H12BrN2O3SCl requires 
C, 41.7; H, 3.00; N, 6.94; S, 7.94%); 
 
4. N-(Benzylcarbamoyl)-4-chlorobenzenesulfonamide RKG331 
White powder (46.1mg, 65%); m.p. 248 - 252 
°C; IR (NaCl) vmax (cm
-1) 3378 (s) (N-H), 3028 
(w) (C-H), 1603 (s) (C=O), 1476 (w) (C=C), 
1458 (s) (C=C), 1344 (s) (S=O), 1220 (s) (C-O), 
1134 (s) (S=O) and 728 (s) (C-Cl); 1H NMR (400 MHz; d6-DMSO) δ 7.72 (d, 2H, J 8.3, 2 x 
ArH5), 7.37 (d, 2H, J 8.4, 2 x ArH6), 7.22 (t, 2H, J 7.9, 2 x Ar-H3), 7.14 (m, 3H, 3 x Ar-H2+4) 
and 4.05 (s, 2H, CH2
1); 13C NMR (100.6 MHz; d6-DMSO) δ 160.50, 146.73, 133.53, 128.35 
(2C), 127.79 (2C), 127.33 (2C), 126.83 (2C), 125.95, 123.46 and 43.06; LRMS (EI): m/z = 
324.0 [M+]; Anal. Calc. (Found C, 51.3; H, 3.73; N, 8.08; S, 9.24. C14H13N2O3SCl requires C, 
51.8; H, 4.03; N, 8.63; S, 9.87%);  
 
General procedure for the synthesis of compounds (RKG357, RKG360, RKG359, RKG351, 
RKG426A, RKG426B and RKG427A) 
 
One equivalent of sulfonamide was added to a solution of alkylated 1,2,4-dithiazolidine-3,5-
dione (60 mg) and PPh3 (1 equiv.) dissolved in toluene (2.0 ml). K2CO3 (1 equiv.) was added, and 
the reaction was stirred under reflux for 24 hrs. The reaction mixture was allowed to cool to 
room temperature. The suspended material was filtered off and washed with deionised H2O 
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1. N-(2-Bromobenzylcarbamoyl)benzenesulfonamide RKG357 
White powder (58.6 mg, 79%); m.p. 214 - 216 °C; 
IR (NaCl) vmax (cm
-1) 3334 (s) (N-H), 3054 (w) (C-
H), 2905 (w) (C-H), 1623 (s) (C=O), 1588 (m) 
(C=C), 1532 (s) (C=C), 1443 (s) (C=C), 1366 (s) 
(S=O), 1293 (C-N), 1133 (s) (S=O), 753 (s) (C-Cl) and 579 (s) (C-Br); 1H NMR (400 MHz; d6-
DMSO) δ 7.71 (m, 2H, 2 x ArH6), 7.49 (d, 1H, J 7.5, ArH5), 7.32 (m, 3H, 3 x Ar-H7+8), 7.23 
(m, 2H, 2 x Ar-H2+3), 7.10 (t, 1H, J 7.6), ArH4) and 4.07 (s, 2H, CH2
1); 13C NMR (100.6 MHz; 
d6-DMSO) δ 166.42, 141.04, 132.90, 132.50, 129.70, 129.17, 128.71, 128.11 (2C), 
127.96, 126.98 (2C), 122.57 and 44.10; LRMS (EI): m/z = 368.0 [M+]; Anal. Calc. (Found C, 
45.0; H, 2.96; N, 7.66; S, 8.04. C14H13BrN2O3S requires C, 45.5; H, 3.55; N, 7.59; S, 8.68%);  
 
2. N-(2-Bromobenzylcarbamoyl)naphthalene-2-sulfonamide RKG360 
White powder (56.5 mg, 67%); m.p. 160 - 170 
°C; IR (NaCl) vmax (cm
-1) 3371 (m) (N-H), 1624 
(s) (C=O), 1590 (m) (C=C), 1453 (s) (C=C), 1337 
(s) (S=O), 1260 (C-N), 1182 (s) (S=O) and 744 
(s) (C-Br); 1H NMR (400 MHz; d6-DMSO) δ 
8.24 (s, 1H, ArH12), 7.92 (m, 2H, 2 x ArH6+7), 
7.84 (m, 2H, 2 x ArH8+11), 7.54 (m, 2H, 2 x Ar-H9+10), 7.47 (d, 1H, J 8.1, ArH5), 7.18 (m, 2H, 
2 x ArH2+3), 7.08 (t, 1H, J 8.0, ArH4) and 4.05 (s, 2H, CH2
1); 13C NMR (100.6 MHz; d6-
DMSO) δ 145.74, 133.75, 132.89, 132.62, 132.48, 129.25, 129.13, 128.68, 128.12, 
127.90, 127.71, 127.42, 126.99, 126.17, 124.98, 122.55 and 44.10; LRMS (EI): m/z = 
418.0 [M+]; Anal. Calc. (Found C, 51.1; H, 3.28; N, 6.72; S, 6.30. C18H15BrN2O3S requires C, 




















































White powder (92.6 
mg, 80%); m.p. 206 - 
210 °C; IR (NaCl) vmax 
(cm-1) 3363 (m) (N-H), 
3285 (m) (CON-H), 
2902 (w) (C-H), 1638 
(s) (C=O), 1615 (s) (C=O), 1535 (s) (C=C), 1508 (s) (C=C), 1462 (s) (C=C), 1342 (s) (S=O), 
1295 (s) (C-N), 1227 (s) (C-O), 1163 (s) (S=O), 743 (s) (C-Cl) and 572 (s) (C-Br);1H NMR 
(400 MHz; d6-DMSO) δ 8.20 (t, 1H, J 5.5, NHCO), 7.65 (m, 3H, 3 x ArH6+10), 7.48 (m, 2H, 2 
x ArH5+11), 7.23 (m, 2H, 2 x ArH2+3), 7.21 (d, 2H, J 8.1, 2 x ArH7), 7.12 (m, 2H, 2 x ArH4+12), 
4.07 (s, 2H, CH2
1), 3.78 (s, 3H, -OCH3), 3.51 (m, 2H, CH2
9) and 2.82 (t, 2H, J 7.0, CH2
8); 13C 
NMR (75.5 MHz; d6-DMSO) δ 163.36, 160.44, 155.70, 145.84, 140.35, 132.15, 131.71, 
131.43, 129.52, 128.93, 128.47, 127.91, 127.61, 127.16, 126.41, 125.56, 124.28, 122.14, 
121.83, 114.11, 56.22, 43.34, 40.45 and 34.52; LRMS (EI): m/z = 579.0 [M+]; Anal. Calc. 
(Found C, 49.0; H, 3.54; N, 6.25; S, 5.22. C24H23BrN3O5SCl requires C, 49.6; H, 3.99; N, 




White powder (50.7 mg, 
47%); m.p. 213 - 217 °C; IR 
(NaCl) vmax (cm
-1) 3366 (s) 
(N-H), 3262 (m) (CON-H), 
2978 (w) (C-H), 1706 (s) 
(C=O), 1673 (s) (C=O), 1599 
(s) (C=O, C=C), 1512 (s) 
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(C-Cl) and 573 (m) (C-Br); 1H NMR (400 MHz; d6-DMSO) δ 8.30 (d, 1H, J 2.1, ArH4), 8.27 
(d, 1H, J 2.1, ArH5), 8.16 (d, 1H, J 8.3, ArH13), 7.94 (d, 1H, J 7.7, ArH10), 7.85 (d, 1H, J 8.1, 
ArH9), 7.53 (m, 3H, 3 x ArH8+11+12), 7.48 (d, 2H, J 8.5), 2 x ArH3), 7.38 (d, 1H, J 8.3, ArH7), 
7.18 (d, 2H, J 8.5, 2 x ArH2), 4.29 (m, 4H, CH2
6 and –OCH2-),  3.97 (s, 2H, CH2
1) and 1.28 (t, 
3H, J 7.1, -OCH2CH3); 
13C NMR (100.6 MHz; d6-DMSO) δ 170.68, 170.37, 165.51, 147.25, 
141.17, 134.10, 132.81, 132.65, 131.70 (2C), 131.33 (2C), 129.88, 129.80, 129.13, 
128.79, 128.09, 127.93, 127.60, 126.85, 126.44, 126.24, 124.86, 120.14, 119.57, 62.29, 
61.78, 43.06 and 14.83; LRMS (EI): m/z = 657.0 [M+]; Anal. Calc. (Found C, 51.5; H, 3.47; 
N, 5.76; S, 4.17. C29H25BrN3O6SCl requires C, 52.9; H, 3.82; N, 6.38; S, 4.87%); 
 
5. 4-Chloro-N-(3-methoxybenzylcarbamoyl)benzenesulfonamide (RKG426A) 
White solid (47.6 mg, 67%); 1H NMR 
(400 MHz; d6-DMSO) δ 7.75 (d, 2H, J 
8.4, 2 x ArH6), 7.35 (d, 2H, J 8.5, 2 x 
ArH7), 7.13 (t, 1H, J 7.8, ArH4), 6.76 (m, 
3H, 3 x Ar-H2+3+5), 4.07 (d, 2H, J 6.5, CH2
1) and 3.70 (s, 3H, -OCH3); 
13C NMR (100.6 MHz; 
d6-DMSO) δ 160.58, 159.07, 146.76, 143.57, 133.45, 128.75, 128.34 (2C), 127.28 (2C), 
119.02, 112.31, 111.52, 54.74 and 42.82; LRMS (EI): m/z = 354.0 [M+]; Anal. Calc. (Found 
C, 50.2; H, 3.87; N, 6.76; S, 8.17. C15H15ClN2O4S requires C, 50.8; H, 4.26; N, 7.90; S, 
9.04%); 
 
6. 2,4,6-Triisopropyl-N-(3-methoxybenzylcarbamoyl)benzenesulfonamide (RKG426B)  
(purified by column chromatography; 1:4, EtOAc:hexane) 
White solid (28.4 mg, 32%); Rf = 
0.17); 1H NMR (300 MHz; d6-
acetone) δ 7.29 (s, 2H, 2 x Ar-H6), 
7.13 (t, 1H, J 7.8, ArH4), 6.79 (m, 3H, 
3 x Ar-H2+3+5), 4.36 (hep, 2H, J 6.8, 2 
x CH7), 4.29 (s, 2H, CH2
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-OCH3), 2.96 (hep, 1H, J 6.9, CH
9), 2.06 (m, 3H, 3 x CH7+9) and 1.25 (m, 18H, 6 x CH3
8+10); 
13C NMR (75.5 MHz; d6-acetone) δ 160.17, 159.54, 153.19, 150.98 (2C), 141.07, 133.78, 
129.56, 123.91 (2C), 119.43, 112.89, 112.74, 54.74, 43.15 (2C), 34.15, 29.28, 24.29 (4C) 
and 23.15 (2C); HRMS (EI): m/z = 446.22338 [M+]; Anal. Calc. (Found C, 63.9; H, 6.87; N, 
6.76; S, 8.17. C24H34N2O4S requires C, 64.5; H, 7.67; N, 6.27; S, 7.18%); 
 
7. N-(Biphenyl-2-ylmethylcarbamoyl)-4-chlorobenzenesulfonamide (RKG427A) 
White solid (56.9 mg, 71%); NMR (400 MHz; d6-
DMSO) δ 7.70 (d, 2H, J 8.4, 2 x ArH9), 7.48 – 7.11 
(m, 11H, 11 x ArH2+3+4+5+6+7+8+10), 6.49 (t, 1H, J 5.8, 
CH2NH), 4.05 (d, 2H, J 5.7, CH2
1) and 3.70 (s, 3H, -
OCH3); 
13C NMR (100.6 MHz; d6-DMSO) δ 160.58, 
146.72, 140.41, 140.07, 137.65, 133.48, 129.13, 128.89 (2C), 128.41, 128.30 (2C), 128.07 
(2C), 127.31 (2C), 127.03, 126.83, 125.99 and 40.83; LRMS (EI): m/z = 400.0 [M+]; Anal. 
Calc. (Found C, 59.2; H, 3.99; N, 6.76; S, 7.17. C20H17ClN2O3S requires C, 59.9; H, 4.27; N, 
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APPENDIX A 
CHEMICALS AND INSTRUMENTATION 
 
 
Chemicals and Solvents: All commercially available chemicals or reagents were products of 
Sigma-Aldrich, Fluka or Merck, unless otherwise stated. Bulk solvents (namely 
dichloromethane, ethylacetate and hexane) used for column chromatography and thin layer 
chromatography were purchased from Protea Chemicals and Kimix, and were further purified 
via distillation where necessary.  
 
Thin Layer Chromatography: Reactions were monitored by thin layer chromatography using 
pre-coated aluminium-backed F254 silica gel plates from Merck. UV light was used for 
visualisation. 
 
Silica Gel Column Chromatography: Merck Silica kieselgel 60: 70-230 mesh was used for all 
gravity column chromatography. 
 
Melting Points: all melting points were determined using a Reichert-Jung Thermovar hotstage 
microscope. 
 
IR Spectroscopy: Infrared spectra were recorded on a Thermo Nicolete FTIR instrument in the 
4000 – 600 cm-1 range. Samples were analyzed as a thin film deposited (samples initially 
dissolved in chloroform) on NaCl or KBr discs. 
 
Microanalysis: A Fisons EA 1108 CHNO-S instrument was used to determine the elemental 
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NMR Spectroscopy: 1H spectra were recorded on either a Varian Mercury Spectrometer at 300 
MHz or a Varian Unity Spectrometer at 400 MHz. 
13C spectra were recorded on either a Varian Mercury Spectrometer at 75 MHz or a Varian 
Unity Spectrometer at 100 MHz.  
All NMR spectra were measured as solutions of sample dissolved in deuterochloroform, 
deuteromethanol, deuteroacetonitrile, deuterodimethylsulfoxide, deuterated acetone or 
deuterated water (D2O) with tetramethylsilane (TMS) as internal standard. All deuterated 
solvents were purchased products of Sigma-Aldrich. 
Note: All 1H NMR coupling constants (J) were rounded off to one decimal place. 
 
Mass Spectroscopy: Low resolution mass spectra were recorded with an Applied Systems API 
4000 Triple Quadropole with a Turbo Ion Spray source and a Harvard Syringe Pump as solutions 
in methanol, acetonitrile or deionised water, or mixtures, respectively (Department of 
Pharmacology, University of Cape Town). 
High and low resolution mass spectra were recorded with a VG70-SEQ (EI, operating at 8kV) 
instrument (School of Chemistry, University of Witwatersrand). 
 
Dried Solvents:  Tetrahydrofuran, toluene and diethyl ether were initially dried over lithium 
aluminium hydride, and subsequently distilled over sodium wire, using benzophenone as 
indicator, before use. 
Thionyl chloride (SOCl2) was freshly distilled, under reduced pressure, prior to use. 
Anhydrous NMP, DMAP, methanol and 1,4-dioxane were purchased products of Sigma-Aldrich, 
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APPENDIX B 
In Vitro Testing against Trypanosoma Brucei Strain 
 
The primary aims of this research was to synthesize compounds to inhibit new permeability 
pathways (NPP) induced by the malaria parasite P. falciparum, and compounds that inhibit M. 
tuberculosis. There is, however, evidence to suggest that compounds that are active 
antimalarials also demonstrate potent activity against other protozoan parasites.1 
 
Protozoan parasites of the genus Trypanosoma brucei are responsible for African 
Trypanosomiasis in humans, also known as sleeping sickness.2 The parasite is limited to mainly 
the sub-Saharan regions of Africa, and is spread by the tsetse fly. It is estimated that 300 000 – 
500 000 people in Africa are infected. Infection occurs when a tsetse fly bites a human and the 
parasite is transmitted into the human hosts’ bloodstream. The infective forms of the parasite, 
known as trypanosomes, travel to the brain via the bloodstream, resulting in multiple 
neurological symptoms. If the disease remains untreated, the probable outcome is death of the 
human host. There are two species of T. brucei that infect humans, each resulting in different 
symptoms and illness. If the disease is diagnosed early enough it can be treated. Current drugs, 
however, are associated with cytotoxicity, and there is no vaccine currently available. 
 
In 2004, a small library was submitted to the laboratories of V. Yardley (London School of 
Hygiene & Tropical Medicine, UK) for in vitro testing against T. brucei brucei. The results are 
shown in Table AC1 (next page). Inhibition studies, to inhibit the activity of cultured T. brucei 
brucei, at four different concentrations were initially determined. The actual ED50 was then 
determined. All compounds, with exception of RKG136A and RKG162A, did not show any 
effective inhibition of the growth of the parasite at a concentration lower than 30 µg/ml. Data 
for the standard control drugs pentamidine (T. brucei) and Podophyllotoxin (cytotoxicity) is 
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Table AC1: In vitro activities against T. brucei brucei 
Compound % inhibition ED50 µg/ml ED50 µM Cytotoxicity Cytotoxicity TI 
ID 30 10 3 1 +/- 95% CL +/- 95% CL ED50 µg/ml ED50 µM   
RKG 114A 6.36 7.97 8.36 6.12 >30 - >300 - - 
RKG 119A 5.65 1.39 0 - >30 - >300 - - 
RKG 123A 14.4 8.48 4.12 7.2 >30 - 185.1 592.6 - 
RKG 125A 6.2 5.12 4.25 0 >30 - >300 - - 
RKG 131A 9.46 3.07 1.54 0 >30 - >300 - - 
RKG 133A 15.8 10.7 12.2 9.3 >30 - >300 - - 
RKG 136A 60.7 8.65 13.7 14.0 25.8 ± 2.96 95.3 ± 11.0 >300 - >12 
RKG 139 F3 14.2 8.53 803 9.31 >30 - 133.4 322.5 - 
RKG 145A 4.9 8.15 4.22 3.62 >30 - >300 - - 
RKG 1491 8.64 2.65 8.42 5.2 >30 - 39.1 100.3 - 
RKG 1493A 9.42 6.43 4.07 7.77 >30 - >300 - - 
RKG 150A 6.43 6.62 10.7 9.15 >30 - >300 - - 
RKG 151A 47.0 34.3 29.8 29.6 >30 - >300 - - 
RKG 1531 5.42 0.13 0   >30 - >300 - - 
RKG 1532 11.2 5.7 2.54 7.75 >30 - >300 - - 
RKG 1533 PC 3.7 28.7 38.6 31.1 >30 - >300 - - 
RKG 1541 18.5 37.0 34.3 27.8 >30 - 66.0 178.5 - 
RKG 1542 43.7 41.6 35.8 35.0 >30 - 75.3 203.2 - 
RKG 1543 18.3 16.8 4.79 4.69 >30 - 62.0 175.7 - 
RKG 162A 88.7 55.6 40.1 45.7 3.43 ± 1.20 13.4 ± 4.67 >300 - >87 
RKG ANT 3 35.5 32.2 29.2 26.5 >30 - 26.1 98.8 - 
RKG C1 lm 20.0 0 - - >30 - >300 - - 
RKG C2 Bc 16.1 5.8 0 - >30 - >300 - - 
RKG C4 Ci 14.4 12.6 4.55 2.35 >30 - >300 - - 
RKG C10 Ri 9.99 0.71 3.68   >30 - >300 - - 
RKG C11 Tria 28.0 11.6 9.27 4 >30 - >300 - - 
RKG C12 Th 17.8 15.9 13.5 10.1 >30 - >300 - - 
RKG C13 Trib 26.4 3.91 0 - >30 - >300 - - 
RKG C3 Ch 16.4 4.14 0 - >30 - 279.4 780.8 - 
RKG C5 Et 44.3 12.6 5.77 4.19 >30 - 123.9 311.0 - 
RKG C6 Me 0.54 0.33 0 - >30 - 147.6 387.0 - 
RKG C7 Pri 5.49 0 0.31 1.53 >30 - 182.7 390.0 - 
RKG C8 Pro 12.2 7.47 0.35 3.3 >30 - >300 - - 
RKG C9 Py 16.8 12.4 17.6 15.7 >30 - >300 - - 
RKG C14 Trif 28.4 3.91 0 0.97 >30 - >300 - - 
Pentamidine - - - - 0.00307 0.00902 - - - 
Podophyllotoxin - - - - - - 0.00024 - - 
 
 
Eighteen sulfonyl urea derivatives, five synthesized (RKG1491, RKG1493A, RKG1531, RKG1532 
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tested, and found to have had no antiprotozoal activity in the ED50 range of below and up to the 
concentration of 30 μg/ml.  
 
Four acylthiourea derivatives (RKG1541, RKG1542, RKG1543 and RKG162A) were tested. All 
four compounds contain the p-chlorobenzoyl moiety, however, the three compounds 
containing a second aromatic or heteroaromatic moiety showed no activity in the ED50 range of 
below and up to the concentration of 30 μg/ml. Compound RKG162A (containing an iso-propyl 
moiety) proved to be the most potent in this limited library, and displayed an ED50 of 13.4 μM. 
The cytotoxicity of RKG162A was not determined as it had an ED50 concentration greater than 
300 μg/ml. This results in a favourable therapeutic index of greater than 87. 
 
Two sulfonylcyanoguanidine derivatives (RKG139F3 and RKG151A) both containing the p-
chlorobenzenesulphonamide moiety were tested. Both sulfonylcyanoguanidines showed no 
activity in the concentration range of below and upto 30 μg/ml. Compound (RKG136A), an 
intermediate compound in the synthesis of sulfonylcyanoguanidines, proved to be active with 
an ED50 value of 95.3 μM, and favourable cytotoxicity ED50 of greater than 300 μg/ml, where 
intermediate compound RKG150A showed no activity in the same concentration range. 
 
Four phthalamic acid intermediate products (RKG114A, RKGANT3, RKG125A and RKG123A) 
and four phthalimide derivatives (RKG119A, RKG145A, RKG131A and RKG133A) were also 
submitted for testing. None of these compounds, along with the commercially available 
herbicide, imazapyr (RKGC1Im), showed any activity in the concentration range of below and 
up to 30 μg/ml. 
 
B1 Conclusions and future work 
 
A small library of 35 compounds was tested for in vitro activity against T. t. brucei. Of these 35 
compounds, two proved to be active in the concentration range below 30 μg/ml; RKG162, ED50 










Appendix B In Vitro Testing against Trypanosoma Brucei Strain | 212  
 
Pentamidine, ED50 = 0.00902 μM, these two compounds are moderately active against T. brucei. 
These compounds were, however, not synthesized for antiprotozoal activity evaluation, and the 
activity displayed is interesting in itself.  
 
Future work may include SAR studies of acylthioureas (using RKG162A as a starting scaffold) 
and the synthesis of a library of acylthiourea derivatives where the iso-propyl moiety is 








B2 Experimental Protocol: In Vitro Activities against Trypanosoma 
brucei brucei S427 
 
Trypomastigotes (in bloodstream form) are maintained in MEM medium with Earle’s salts 
supplemented with 25 mM HEPES, 1 g/l additional glucose, 10ml/l MEM nonessential 
aminoacids (100x), 0.2 mM 2-mercaptoethanol, 2 mM Na-pyruvate, 0.1 mM hypoxanthine, 0.05 
mM bathocuprionedisulphonic acid, 0.15 mM L-cysteine and 15% heat inactivated, foetal calf 
serum. All the cultures and assays are conducted under an atmosphere of 5% CO2/95% air 
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Drug sensitivity assays 
The stock drug solutions are prepared in 100% DMSO unless otherwise suggested by the 
supplier at 20 mg/ml, and ball milled or sonicated if necessary, and stored at 4 °C. For the 
assays, the compound is further diluted to the appropriate concentration using complete 
medium. Assays are performed in sterile 96-well microtiter plates, each well containing 100 μl 
of parasite culture (1 x 104 bloodstream forms) with or without serial drug dilutions at 37°C for 
72 hours in 5% CO2. The highest concentration for the test compounds is 30 μg/ml. Each drug is 
tested in triplicate. A 3-fold serial dilution is performed down to a suitable concentration to 
obtain an ED50 value. Initial testing is 30, 10, 3 and 0.1 μg/ml. The control drug is Pentamidine 
and is diluted down to 0.0001 μg/ml (12 dilutions). Control wells are without drug, blanks are 
medium only. After 72 h of incubation the plates are inspected under an inverted microscope to 
assure growth of the controls and to determine the minimum inhibitory concentration (MIC): 
this is the lowest drug concentration at which no trypanosomes with normal morphology and 
motility as compared to the control wells can be seen. 20 μl of Alamar Blue are added to each 
well and the plates incubated for another 2 – 4 h. Then the plates are read on a Gemini Plate 
Reader (Molecular Devices) using an excitation wave length of 530 nm and an emission wave 
length of 580 nm (cut off 550 nm). 
 
Primary screen 
The primary screen uses the T. b. brucei strain. The compounds are tested at 7 concentrations 
(drug concentration range from 30 μg/ml to 0.1 μg/ml in 3-fold dilutions). In this assay  
Pentamidine had a mean ED50 value of 3.07 ng/ml. 
 
Secondary screen 
Active compounds (ED50 <0.2 μg/ml) are tested again over the appropriate dose range against 
Trypanosoma brucei rhodesiense STIB 900 to confirm IC50 and IC90 values in comparison to 
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B3 Toxicity Test Protocol 
 
Cell cultures 
KB cells (a cell line derived from a human carcinoma of the nasopharynx) is typically used as an 
assay for antineoplastic agents. KB cells are maintained as monolayers in RPMI 1640 + 10% 
HIFCS. All cultures and assays are conducted at 37 °C under an atmosphere of 5% CO2/95% air 
mixture. 
 
Drug toxicity assays 
Stock drug solutions are prepared in 100% DMSO unless otherwise suggested by the supplier at 
20 mg/ml, and ball milled or sonicated if necessary, and stored at 4 °C. For the assays, the 
compound is further diluted to the appropriate concentration using complete medium. 
 
The cytotoxicity test is carried out as detailed in following steps:  
 
Day 1 
KB cells are harvested, counted and washed in serum-free medium (2000 rpm, 10 mins, 4 oC) 
and resuspended in fresh medium (RPMI 1640 + 10%HIFC) at a concentration of 4 x 104/ml. 
100μl is added to wells on a 96-well plate (4 x 103/well). The plate is incubated overnight at 37 
oC, 5% CO2/air mix to allow the cells to adhere. 
 
Day 2 
Test compounds are prepared in 100% DMSO 20 mg/ml and diluted down to a starting 
concentration of 600 μg/ml (2X top concentration) with RPMI + 10% HIFCS. Control wells had 
no drug. A 10-fold serial dilution is performed across the plate – 300, 30, 3 etc. Podophyllotoxin 
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Day 5 
Each well is assessed by microscope observation. 20 μl Alamar Blue™ is then added to each 
well. Plates are incubated for a further 2 - 4 hours before reading (Gemini), EX/EM 530/580, 
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